Genetic . . O O
alterations . . B-Mutation O
of . . O O
microsatellites . . O O
on . . O O
chromosome . . O O
18 . . O O
in . . O O
human . . O O
breast . . O O
carcinoma . . O O
. . . O O

Allelic . . O B-Mutation
alterations . . B-Mutation I-Mutation
of . . O O
chromosome . . O O
18 . . O O
microsatellites . . O O
were . . O O
determined . . O O
using . . O O
normal . . O O
and . . O O
tumor . . O O
DNA . . O O
pairs . . O O
from . . O O
29 . . O O
patients . . O O
with . . O O
infiltrating . . O O
ductal . . O O
carcinoma . . O O
of . . O O
the . . O O
breast . . O O
. . . O O

Loss . . B-Mutation B-Mutation
of . . I-Mutation I-Mutation
heterozygosity . . I-Mutation I-Mutation
was . . O O
detected . . O O
in . . O O
62 . . O O
% . . O O
( . . O O
18 . . O O
of . . O O
29 . . O O
patients . . O O
) . . O O
of . . O O
the . . O O
tumors . . O O
at . . O O
one . . O O
or . . O O
more . . O O
of . . O O
these . . O O
microsatellites . . O O
. . . O O

Eight . . O O
of . . O O
the . . O O
18 . . O O
patients . . O O
exhibited . . O O
deletions . . B-Mutation O
in . . O O
the . . O O
region . . O O
at . . O O
18q21 . . O O
. . . O O
1 . . O O
. . . O O

This . . O O
chromosomal . . O O
band . . O O
is . . O O
known . . O O
to . . O O
contain . . O O
a . . O O
tumor . . O O
suppressor . . O O
gene . . O O
( . . O O
DCC . . O O
) . . O O
whose . . O O
expression . . O O
is . . O O
frequently . . O O
inactivated . . O O
in . . O O
several . . O O
types . . O O
of . . O O
cancer . . O O
. . . O O

Ten . . O O
other . . O O
patients . . O O
had . . O O
deletions . . B-Mutation O
in . . O O
regions . . O O
not . . O O
included . . O O
in . . O O
the . . O O
DCC . . O O
locus . . O O
. . . O O

Five . . O O
of . . O O
these . . O O
patients . . O O
revealed . . O O
a . . O O
common . . O O
deletion . . O B-Mutation
at . . O O
the . . O O
D18S50 . . O O
locus . . O O
( . . O O
18q23 . . O O
) . . O O
, . . O O
and . . O O
the . . O O
other . . O O
five . . O O
patients . . O O
had . . O O
deletions . . B-Mutation O
in . . O O
various . . O O
other . . O O
regions . . O O
of . . O O
the . . O O
chromosome . . O O
. . . O O

No . . O O
apparent . . O O
correlation . . O O
between . . O O
loss . . B-Mutation B-Mutation
of . . I-Mutation I-Mutation
heterozygosity . . I-Mutation I-Mutation
of . . O O
chromosome . . O O
18 . . O O
microsatellites . . O O
and . . O O
the . . O O
clinical . . O O
stage . . O O
was . . O O
found . . O O
in . . O O
this . . O O
series . . O O
. . . O O

The . . O O
results . . O O
indicate . . O O
that . . O O
, . . O O
in . . O O
addition . . O O
to . . O O
the . . O O
DCC . . O O
locus . . O O
, . . O O
the . . O O
18q23 . . O O
region . . O O
is . . O O
likely . . O O
to . . O O
contain . . O O
a . . O O
second . . O O
tumor . . O O
suppressor . . O O
gene . . O O
relevant . . O O
to . . O O
breast . . O O
carcinogenesis . . O O
. . . O O

Four . . O O
percent . . O O
of . . O O
all . . O O
microsatellites . . O O
tested . . O O
in . . O O
these . . O O
patients . . O O
showed . . O O
allelic . . O O
differences . . O O
in . . O O
the . . O O
sizes . . O O
of . . O O
repeat . . O O
units . . O O
between . . O O
tumor . . O O
and . . O O
the . . O O
corresponding . . O O
constitutional . . O O
DNAs . . O O
. . . O O

The . . O O
pattern . . O O
of . . O O
allele . . O O
instability . . O O
observed . . O O
in . . O O
breast . . O O
carcinoma . . O O
differed . . O O
from . . O O
that . . O O
originally . . O O
reported . . O O
in . . O O
a . . O O
hereditary . . O O
type . . O O
of . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

The . . O O
observation . . O O
suggests . . O O
that . . O O
this . . O O
phenomenon . . O O
is . . O O
not . . O O
a . . O O
mechanism . . O O
specific . . O O
to . . O O
neoplastic . . O O
processes . . O O
in . . O O
breast . . O O
carcinoma . . O O
. . . O O

Allelic . . O O
status . . O O
of . . O O
chromosomes . . O O
17p . . O O
, . . O O
18q . . O O
, . . O O
22q . . O O
[ . . O O
corrected . . O O
] . . O O
3p . . O O
and . . O O
their . . O O
clinical . . O O
usefulness . . O O
in . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

To . . O O
determine . . O O
whether . . O O
the . . O O
allelic . . O O
status . . O O
of . . O O
chromosomes . . O O
is . . O O
clinically . . O O
useful . . O O
in . . O O
colorectal . . O O
cancer . . O O
, . . O O
the . . O O
allelic . . B-Mutation O
losses . . I-Mutation O
at . . O O
chromosomes . . O O
17p . . O O
, . . O O
18q . . O O
, . . O O
22q . . O O
and . . O O
3p . . O O
and . . O O
their . . O O
relationships . . O O
with . . O O
the . . O O
clinicopathological . . O O
features . . O O
in . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
patients . . O O
, . . O O
who . . O O
had . . O O
undergone . . O O
curative . . O O
surgery . . O O
without . . O O
adjuvant . . O O
chemotherapy . . O O
, . . O O
were . . O O
examined . . O O
. . . O O

# . . O O
# . . O O
MATERIALS . . O O
AND . . O O
METHODS . . O O

The . . O O
allelic . . O O
status . . O O
at . . O O
17p . . O O
, . . O O
18q . . O O
, . . O O
22q . . O O
and . . O O
3p . . O O
was . . O O
analyzed . . O O
by . . O O
PCR . . O O
- . . O O
SSCP . . O O
( . . O O
polymerase . . O O
chain . . O O
reaction . . O O
single . . O O
- . . O O
strand . . O O
conformation . . O O
polymorphism . . O O
) . . O O
in . . O O
139 . . O O
CRC . . O O
from . . O O
patients . . O O
who . . O O
had . . O O
undergone . . O O
curative . . O O
surgery . . O O
between . . O O
October . . O O
1994 . . O O
and . . O O
June . . O O
1996 . . O O
. . . O O

The . . O O
relationships . . O O
between . . O O
these . . O O
allelic . . B-Mutation O
losses . . I-Mutation O
and . . O O
the . . O O
clinicopathological . . O O
features . . O O
were . . O O
investigated . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
lymph . . O O
node . . O O
status . . O O
was . . O O
significantly . . O O
associated . . O O
with . . O O
the . . O O
allelic . . O O
status . . O O
of . . O O
17p . . O O
, . . O O
18q . . O O
and . . O O
22q . . O O
. . . O O

The . . O O
tumor . . O O
site . . O O
and . . O O
tumor . . O O
differentiation . . O O
were . . O O
significantly . . O O
associated . . O O
with . . O O
the . . O O
allelic . . O O
status . . O O
of . . O O
18q . . O O
. . . O O

When . . O O
patients . . O O
with . . O O
more . . O O
than . . O O
two . . O O
allelic . . B-Mutation O
losses . . I-Mutation O
were . . O O
defined . . O O
as . . O O
the . . O O
high . . O O
allelic . . B-Mutation O
loss . . I-Mutation O
group . . O O
and . . O O
those . . O O
with . . O O
no . . O O
, . . O O
or . . O O
only . . O O
one . . O O
allelic . . B-Mutation O
loss . . I-Mutation O
were . . O O
defined . . O O
as . . O O
the . . O O
low . . O O
allelic . . B-Mutation O
loss . . I-Mutation O
group . . O O
, . . O O
it . . O O
was . . O O
found . . O O
that . . O O
the . . O O
lymph . . O O
node . . O O
involvement . . O O
was . . O O
significantly . . O O
higher . . O O
in . . O O
the . . O O
high . . O O
than . . O O
in . . O O
the . . O O
low . . O O
allelic . . B-Mutation O
loss . . I-Mutation O
group . . O O
. . . O O

Only . . O O
three . . O O
out . . O O
of . . O O
25 . . O O
patients . . O O
in . . O O
the . . O O
low . . O O
allelic . . B-Mutation O
loss . . I-Mutation O
group . . O O
had . . O O
lymph . . O O
node . . O O
metastasis . . O O
, . . O O
and . . O O
15 . . O O
patients . . O O
in . . O O
this . . O O
group . . O O
without . . O O
lymphatic . . O O
invasion . . O O
had . . O O
no . . O O
lymph . . O O
node . . O O
metastasis . . O O
. . . O O

There . . O O
was . . O O
no . . O O
relationship . . O O
between . . O O
the . . O O
allelic . . O O
status . . O O
and . . O O
survival . . O O
at . . O O
any . . O O
stage . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

The . . O O
allelic . . O O
status . . O O
was . . O O
significantly . . O O
associated . . O O
with . . O O
lymph . . O O
node . . O O
metastasis . . O O
. . . O O

A . . O O
combination . . O O
of . . O O
allelic . . O O
status . . O O
and . . O O
lymphatic . . O O
invasion . . O O
assessment . . O O
can . . O O
predict . . O O
the . . O O
lymph . . O O
node . . O O
status . . O O
before . . O O
radical . . O O
surgery . . O O
. . . O O

Colorectal . . O O
carcinoma . . O O
. . . O O

DNA . . O O
ploidy . . O O
pattern . . O O
and . . O O
prognosis . . O O
with . . O O
reference . . O O
to . . O O
tumor . . O O
DNA . . O O
heterogeneity . . O O
. . . O O

Nuclear . . O O
DNA . . O O
content . . O O
was . . O O
measured . . O O
in . . O O
72 . . O O
colorectal . . O O
carcinomas . . O O
using . . O O
single . . O O
- . . O O
cell . . O O
microspectrophotometry . . O O
on . . O O
Feulgen . . O O
- . . O O
stained . . O O
smears . . O O
. . . O O

Four . . O O
samples . . O O
were . . O O
analyzed . . O O
from . . O O
each . . O O
tumor . . O O
. . . O O

Patients . . O O
were . . O O
followed . . O O
for . . O O
41 . . O O
- . . O O
65 . . O O
months . . O O
( . . O O
average . . O O
, . . O O
53 . . O O
) . . O O
. . . O O

DNA . . O O
heterogeneity . . O O
( . . O O
both . . O O
aneuploid . . B-Mutation O
and . . O O
nonaneuploid . . O O
patterns . . O O
) . . O O
was . . O O
present . . O O
in . . O O
44 . . O O
% . . O O
of . . O O
the . . O O
cases . . O O
. . . O O

Sixty . . O O
- . . O O
eight . . O O
percent . . O O
of . . O O
the . . O O
tumors . . O O
showed . . O O
an . . O O
aneuploid . . B-Mutation O
DNA . . O O
pattern . . O O
in . . O O
at . . O O
least . . O O
one . . O O
of . . O O
the . . O O
samples . . O O
. . . O O

Patients . . O O
with . . O O
nonaneuploid . . O O
tumors . . O O
tended . . O O
to . . O O
have . . O O
a . . O O
survival . . O O
advantage . . O O
over . . O O
patients . . O O
with . . O O
homogeneously . . O O
aneuploid . . B-Mutation O
tumors . . O O
and . . O O
demonstrated . . O O
a . . O O
significantly . . O O
longer . . O O
disease . . O O
- . . O O
free . . O O
survival . . O O
. . . O O

The . . O O
DNA . . O O
ploidy . . O O
pattern . . O O
is . . O O
of . . O O
potential . . O O
value . . O O
in . . O O
conjunction . . O O
with . . O O
histopathologic . . O O
prognostic . . O O
parameters . . O O
in . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

Since . . O O
colorectal . . O O
tumors . . O O
exhibit . . O O
pronounced . . O O
DNA . . O O
heterogeneity . . O O
, . . O O
multiple . . O O
samples . . O O
are . . O O
required . . O O
from . . O O
each . . O O
tumor . . O O
to . . O O
permit . . O O
a . . O O
proper . . O O
evaluation . . O O
of . . O O
its . . O O
DNA . . O O
pattern . . O O
. . . O O

The . . O O
DNA . . O O
heterogeneity . . O O
may . . O O
represent . . O O
tumor . . O O
progression . . O O
and . . O O
can . . O O
partly . . O O
explain . . O O
the . . O O
conflicting . . O O
results . . O O
reported . . O O
concerning . . O O
DNA . . O O
pattern . . O O
and . . O O
prognosis . . O O
in . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

Somatic . . O O
mutation . . B-Mutation B-Mutation
of . . O O
hPMS2 . . O O
as . . O O
a . . O O
possible . . O O
cause . . O O
of . . O O
sporadic . . O O
human . . O O
colon . . O O
cancer . . O O
with . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
. . . O O

Inactivation . . B-Mutation O
of . . O O
DNA . . O O
- . . O O
mismatch . . O O
repair . . O O
underlies . . O O
the . . O O
genesis . . O O
of . . O O
microsatellite . . B-Mutation O
unstable . . I-Mutation O
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
colon . . O O
cancers . . O O
. . . O O

hPMS2 . . O O
is . . O O
one . . O O
of . . O O
several . . O O
genes . . O O
encoding . . O O
components . . O O
of . . O O
the . . O O
DNA . . O O
- . . O O
mismatch . . O O
repair . . O O
complex . . O O
, . . O O
and . . O O
germline . . O O
hPMS2 . . O O
mutations . . B-Mutation B-Mutation
have . . O O
been . . O O
found . . O O
in . . O O
a . . O O
few . . O O
kindreds . . O O
with . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
carcinoma . . O O
( . . O O
HNPCC . . O O
) . . O O
, . . O O
in . . O O
whom . . O O
hereditary . . O O
MSI . . B-Mutation O
colon . . O O
cancers . . O O
develop . . O O
. . . O O

However . . O O
, . . O O
mice . . O O
bearing . . O O
null . . B-Mutation O
hPMS2 . . O O
genes . . O O
do . . O O
not . . O O
develop . . O O
colon . . O O
cancers . . O O
and . . O O
hPMS2 . . O O
mutations . . B-Mutation B-Mutation
in . . O O
sporadic . . O O
human . . O O
colon . . O O
cancers . . O O
have . . O O
not . . O O
been . . O O
described . . O O
. . . O O

Here . . O O
we . . O O
report . . O O
that . . O O
in . . O O
Vaco481 . . O O
colon . . O O
cancer . . O O
the . . O O
hPMS2 . . O O
gene . . O O
is . . O O
inactivated . . B-Mutation O
by . . O O
somatic . . O O
mutations . . B-Mutation B-Mutation
of . . O O
both . . O O
hPMS2 . . O O
alleles . . O O
. . . O O

The . . O O
cell . . O O
line . . O O
derived . . O O
from . . O O
this . . O O
tumor . . O O
is . . O O
functionally . . O O
deficient . . O O
in . . O O
DNA . . O O
mismatch . . B-Mutation O
repair . . I-Mutation O
. . . O O

This . . O O
deficiency . . O O
can . . O O
be . . O O
biochemically . . O O
complemented . . O O
by . . O O
addition . . O O
of . . O O
a . . O O
purified . . O O
hMLH1 . . O O
- . . O O
hPMS2 . . O O
( . . O O
hMutLalpha . . O O
) . . O O
complex . . O O
. . . O O

The . . O O
hPMS2 . . O O
deficient . . O O
Vaco481 . . O O
cancer . . O O
cell . . O O
line . . O O
demonstrates . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
, . . O O
an . . O O
elevated . . O O
HPRT . . O O
gene . . O O
mutation . . B-Mutation B-Mutation
rate . . O O
, . . O O
and . . O O
resistance . . O O
to . . O O
the . . O O
cytotoxicity . . O O
of . . O O
the . . O O
alkylator . . O O
MNNG . . O O
. . . O O

We . . O O
conclude . . O O
that . . O O
somatic . . O O
inactivation . . B-Mutation O
of . . O O
hPMS2 . . O O
can . . O O
play . . O O
a . . O O
role . . O O
in . . O O
development . . O O
of . . O O
sporadic . . O O
MSI . . B-Mutation B-Mutation
colon . . O O
cancer . . O O
expressing . . O O
the . . O O
full . . O O
range . . O O
of . . O O
cancer . . O O
phenotypes . . O O
associated . . O O
with . . O O
inactivation . . B-Mutation O
of . . O O
the . . O O
mismatch . . B-Mutation O
repair . . I-Mutation O
system . . O O
. . . O O

Expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
, . . O O
an . . O O
autophagy . . O O
- . . O O
related . . O O
protein . . O O
, . . O O
in . . O O
gastric . . O O
and . . O O
colorectal . . O O
cancers . . O O
. . . O O

Autophagy . . O O
plays . . O O
important . . O O
roles . . O O
in . . O O
both . . O O
cell . . O O
death . . O O
and . . O O
cell . . O O
survival . . O O
. . . O O

Beclin . . O O
- . . O O
1 . . O O
, . . O O
a . . O O
key . . O O
regulator . . O O
of . . O O
autophagy . . O O
formation . . O O
, . . O O
has . . O O
been . . O O
considered . . O O
as . . O O
a . . O O
haploinsufficient . . B-Mutation O
tumor . . O O
suppressor . . O O
. . . O O

Loss . . O O
of . . O O
expression . . O O
or . . O O
point . . O O
mutation . . B-Mutation B-Mutation
could . . O O
serve . . O O
as . . O O
a . . O O
mechanism . . O O
of . . O O
loss . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
tumor . . O O
suppressor . . O O
function . . O O
in . . O O
cancers . . O O
. . . O O

However . . O O
, . . O O
our . . O O
recent . . O O
study . . O O
revealed . . O O
that . . O O
point . . O O
mutation . . B-Mutation B-Mutation
of . . O O
the . . O O
beclin . . O O
- . . O O
1 . . O O
gene . . O O
is . . O O
a . . O O
rare . . O O
event . . O O
in . . O O
common . . O O
human . . O O
cancers . . O O
. . . O O

In . . O O
this . . O O
study . . O O
we . . O O
investigated . . O O
beclin . . O O
- . . O O
1 . . O O
protein . . O O
expression . . O O
in . . O O
103 . . O O
colorectal . . O O
and . . O O
60 . . O O
gastric . . O O
carcinoma . . O O
tissues . . O O
by . . O O
immunohistochemistry . . O O
using . . O O
a . . O O
tissue . . O O
microarray . . O O
approach . . O O
. . . O O

In . . O O
the . . O O
cancers . . O O
, . . O O
expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
was . . O O
detected . . O O
in . . O O
95 . . O O
% . . O O
of . . O O
the . . O O
colorectal . . O O
carcinomas . . O O
and . . O O
83 . . O O
% . . O O
of . . O O
the . . O O
gastric . . O O
carcinomas . . O O
. . . O O

In . . O O
contrast . . O O
, . . O O
normal . . O O
mucosal . . O O
cells . . O O
of . . O O
both . . O O
stomach . . O O
and . . O O
colon . . O O
showed . . O O
no . . O O
or . . O O
very . . O O
weak . . O O
expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
. . . O O

There . . O O
was . . O O
no . . O O
significant . . O O
association . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
expression . . O O
with . . O O
clinocopathologic . . O O
characteristics . . O O
, . . O O
including . . O O
invasion . . O O
, . . O O
metastasis . . O O
and . . O O
stage . . O O
. . . O O

The . . O O
beclin . . O O
- . . O O
1 . . O O
expression . . O O
of . . O O
colorectal . . O O
and . . O O
gastric . . O O
cancers . . O O
in . . O O
the . . O O
present . . O O
study . . O O
is . . O O
quite . . O O
in . . O O
contrast . . O O
to . . O O
that . . O O
of . . O O
the . . O O
breast . . O O
cancers . . O O
in . . O O
the . . O O
previous . . O O
study . . O O
, . . O O
which . . O O
showed . . O O
a . . O O
decreased . . O O
beclin . . O O
- . . O O
1 . . O O
expression . . O O
in . . O O
breast . . O O
cancer . . O O
cells . . O O
compared . . O O
to . . O O
normal . . O O
breast . . O O
cells . . O O
. . . O O

Our . . O O
data . . O O
indicate . . O O
that . . O O
beclin . . O O
- . . O O
1 . . O O
inactivation . . O O
by . . O O
loss . . O O
of . . O O
expression . . O O
may . . O O
not . . O O
occur . . O O
in . . O O
colorectal . . O O
and . . O O
gastric . . O O
cancers . . O O
. . . O O

Rather . . O O
, . . O O
increased . . O O
expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
in . . O O
the . . O O
malignant . . O O
colorectal . . O O
and . . O O
gastric . . O O
epithelial . . O O
cells . . O O
compared . . O O
to . . O O
their . . O O
normal . . O O
mucosal . . O O
epithelial . . O O
cells . . O O
suggests . . O O
that . . O O
neo . . O O
- . . O O
expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
may . . O O
play . . O O
a . . O O
role . . O O
in . . O O
both . . O O
colorectal . . O O
and . . O O
gastric . . O O
tumorigenesis . . O O
. . . O O

Cost . . O O
comparison . . O O
of . . O O
predictive . . O O
genetic . . O O
testing . . O O
versus . . O O
conventional . . O O
clinical . . O O
screening . . O O
for . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Mutations . . O B-Mutation
of . . O O
the . . O O
APC . . O O
gene . . O O
cause . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
( . . O O
FAP . . O O
) . . O O
, . . O O
a . . O O
hereditary . . O O
colorectal . . O O
cancer . . O O
predisposition . . O O
syndrome . . O O
. . . O O

# . . O O
# . . O O
AIMS . . O O

To . . O O
conduct . . O O
a . . O O
cost . . O O
comparison . . O O
analysis . . O O
of . . O O
predictive . . O O
genetic . . O O
testing . . O O
versus . . O O
conventional . . O O
clinical . . O O
screening . . O O
for . . O O
individuals . . O O
at . . O O
risk . . O O
of . . O O
inheriting . . O O
FAP . . O O
, . . O O
using . . O O
the . . O O
perspective . . O O
of . . O O
a . . O O
third . . O O
party . . O O
payer . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

All . . O O
direct . . O O
health . . O O
care . . O O
costs . . O O
for . . O O
both . . O O
screening . . O O
strategies . . O O
were . . O O
measured . . O O
according . . O O
to . . O O
time . . O O
and . . O O
motion . . O O
, . . O O
and . . O O
the . . O O
expected . . O O
costs . . O O
evaluated . . O O
using . . O O
a . . O O
decision . . O O
analysis . . O O
model . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
baseline . . O O
analysis . . O O
predicted . . O O
that . . O O
screening . . O O
a . . O O
prototype . . O O
FAP . . O O
family . . O O
would . . O O
cost . . O O
$ . . O O
4975 . . O O
/ . . O O
pound3109 . . O O
by . . O O
molecular . . O O
testing . . O O
and . . O O
$ . . O O
8031 . . O O
/ . . O O
pound5019 . . O O
by . . O O
clinical . . O O
screening . . O O
strategy . . O O
, . . O O
when . . O O
family . . O O
members . . O O
were . . O O
monitored . . O O
with . . O O
the . . O O
same . . O O
frequency . . O O
of . . O O
clinical . . O O
surveillance . . O O
( . . O O
every . . O O
two . . O O
to . . O O
three . . O O
years . . O O
) . . O O
. . . O O

Sensitivity . . O O
analyses . . O O
revealed . . O O
that . . O O
the . . O O
genetic . . O O
testing . . O O
approach . . O O
is . . O O
cost . . O O
saving . . O O
for . . O O
key . . O O
variables . . O O
including . . O O
the . . O O
kindred . . O O
size . . O O
, . . O O
the . . O O
age . . O O
of . . O O
screening . . O O
onset . . O O
, . . O O
and . . O O
the . . O O
cost . . O O
of . . O O
mutation . . B-Mutation B-Mutation
identification . . O O
in . . O O
a . . O O
proband . . O O
. . . O O

However . . O O
, . . O O
if . . O O
the . . O O
APC . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
were . . O O
monitored . . O O
at . . O O
an . . O O
increased . . O O
( . . O O
annual . . O O
) . . O O
frequency . . O O
, . . O O
the . . O O
cost . . O O
of . . O O
the . . O O
genetic . . O O
screening . . O O
strategy . . O O
increased . . O O
to . . O O
$ . . O O
7483 . . O O
/ . . O O
pound4677 . . O O
and . . O O
was . . O O
especially . . O O
sensitive . . O O
to . . O O
variability . . O O
in . . O O
age . . O O
of . . O O
onset . . O O
of . . O O
screening . . O O
, . . O O
family . . O O
size . . O O
, . . O O
and . . O O
cost . . O O
of . . O O
genetic . . O O
testing . . O O
of . . O O
at . . O O
risk . . O O
relatives . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

In . . O O
FAP . . O O
kindreds . . O O
, . . O O
a . . O O
predictive . . O O
genetic . . O O
testing . . O O
strategy . . O O
costs . . O O
less . . O O
than . . O O
conventional . . O O
clinical . . O O
screening . . O O
, . . O O
provided . . O O
that . . O O
the . . O O
frequency . . O O
of . . O O
surveillance . . O O
is . . O O
identical . . O O
using . . O O
either . . O O
strategy . . O O
. . . O O

An . . O O
additional . . O O
significant . . O O
benefit . . O O
is . . O O
the . . O O
elimination . . O O
of . . O O
unnecessary . . O O
colonic . . O O
examinations . . O O
for . . O O
those . . O O
family . . O O
members . . O O
found . . O O
to . . O O
be . . O O
non . . O O
- . . O O
carriers . . O O
. . . O O

Cells . . O O
with . . O O
pathogenic . . O O
biallelic . . B-Mutation O
mutations . . I-Mutation B-Mutation
in . . O O
the . . O O
human . . O O
MUTYH . . O O
gene . . O O
are . . O O
defective . . O O
in . . O O
DNA . . O O
damage . . O O
binding . . O O
and . . O O
repair . . O O
. . . O O

Inherited . . O O
biallelic . . B-Mutation O
mutations . . I-Mutation B-Mutation
in . . O O
the . . O O
human . . O O
MUTYH . . O O
gene . . O O
are . . O O
responsible . . O O
for . . O O
the . . O O
recessive . . O O
syndrome . . O O
- . . O O
- . . O O
adenomatous . . O O
colorectal . . O O
polyposis . . O O
( . . O O
MUTYH . . O O
associated . . O O
polyposis . . O O
, . . O O
MAP . . O O
) . . O O
- . . O O
- . . O O
which . . O O
significantly . . O O
increases . . O O
the . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
. . . O O

Defective . . O O
MUTYH . . O O
activity . . O O
causes . . O O
G . . O O
: . . O O
C . . O O
to . . O O
T . . O O
: . . O O
A . . O O
transversions . . B-Mutation B-Mutation
in . . O O
tumour . . O O
APC . . O O
and . . O O
other . . O O
genes . . O O
thereby . . O O
altering . . O O
genomic . . O O
integrity . . O O
. . . O O

We . . O O
report . . O O
that . . O O
of . . O O
the . . O O
four . . O O
established . . O O
cell . . O O
lines . . O O
, . . O O
derived . . O O
from . . O O
patients . . O O
with . . O O
the . . O O
MAP . . O O
phenotype . . O O
and . . O O
containing . . O O
biallelic . . O O
MUTYH . . O O
mutations . . B-Mutation B-Mutation
, . . O O
three . . O O
contain . . O O
altered . . O O
expressions . . O O
of . . O O
MUTYH . . O O
protein . . O O
( . . O O
MUTYH . . O O
Y165C . . B-Mutation B-Mutation
( . . I-Mutation O
- . . I-Mutation O
/ . . I-Mutation O
- . . I-Mutation O
) . . I-Mutation O
, . . O O
MUTYH . . O O
1103delC . . B-Mutation O
/ . . I-Mutation O
G382D . . I-Mutation B-Mutation
and . . O O
MUTYH . . O O
Y165C . . B-Mutation B-Mutation
/ . . I-Mutation O
G382D . . I-Mutation B-Mutation
but . . O O
not . . O O
MUTYH . . O O
G382D . . B-Mutation B-Mutation
( . . I-Mutation O
- . . I-Mutation O
/ . . I-Mutation O
- . . I-Mutation O
) . . I-Mutation O
) . . O O
, . . O O
but . . O O
that . . O O
all . . O O
four . . O O
cell . . O O
lines . . O O
have . . O O
wild . . O O
type . . O O
levels . . O O
of . . O O
MUTYH . . O O
mRNA . . O O
. . . O O

Mutant . . B-Mutation O
MUTYH . . O O
proteins . . O O
in . . O O
these . . O O
four . . O O
cell . . O O
lines . . O O
possess . . O O
significantly . . O O
lowered . . O O
binding . . O O
and . . O O
cleavage . . O O
activities . . O O
with . . O O
heteroduplex . . O O
oligonucleotides . . O O
containing . . O O
A . . O O
. . . O O
8 . . O O
- . . O O
oxoG . . O O
and . . O O
8 . . O O
- . . O O
oxoA . . O O
. . . O O
G . . O O
mispairs . . O O
. . . O O

Transfection . . O O
of . . O O
mitochondrial . . O O
or . . O O
nuclear . . O O
MUTYH . . O O
cDNAs . . O O
partially . . O O
correct . . O O
altered . . O O
MUTYH . . O O
expression . . O O
and . . O O
activity . . O O
in . . O O
these . . O O
defective . . O O
cell . . O O
lines . . O O
. . . O O

Finally . . O O
, . . O O
we . . O O
surprisingly . . O O
find . . O O
that . . O O
defective . . O O
MUTYH . . O O
may . . O O
not . . O O
alter . . O O
cell . . O O
survival . . O O
after . . O O
hydrogen . . O O
peroxide . . O O
and . . O O
menadione . . O O
treatments . . O O
. . . O O

The . . O O
Y165C . . B-Mutation O
and . . O O
1103delC . . B-Mutation O
mutations . . I-Mutation B-Mutation
significantly . . O O
reduce . . O O
MUTYH . . O O
protein . . O O
stability . . O O
and . . O O
thus . . O O
repair . . O O
activity . . O O
, . . O O
whereas . . O O
the . . O O
G382D . . B-Mutation O
mutation . . I-Mutation B-Mutation
produces . . O O
dysfunctional . . O O
protein . . O O
only . . O O
suggesting . . O O
different . . O O
functional . . O O
molecular . . O O
mechanisms . . O O
by . . O O
which . . O O
the . . O O
MAP . . O O
phenotype . . O O
may . . O O
contribute . . O O
to . . O O
the . . O O
development . . O O
of . . O O
CRC . . O O
. . . O O

Self . . O O
administered . . O O
screening . . O O
for . . O O
hereditary . . O O
cancers . . O O
in . . O O
conjunction . . O O
with . . O O
mammography . . O O
and . . O O
ultrasound . . O O
. . . O O

We . . O O
evaluated . . O O
the . . O O
feasibility . . O O
of . . O O
an . . O O
automated . . O O
tablet . . O O
computer . . O O
application . . O O
providing . . O O
a . . O O
family . . O O
and . . O O
personal . . O O
history . . O O
based . . O O
cancer . . O O
risk . . O O
assessment . . O O
for . . O O
hereditary . . O O
breast . . O O
, . . O O
ovarian . . O O
, . . O O
endometrial . . O O
and . . O O
colorectal . . O O
cancers . . O O
. . . O O

1 . . O O
, . . O O
002 . . O O
women . . O O
presenting . . O O
for . . O O
screening . . O O
mammography . . O O
and . . O O
1 . . O O
, . . O O
000 . . O O
presenting . . O O
for . . O O
ultrasound . . O O
were . . O O
offered . . O O
screening . . O O
. . . O O

The . . O O
application . . O O
calculated . . O O
the . . O O
risk . . O O
of . . O O
BRCA . . O O
mutations . . O B-Mutation
using . . O O
BRCAPRO . . O O
, . . O O
Myriad . . O O
and . . O O
Tyrer . . O O
- . . O O
Cuzick . . O O
risk . . O O
assessment . . O O
models . . O O
. . . O O

Lifetime . . O O
risk . . O O
of . . O O
breast . . O O
and . . O O
ovarian . . O O
cancer . . O O
was . . O O
assessed . . O O
with . . O O
the . . O O
BRCAPRO . . O O
, . . O O
Claus . . O O
and . . O O
Tyrer . . O O
- . . O O
Cuzick . . O O
models . . O O
. . . O O

Colorectal . . O O
and . . O O
endometrial . . O O
cancer . . O O
risk . . O O
was . . O O
calculated . . O O
via . . O O
the . . O O
MMRpro . . O O
model . . O O
. . . O O

Patients . . O O
were . . O O
identified . . O O
as . . O O
high . . O O
- . . O O
risk . . O O
based . . O O
on . . O O
thresholds . . O O
10 . . O O
% . . O O
or . . O O
greater . . O O
risk . . O O
for . . O O
carrying . . O O
genetic . . O O
mutations . . O B-Mutation
or . . O O
20 . . O O
% . . O O
or . . O O
greater . . O O
lifetime . . O O
risk . . O O
of . . O O
breast . . O O
or . . O O
ovarian . . O O
cancer . . O O
. . . O O

The . . O O
percent . . O O
of . . O O
women . . O O
found . . O O
to . . O O
be . . O O
high . . O O
- . . O O
risk . . O O
by . . O O
a . . O O
single . . O O
risk . . O O
assessment . . O O
tool . . O O
ranged . . O O
from . . O O
0 . . O O
. . . O O
5 . . O O
to . . O O
5 . . O O
. . . O O
3 . . O O
% . . O O
. . . O O

Combining . . O O
assessment . . O O
tools . . O O
found . . O O
9 . . O O
. . . O O
3 . . O O
% . . O O
of . . O O
women . . O O
to . . O O
be . . O O
high . . O O
- . . O O
risk . . O O
. . . O O

The . . O O
risk . . O O
assessments . . O O
performed . . O O
similarly . . O O
for . . O O
the . . O O
mammography . . O O
and . . O O
ultrasound . . O O
cohorts . . O O
with . . O O
yields . . O O
( . . O O
combining . . O O
assessment . . O O
tools . . O O
) . . O O
of . . O O
9 . . O O
. . . O O
2 . . O O
and . . O O
9 . . O O
. . . O O
4 . . O O
% . . O O
respectively . . O O
. . . O O

The . . O O
average . . O O
ages . . O O
of . . O O
all . . O O
the . . O O
high . . O O
- . . O O
risk . . O O
women . . O O
were . . O O
45 . . O O
. . . O O
8 . . O O
and . . O O
39 . . O O
. . . O O
6 . . O O
years . . O O
for . . O O
the . . O O
mammography . . O O
and . . O O
ultrasound . . O O
cohorts . . O O
respectively . . O O
. . . O O

Difficulties . . O O
encountered . . O O
included . . O O
a . . O O
need . . O O
for . . O O
software . . O O
upgrade . . O O
, . . O O
wireless . . O O
network . . O O
unreliability . . O O
and . . O O
hardware . . O O
theft . . O O
. . . O O

Automated . . O O
family . . O O
history . . O O
screening . . O O
can . . O O
identify . . O O
women . . O O
probably . . O O
at . . O O
high . . O O
- . . O O
risk . . O O
for . . O O
hereditary . . O O
cancers . . O O
efficiently . . O O
. . . O O

The . . O O
number . . O O
of . . O O
women . . O O
identified . . O O
is . . O O
increased . . O O
by . . O O
employing . . O O
multiple . . O O
risk . . O O
assessment . . O O
models . . O O
simultaneously . . O O
. . . O O

Surveying . . O O
women . . O O
in . . O O
conjunction . . O O
with . . O O
ultrasound . . O O
identified . . O O
women . . O O
at . . O O
increased . . O O
risk . . O O
as . . O O
effectively . . O O
and . . O O
at . . O O
a . . O O
younger . . O O
age . . O O
than . . O O
with . . O O
screening . . O O
mammography . . O O
. . . O O

Possible . . O O
role . . O O
of . . O O
telomerase . . O O
activation . . O O
in . . O O
the . . O O
cancer . . O O
predisposition . . O O
of . . O O
patients . . O O
with . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancers . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
syndrome . . O O
( . . O O
HNPCC . . O O
syndrome . . O O
; . . O O
also . . O O
called . . O O
Lynch . . O O
syndrome . . O O
) . . O O
is . . O O
one . . O O
of . . O O
the . . O O
most . . O O
common . . O O
cancer . . O O
predisposition . . O O
syndromes . . O O
. . . O O

Most . . O O
cases . . O O
of . . O O
cancer . . O O
associated . . O O
with . . O O
this . . O O
syndrome . . O O
are . . O O
due . . O O
to . . O O
the . . O O
inheritance . . O O
of . . O O
germline . . O O
mutations . . B-Mutation B-Mutation
in . . O O
genes . . O O
that . . O O
encode . . O O
proteins . . O O
required . . O O
for . . O O
DNA . . O O
mismatch . . O O
repair . . O O
; . . O O
defects . . O O
in . . O O
these . . O O
proteins . . O O
allow . . O O
mutations . . B-Mutation B-Mutation
to . . O O
accumulate . . O O
more . . O O
rapidly . . O O
in . . O O
the . . O O
DNA . . O O
and . . O O
influence . . O O
the . . O O
rate . . O O
of . . O O
cancer . . O O
development . . O O
. . . O O

Recent . . O O
studies . . O O
indicate . . O O
that . . O O
the . . O O
reactivation . . O O
of . . O O
the . . O O
activity . . O O
of . . O O
telomerase . . O O
, . . O O
an . . O O
enzyme . . O O
involved . . O O
in . . O O
the . . O O
synthesis . . O O
of . . O O
chromosomal . . O O
ends . . O O
, . . O O
in . . O O
somatic . . O O
cells . . O O
may . . O O
play . . O O
a . . O O
role . . O O
in . . O O
carcinogenesis . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
evaluated . . O O
the . . O O
expression . . O O
of . . O O
telomerase . . O O
in . . O O
normal . . O O
and . . O O
cancerous . . O O
colorectal . . O O
tissue . . O O
specimens . . O O
from . . O O
HNPCC . . O O
and . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

The . . O O
polymerase . . O O
chain . . O O
reaction . . O O
- . . O O
based . . O O
telomeric . . O O
repeat . . O O
amplification . . O O
protocol . . O O
was . . O O
used . . O O
to . . O O
assay . . O O
telomerase . . O O
activity . . O O
in . . O O
colorectal . . O O
tissue . . O O
specimens . . O O
from . . O O
33 . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
( . . O O
23 . . O O
normal . . O O
, . . O O
26 . . O O
polyps . . O O
, . . O O
and . . O O
37 . . O O
cancer . . O O
specimens . . O O
) . . O O
and . . O O
from . . O O
24 . . O O
HNPCC . . O O
patients . . O O
( . . O O
24 . . O O
normal . . O O
, . . O O
0 . . O O
polyps . . O O
, . . O O
and . . O O
28 . . O O
cancer . . O O
specimens . . O O
) . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Thirty . . O O
- . . O O
one . . O O
of . . O O
37 . . O O
carcinoma . . O O
samples . . O O
from . . O O
18 . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
and . . O O
27 . . O O
of . . O O
28 . . O O
carcinoma . . O O
samples . . O O
from . . O O
24 . . O O
HNPCC . . O O
patients . . O O
were . . O O
found . . O O
to . . O O
be . . O O
positive . . O O
for . . O O
telomerase . . O O
activity . . O O
. . . O O

Whereas . . O O
only . . O O
one . . O O
of . . O O
23 . . O O
normal . . O O
mucosa . . O O
samples . . O O
from . . O O
23 . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
was . . O O
found . . O O
to . . O O
have . . O O
( . . O O
weak . . O O
) . . O O
telomerase . . O O
activity . . O O
, . . O O
eight . . O O
of . . O O
24 . . O O
normal . . O O
mucosa . . O O
samples . . O O
from . . O O
24 . . O O
HNPCC . . O O
patients . . O O
were . . O O
positive . . O O
for . . O O
telomerase . . O O
; . . O O
the . . O O
difference . . O O
between . . O O
the . . O O
two . . O O
groups . . O O
was . . O O
statistically . . O O
significant . . O O
( . . O O
two . . O O
- . . O O
sided . . O O
P . . O O
= . . O O
. . . O O
0226 . . O O
) . . O O
. . . O O

# . . O O
# . . O O
IMPLICATION . . O O

This . . O O
study . . O O
generates . . O O
the . . O O
hypothesis . . O O
that . . O O
genetic . . O O
defects . . O O
in . . O O
individuals . . O O
with . . O O
HNPCC . . O O
syndrome . . O O
facilitate . . O O
the . . O O
reactivation . . O O
of . . O O
telomerase . . O O
activity . . O O
, . . O O
a . . O O
process . . O O
which . . O O
may . . O O
be . . O O
associated . . O O
with . . O O
their . . O O
predisposition . . O O
to . . O O
develop . . O O
cancer . . O O
. . . O O

[ . . O O
Application . . O O
of . . O O
molecular . . O O
targeted . . O O
agents . . O O
in . . O O
comprehensive . . O O
treatment . . O O
of . . O O
gastrointestinal . . O O
cancer . . O O
] . . O O
. . . O O

Targeted . . O O
agents . . O O
increase . . O O
response . . O O
rates . . O O
and . . O O
improved . . O O
overall . . O O
survival . . O O
in . . O O
treatment . . O O
of . . O O
metastatic . . O O
gastrointestinal . . O O
cancer . . O O
. . . O O

Therefore . . O O
, . . O O
physicians . . O O
pay . . O O
more . . O O
attention . . O O
to . . O O
the . . O O
role . . O O
of . . O O
targeted . . O O
agents . . O O
in . . O O
treatment . . O O
of . . O O
local . . O O
advanced . . O O
gastrointestinal . . O O
cancer . . O O
. . . O O

The . . O O
clinical . . O O
trials . . O O
are . . O O
ongoing . . O O
to . . O O
evaluate . . O O
the . . O O
efficacy . . O O
of . . O O
Trastuzumab . . O O
in . . O O
neoadjuvant . . O O
treatment . . O O
of . . O O
local . . O O
advanced . . O O
gastric . . O O
cancer . . O O
with . . O O
HER . . O O
- . . O O
2 . . O O
gene . . O O
over . . O O
expression . . O O
. . . O O

Many . . O O
studies . . O O
reported . . O O
Cetuximab . . O O
plus . . O O
chemotherapy . . O O
as . . O O
a . . O O
conversion . . O O
treatment . . O O
improve . . O O
R0 . . O O
resection . . O O
rates . . O O
and . . O O
prolonged . . O O
overall . . O O
survival . . O O
of . . O O
the . . O O
patients . . O O
with . . O O
potentially . . O O
resectable . . O O
colorectal . . O O
cancer . . O O
liver . . O O
metastasis . . O O
with . . O O
wild . . O O
type . . O O
KRAS . . O O
gene . . O O
status . . O O
. . . O O

A . . O O
phase . . O O
III . . O O
( . . O O
clinical . . O O
trial . . O O
is . . O O
assessing . . O O
the . . O O
conversion . . O O
efficacy . . O O
of . . O O
Bevacizumab . . O O
in . . O O
unresectable . . O O
disease . . O O
with . . O O
KRAS . . O O
gene . . O O
mutation . . B-Mutation B-Mutation
. . . O O

Current . . O O
evidence . . O O
showed . . O O
that . . O O
neoadjuvant . . O O
therapy . . O O
of . . O O
targeted . . O O
agents . . O O
did . . O O
not . . O O
prolong . . O O
survival . . O O
of . . O O
patients . . O O
with . . O O
resectable . . O O
liver . . O O
metastasis . . O O
. . . O O

However . . O O
, . . O O
this . . O O
is . . O O
controversial . . O O
. . . O O

In . . O O
neoadjuvant . . O O
therapy . . O O
of . . O O
local . . O O
advanced . . O O
rectal . . O O
cancer . . O O
, . . O O
Cetuximab . . O O
did . . O O
not . . O O
improve . . O O
the . . O O
rates . . O O
of . . O O
pathological . . O O
complete . . O O
response . . O O
in . . O O
most . . O O
of . . O O
the . . O O
phase . . O O
II . . O O
( . . O O
trials . . O O
. . . O O

Furthermore . . O O
, . . O O
there . . O O
are . . O O
no . . O O
phase . . O O
III . . O O
( . . O O
trials . . O O
to . . O O
assess . . O O
the . . O O
role . . O O
of . . O O
Bevacizumab . . O O
. . . O O

Compared . . O O
to . . O O
chemotherapy . . O O
alone . . O O
for . . O O
metastatic . . O O
cancer . . O O
, . . O O
it . . O O
is . . O O
more . . O O
important . . O O
to . . O O
evaluate . . O O
the . . O O
interaction . . O O
and . . O O
synergistic . . O O
action . . O O
of . . O O
targeted . . O O
agents . . O O
, . . O O
cytotoxic . . O O
drugs . . O O
, . . O O
surgery . . O O
and . . O O
radiation . . O O
, . . O O
to . . O O
make . . O O
a . . O O
scientific . . O O
multidisciplinary . . O O
model . . O O
in . . O O
comprehensive . . O O
treatment . . O O
of . . O O
local . . O O
advanced . . O O
cancer . . O O
. . . O O

Distinct . . O O
high . . O O
resolution . . O O
genome . . O O
profiles . . O O
of . . O O
early . . O O
onset . . O O
and . . O O
late . . O O
onset . . O O
colorectal . . O O
cancer . . O O
integrated . . O O
with . . O O
gene . . O O
expression . . O O
data . . O O
identify . . O O
candidate . . O O
susceptibility . . O O
loci . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Estimates . . O O
suggest . . O O
that . . O O
up . . O O
to . . O O
30 . . O O
% . . O O
of . . O O
colorectal . . O O
cancers . . O O
( . . O O
CRC . . O O
) . . O O
may . . O O
develop . . O O
due . . O O
to . . O O
an . . O O
increased . . O O
genetic . . O O
risk . . O O
. . . O O

The . . O O
mean . . O O
age . . O O
at . . O O
diagnosis . . O O
for . . O O
CRC . . O O
is . . O O
about . . O O
70 . . O O
years . . O O
. . . O O

Time . . O O
of . . O O
disease . . O O
onset . . O O
20 . . O O
years . . O O
younger . . O O
than . . O O
the . . O O
mean . . O O
age . . O O
is . . O O
assumed . . O O
to . . O O
be . . O O
indicative . . O O
of . . O O
genetic . . O O
susceptibility . . O O
. . . O O

We . . O O
have . . O O
compared . . O O
high . . O O
resolution . . O O
tumor . . O O
genome . . O O
copy . . O B-Mutation
number . . O I-Mutation
variation . . O I-Mutation
( . . O O
CNV . . O O
) . . O O
( . . O O
Roche . . O O
NimbleGen . . O O
, . . O O
385 . . O O
000 . . O O
oligo . . O O
CGH . . O O
array . . O O
) . . O O
in . . O O
microsatellite . . O O
stable . . O O
( . . O O
MSS . . O O
) . . O O
tumors . . O O
from . . O O
two . . O O
age . . O O
groups . . O O
, . . O O
including . . O O
23 . . O O
young . . O O
at . . O O
onset . . O O
patients . . O O
without . . O O
known . . O O
hereditary . . O O
syndromes . . O O
and . . O O
with . . O O
a . . O O
median . . O O
age . . O O
of . . O O
44 . . O O
years . . O O
( . . O O
range . . O O
: . . O O
28 . . O O
- . . O O
53 . . O O
) . . O O
and . . O O
17 . . O O
elderly . . O O
patients . . O O
with . . O O
median . . O O
age . . O O
79 . . O O
years . . O O
( . . O O
range . . O O
: . . O O
69 . . O O
- . . O O
87 . . O O
) . . O O
. . . O O

Our . . O O
aim . . O O
was . . O O
to . . O O
identify . . O O
differences . . O O
in . . O O
the . . O O
tumor . . O O
genomes . . O O
between . . O O
these . . O O
groups . . O O
and . . O O
pinpoint . . O O
potential . . O O
susceptibility . . O O
loci . . O O
. . . O O

Integration . . O O
analysis . . O O
of . . O O
CNV . . O O
and . . O O
genome . . O O
wide . . O O
mRNA . . O O
expression . . O O
data . . O O
, . . O O
available . . O O
for . . O O
the . . O O
same . . O O
tumors . . O O
, . . O O
was . . O O
performed . . O O
to . . O O
identify . . O O
a . . O O
restricted . . O O
candidate . . O O
gene . . O O
list . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
total . . O O
fraction . . O O
of . . O O
the . . O O
genome . . O O
with . . O O
aberrant . . O O
copy . . O O
number . . O O
, . . O O
the . . O O
overall . . O O
genomic . . O O
profile . . O O
and . . O O
the . . O O
TP53 . . O O
mutation . . O B-Mutation
spectrum . . O O
were . . O O
similar . . O O
between . . O O
the . . O O
two . . O O
age . . O O
groups . . O O
. . . O O

However . . O O
, . . O O
both . . O O
the . . O O
number . . O O
of . . O O
chromosomal . . O O
aberrations . . O O
and . . O O
the . . O O
number . . O O
of . . O O
breakpoints . . O O
differed . . O O
significantly . . O O
between . . O O
the . . O O
groups . . O O
. . . O O

Gains . . B-Mutation O
of . . O O
2q35 . . O O
, . . O O
10q21 . . O B-Mutation
. . . O O
3 . . O O
- . . O O
22 . . O O
. . . O O
1 . . O O
, . . O O
10q22 . . O O
. . . O O
3 . . O O
and . . O O
19q13 . . O O
. . . O O
2 . . O O
- . . O O
13 . . O O
. . . O O
31 . . O O
and . . O O
losses . . B-Mutation O
from . . O O
1p31 . . O O
. . . O O
3 . . O O
, . . O O
1q21 . . O O
. . . O O
1 . . O O
, . . O O
2q21 . . O O
. . . O O
2 . . O O
, . . O O
4p16 . . O B-Mutation
. . . O O
1 . . O O
- . . O O
q28 . . O O
. . . O O
3 . . O O
, . . O O
10p11 . . O O
. . . O O
1 . . O O
and . . O O
19p12 . . O O
, . . O O
positions . . O O
that . . O O
in . . O O
total . . O O
contain . . O O
more . . O O
than . . O O
500 . . O O
genes . . O O
, . . O O
were . . O O
found . . O O
significantly . . O O
more . . O O
often . . O O
in . . O O
the . . O O
early . . O O
onset . . O O
group . . O O
as . . O O
compared . . O O
to . . O O
the . . O O
late . . O O
onset . . O O
group . . O O
. . . O O

Integration . . O O
analysis . . O O
revealed . . O O
a . . O O
covariation . . O O
of . . O O
DNA . . O O
copy . . O O
number . . O O
at . . O O
these . . O O
sites . . O O
and . . O O
mRNA . . O O
expression . . O O
for . . O O
107 . . O O
of . . O O
the . . O O
genes . . O O
. . . O O

Seven . . O O
of . . O O
these . . O O
genes . . O O
, . . O O
CLC . . O O
, . . O O
EIF4E . . O O
, . . O O
LTBP4 . . O O
, . . O O
PLA2G12A . . O O
, . . O O
PPAT . . O O
, . . O O
RG9MTD2 . . O O
, . . O O
and . . O O
ZNF574 . . O O
, . . O O
had . . O O
significantly . . O O
different . . O O
mRNA . . O O
expression . . O O
comparing . . O O
median . . O O
expression . . O O
levels . . O O
across . . O O
the . . O O
transcriptome . . O O
between . . O O
the . . O O
two . . O O
groups . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Ten . . O O
genomic . . O O
loci . . O O
, . . O O
containing . . O O
more . . O O
than . . O O
500 . . O O
protein . . O O
coding . . O O
genes . . O O
, . . O O
are . . O O
identified . . O O
as . . O O
more . . O O
often . . O O
altered . . O O
in . . O O
tumors . . O O
from . . O O
early . . O O
onset . . O O
versus . . O O
late . . O O
onset . . O O
CRC . . O O
. . . O O

Integration . . O O
of . . O O
genome . . O O
and . . O O
transcriptome . . O O
data . . O O
identifies . . O O
seven . . O O
novel . . O O
candidate . . O O
genes . . O O
with . . O O
the . . O O
potential . . O O
to . . O O
identify . . O O
an . . O O
increased . . O O
risk . . O O
for . . O O
CRC . . O O
. . . O O

Similar . . O O
colorectal . . O O
cancer . . O O
risk . . O O
in . . O O
patients . . O O
with . . O O
monoallelic . . O O
and . . O O
biallelic . . O O
mutations . . B-Mutation B-Mutation
in . . O O
the . . O O
MYH . . O O
gene . . O O
identified . . O O
in . . O O
a . . O O
population . . O O
with . . O O
adenomatous . . O O
polyposis . . O O
. . . O O

A . . O O
large . . O O
proportion . . O O
of . . O O
non . . O O
- . . O O
FAP . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
with . . O O
multiple . . O O
colorectal . . O O
adenomas . . O O
have . . O O
been . . O O
reported . . O O
to . . O O
carry . . O O
germline . . B-Mutation O
mutations . . I-Mutation B-Mutation
on . . O O
the . . O O
MYH . . O O
gene . . O O
. . . O O

Although . . O O
the . . O O
number . . O O
of . . O O
adenomas . . O O
appears . . O O
to . . O O
be . . O O
dependent . . O O
on . . O O
the . . O O
number . . O O
of . . O O
mutated . . B-Mutation B-Mutation
MYH . . O O
alleles . . O O
present . . O O
in . . O O
a . . O O
patient . . O O
, . . O O
little . . O O
is . . O O
known . . O O
on . . O O
the . . O O
relation . . O O
of . . O O
this . . O O
number . . O O
with . . O O
cancer . . O O
risk . . O O
. . . O O

Four . . O O
hundred . . O O
fifty . . O O
- . . O O
three . . O O
APC . . O O
- . . O O
negative . . O O
patients . . O O
with . . O O
more . . O O
than . . O O
five . . O O
colorectal . . O O
adenomas . . O O
were . . O O
screened . . O O
for . . O O
mutations . . O B-Mutation
on . . O O
the . . O O
entire . . O O
coding . . O O
sequence . . O O
of . . O O
the . . O O
MYH . . O O
gene . . O O
. . . O O

Pathogenic . . B-Mutation O
mutations . . I-Mutation B-Mutation
were . . O O
initially . . O O
found . . O O
in . . O O
74 . . O O
patients . . O O
without . . O O
extradigestive . . O O
tumors . . O O
( . . O O
22 . . O O
. . . O O
5 . . O O
% . . O O
) . . O O
and . . O O
subsequently . . O O
in . . O O
75 . . O O
at . . O O
- . . O O
risk . . O O
relatives . . O O
. . . O O

Polyposis . . O O
was . . O O
more . . O O
severe . . O O
in . . O O
cases . . O O
with . . O O
biallelic . . B-Mutation O
mutations . . I-Mutation B-Mutation
. . . O O

However . . O O
, . . O O
mutation . . B-Mutation B-Mutation
copy . . O O
number . . O O
was . . O O
correlated . . O O
neither . . O O
with . . O O
the . . O O
age . . O O
at . . O O
diagnosis . . O O
of . . O O
adenomas . . O O
or . . O O
adenocarcinomas . . O O
, . . O O
nor . . O O
with . . O O
the . . O O
presence . . O O
of . . O O
a . . O O
family . . O O
history . . O O
of . . O O
colorectal . . O O
tumors . . O O
. . . O O

Heterozygous . . O O
and . . O O
homozygous . . O O
MYH . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
were . . O O
both . . O O
at . . O O
high . . O O
risk . . O O
for . . O O
synchronous . . O O
cancers . . O O
( . . O O
24 . . O O
% . . O O
in . . O O
colorectum . . O O
and . . O O
16 . . O O
% . . O O
in . . O O
the . . O O
upper . . O O
gastrointestinal . . O O
tract . . O O
) . . O O
, . . O O
but . . O O
did . . O O
not . . O O
demonstrate . . O O
an . . O O
increased . . O O
risk . . O O
for . . O O
extradigestive . . O O
tumors . . O O
. . . O O

MYH . . O O
- . . O O
associated . . O O
polyposis . . O O
is . . O O
a . . O O
frequent . . O O
inherited . . O O
colorectal . . O O
cancer . . O O
predisposition . . O O
with . . O O
a . . O O
strong . . O O
dominance . . O O
component . . O O
. . . O O

From . . O O
age . . O O
25 . . O O
- . . O O
30 . . O O
, . . O O
MYH . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
should . . O O
be . . O O
proposed . . O O
an . . O O
early . . O O
screening . . O O
program . . O O
, . . O O
which . . O O
includes . . O O
endoscopies . . O O
of . . O O
the . . O O
upper . . O O
digestive . . O O
tract . . O O
and . . O O
the . . O O
colorectum . . O O
every . . O O
2 . . O O
years . . O O
. . . O O

Somatic . . O O
MED12 . . O O
mutations . . B-Mutation B-Mutation
in . . O O
uterine . . O O
leiomyosarcoma . . O O
and . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Mediator . . O O
complex . . O O
participates . . O O
in . . O O
transcriptional . . O O
regulation . . O O
by . . O O
connecting . . O O
regulatory . . O O
DNA . . O O
sequences . . O O
to . . O O
the . . O O
RNA . . O O
polymerase . . O O
II . . O O
initiation . . O O
complex . . O O
. . . O O

Recently . . O O
, . . O O
we . . O O
discovered . . O O
through . . O O
exome . . O O
sequencing . . O O
that . . O O
as . . O O
many . . O O
as . . O O
70 . . O O
% . . O O
of . . O O
uterine . . O O
leiomyomas . . O O
harbour . . O O
specific . . O O
mutations . . B-Mutation B-Mutation
in . . O O
exon . . O O
2 . . O O
of . . O O
mediator . . O O
complex . . O O
subunit . . O O
12 . . O O
( . . O O
MED12 . . O O
) . . O O
. . . O O

In . . O O
this . . O O
work . . O O
, . . O O
we . . O O
examined . . O O
the . . O O
role . . O O
of . . O O
MED12 . . O O
exon . . O O
2 . . O O
mutations . . B-Mutation B-Mutation
in . . O O
other . . O O
tumour . . O O
types . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

The . . O O
frequency . . O O
of . . O O
MED12 . . O O
exon . . O O
2 . . O O
mutations . . B-Mutation B-Mutation
was . . O O
analysed . . O O
in . . O O
altogether . . O O
1158 . . O O
tumours . . O O
by . . O O
direct . . O O
sequencing . . O O
. . . O O

The . . O O
tumour . . O O
spectrum . . O O
included . . O O
mesenchymal . . O O
tumours . . O O
( . . O O
extrauterine . . O O
leiomyomas . . O O
, . . O O
endometrial . . O O
polyps . . O O
, . . O O
lipomas . . O O
, . . O O
uterine . . O O
leiomyosarcomas . . O O
, . . O O
other . . O O
sarcomas . . O O
, . . O O
gastro . . O O
- . . O O
intestinal . . O O
stromal . . O O
tumours . . O O
) . . O O
, . . O O
hormone . . O O
- . . O O
dependent . . O O
tumours . . O O
( . . O O
breast . . O O
and . . O O
ovarian . . O O
cancers . . O O
) . . O O
, . . O O
haematological . . O O
malignancies . . O O
( . . O O
acute . . O O
myeloid . . O O
leukaemias . . O O
, . . O O
acute . . O O
lymphoid . . O O
leukaemias . . O O
, . . O O
myeloproliferative . . O O
neoplasms . . O O
) . . O O
, . . O O
and . . O O
tumours . . O O
associated . . O O
with . . O O
abnormal . . O O
Wnt . . O O
- . . O O
signalling . . O O
( . . O O
colorectal . . O O
cancers . . O O
( . . O O
CRC . . O O
) . . O O
) . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Five . . O O
somatic . . O O
alterations . . B-Mutation O
were . . O O
observed . . O O
: . . O O
three . . O O
in . . O O
uterine . . O O
leiomyosarcomas . . O O
( . . O O
3 . . O O
/ . . O O
41 . . O O
, . . O O
7 . . O O
% . . O O
; . . O O
Gly44Ser . . B-Mutation O
, . . O O
Ala38 . . B-Mutation O
_ . . I-Mutation O
Leu39ins7 . . I-Mutation O
, . . O O
Glu35 . . B-Mutation O
_ . . I-Mutation O
Leu36delinsVal . . I-Mutation O
) . . O O
, . . O O
and . . O O
two . . O O
in . . O O
CRC . . O O
( . . O O
2 . . O O
/ . . O O
392 . . O O
, . . O O
0 . . O O
. . . O O
5 . . O O
% . . O O
; . . O O
Gly44Cys . . B-Mutation O
, . . O O
Ala67Val . . B-Mutation O
) . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

Somatic . . O O
MED12 . . O O
exon . . O O
2 . . O O
mutations . . B-Mutation B-Mutation
were . . O O
observed . . O O
in . . O O
uterine . . O O
leiomyosarcomas . . O O
, . . O O
suggesting . . O O
that . . O O
a . . O O
subgroup . . O O
of . . O O
these . . O O
malignant . . O O
tumours . . O O
may . . O O
develop . . O O
from . . O O
a . . O O
leiomyoma . . O O
precursor . . O O
. . . O O

Mutations . . B-Mutation B-Mutation
in . . O O
CRC . . O O
samples . . O O
indicate . . O O
that . . O O
MED12 . . O O
may . . O O
, . . O O
albeit . . O O
rarely . . O O
, . . O O
contribute . . O O
to . . O O
CRC . . O O
tumorigenesis . . O O
. . . O O

[ . . O O
Indications . . O O
for . . O O
prophylactic . . O O
hysterectomy . . O O
] . . O O
. . . O O

Endometrial . . O O
cancer . . O O
is . . O O
the . . O O
most . . O O
common . . O O
gynecologic . . O O
cancer . . O O
in . . O O
France . . O O
with . . O O
an . . O O
incidence . . O O
in . . O O
France . . O O
in . . O O
2010 . . O O
, . . O O
of . . O O
6560 . . O O
new . . O O
cases . . O O
and . . O O
1900 . . O O
deaths . . O O
secondary . . O O
to . . O O
endometrial . . O O
cancer . . O O
. . . O O

The . . O O
main . . O O
risk . . O O
factors . . O O
are . . O O
age . . O O
, . . O O
hyperoestrogenic . . O O
factors . . O O
and . . O O
hereditary . . O O
syndroms . . O O
. . . O O

Prophylactic . . O O
hysterectomy . . O O
could . . O O
prevent . . O O
endometrial . . O O
cancer . . O O
in . . O O
case . . O O
of . . O O
risk . . O O
factors . . O O
such . . O O
as . . O O
genetic . . O O
syndroms . . O O
. . . O O

Actually . . O O
, . . O O
only . . O O
Lynch . . O O
syndrome . . O O
is . . O O
a . . O O
validate . . O O
indication . . O O
and . . O O
should . . O O
be . . O O
discussed . . O O
in . . O O
patients . . O O
older . . O O
than . . O O
40 . . O O
- . . O O
45 . . O O
years . . O O
. . . O O

Prophylactic . . O O
hysterectomy . . O O
does . . O O
not . . O O
seem . . O O
a . . O O
reasonable . . O O
option . . O O
to . . O O
patients . . O O
carrying . . O O
BRCA . . O O
1 . . O O
or . . O O
2 . . O O
mutation . . O B-Mutation
. . . O O

Hydrophobic . . O O
bile . . O O
acid . . O O
- . . O O
induced . . O O
micronuclei . . O O
formation . . O O
, . . O O
mitotic . . O O
perturbations . . O O
, . . O O
and . . O O
decreases . . O O
in . . O O
spindle . . O O
checkpoint . . O O
proteins . . O O
: . . O O
relevance . . O O
to . . O O
genomic . . O O
instability . . O O
in . . O O
colon . . O O
carcinogenesis . . O O
. . . O O

We . . O O
show . . O O
, . . O O
for . . O O
the . . O O
first . . O O
time . . O O
, . . O O
that . . O O
hydrophobic . . O O
bile . . O O
acids . . O O
cause . . O O
aberrations . . O O
of . . O O
the . . O O
mitotic . . O O
machinery . . O O
of . . O O
colon . . O O
cells . . O O
that . . O O
can . . O O
give . . O O
rise . . O O
to . . O O
aneuploidy . . O O
, . . O O
the . . O O
chromosomal . . O O
perturbations . . O O
common . . O O
in . . O O
colon . . O O
tumors . . O O
. . . O O

First . . O O
, . . O O
we . . O O
show . . O O
that . . O O
DOC . . O O
induces . . O O
a . . O O
statistically . . O O
significant . . O O
fourfold . . O O
increase . . O O
in . . O O
the . . O O
number . . O O
of . . O O
micronuclei . . O O
in . . O O
NCM . . O O
- . . O O
460 . . O O
cells . . O O
( . . O O
a . . O O
noncancerous . . O O
colon . . O O
cell . . O O
line . . O O
) . . O O
and . . O O
a . . O O
threefold . . O O
increase . . O O
in . . O O
the . . O O
number . . O O
of . . O O
micronuclei . . O O
in . . O O
binucleated . . O O
HT . . O O
- . . O O
29 . . O O
colon . . O O
cancer . . O O
cells . . O O
using . . O O
the . . O O
cytokinesis . . O O
block . . O O
micronucleus . . O O
assay . . O O
. . . O O

Second . . O O
, . . O O
we . . O O
observed . . O O
mitotic . . O O
aberrations . . O O
after . . O O
DOC . . O O
treatment . . O O
, . . O O
including . . O O
improper . . O O
alignment . . O O
of . . O O
chromosomes . . O O
at . . O O
the . . O O
metaphase . . O O
plate . . O O
, . . O O
lagging . . O O
chromosomes . . O O
during . . O O
anaphase . . O O
, . . O O
anaphase . . O O
/ . . O O
telophase . . O O
chromatin . . O O
bridges . . O O
, . . O O
multipolar . . O O
divisions . . O O
, . . O O
and . . O O
formation . . O O
of . . O O
polynucleated . . O O
cells . . O O
. . . O O

It . . O O
was . . O O
determined . . O O
that . . O O
there . . O O
was . . O O
a . . O O
statistically . . O O
significant . . O O
threefold . . O O
increase . . O O
in . . O O
the . . O O
number . . O O
of . . O O
aberrant . . O O
metaphases . . O O
after . . O O
short . . O O
- . . O O
term . . O O
and . . O O
long . . O O
- . . O O
term . . O O
exposure . . O O
of . . O O
HT . . O O
- . . O O
29 . . O O
and . . O O
HCT . . O O
- . . O O
116 . . O O
cells . . O O
, . . O O
respectively . . O O
. . . O O

Third . . O O
, . . O O
we . . O O
showed . . O O
with . . O O
Western . . O O
blots . . O O
and . . O O
immunohistochemistry . . O O
that . . O O
a . . O O
likely . . O O
basis . . O O
for . . O O
these . . O O
mitosis . . O O
- . . O O
related . . O O
perturbations . . O O
included . . O O
decreased . . O O
expression . . O O
of . . O O
the . . O O
spindle . . O O
checkpoint . . O O
proteins . . O O
, . . O O
Mad2 . . O O
, . . O O
BubR1 . . O O
, . . O O
and . . O O
securin . . O O
. . . O O

Fourth . . O O
, . . O O
results . . O O
of . . O O
DOC . . O O
treatment . . O O
on . . O O
nocodazole . . O O
- . . O O
challenged . . O O
cells . . O O
further . . O O
indicated . . O O
deficiencies . . O O
in . . O O
activation . . O O
of . . O O
the . . O O
spindle . . O O
assembly . . O O
checkpoint . . O O
. . . O O

This . . O O
study . . O O
provides . . O O
mechanisms . . O O
by . . O O
which . . O O
hydrophobic . . O O
bile . . O O
acids . . O O
can . . O O
induce . . O O
genomic . . O O
instability . . O O
in . . O O
colon . . O O
epithelial . . O O
cells . . O O
. . . O O

The . . O O
T393C . . B-Mutation O
polymorphism . . O O
in . . O O
the . . O O
gene . . O O
GNAS1 . . O O
of . . O O
G . . O O
protein . . O O
is . . O O
associated . . O O
with . . O O
survival . . O O
of . . O O
patients . . O O
with . . O O
invasive . . O O
breast . . O O
carcinoma . . O O
. . . O O

The . . O O
GNAS1 . . O O
locus . . O O
encodes . . O O
the . . O O
G . . O O
( . . O O
alpha . . O O
) . . O O
s . . O O
protein . . O O
which . . O O
stimulates . . O O
the . . O O
formation . . O O
of . . O O
cyclic . . O O
AMP . . O O
( . . O O
cAMP . . O O
) . . O O
. . . O O

Subsequently . . O O
the . . O O
cAMP . . O O
pathway . . O O
mediates . . O O
various . . O O
pleiotropic . . O O
effects . . O O
including . . O O
regulation . . O O
of . . O O
apoptosis . . O O
and . . O O
proliferation . . O O
. . . O O

We . . O O
have . . O O
recently . . O O
shown . . O O
that . . O O
genotypes . . O O
of . . O O
the . . O O
single . . O O
nucleotide . . O O
polymorphism . . O O
( . . O O
SNP . . O B-Mutation
) . . O O
T393C . . B-Mutation O
in . . O O
the . . O O
gene . . O O
GNAS1 . . O O
are . . O O
associated . . O O
with . . O O
survival . . O O
of . . O O
patients . . O O
suffering . . O O
from . . O O
bladder . . O O
, . . O O
renal . . O O
cell . . O O
and . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

In . . O O
the . . O O
present . . O O
study . . O O
, . . O O
the . . O O
genotypes . . O O
of . . O O
the . . O O
T393C . . B-Mutation O
SNP . . O B-Mutation
were . . O O
determined . . O O
in . . O O
279 . . O O
patients . . O O
with . . O O
invasive . . O O
breast . . O O
carcinoma . . O O
. . . O O

Comparing . . O O
the . . O O
genotypes . . O O
with . . O O
the . . O O
overall . . O O
survival . . O O
as . . O O
well . . O O
as . . O O
important . . O O
clinico . . O O
- . . O O
pathological . . O O
parameters . . O O
showed . . O O
that . . O O
carriers . . O O
of . . O O
the . . O O
T . . O O
allele . . O O
had . . O O
a . . O O
significantly . . O O
less . . O O
favourable . . O O
course . . O O
of . . O O
the . . O O
disease . . O O
when . . O O
compared . . O O
to . . O O
carriers . . O O
of . . O O
the . . O O
homozygous . . O O
CC . . O O
genotype . . O O
. . . O O

In . . O O
multivariate . . O O
analysis . . O O
the . . O O
homozygous . . O O
TT . . O O
genotype . . O O
was . . O O
independently . . O O
associated . . O O
with . . O O
a . . O O
decreased . . O O
overall . . O O
survival . . O O
. . . O O

Our . . O O
results . . O O
suggest . . O O
that . . O O
the . . O O
GNAS1 . . O O
T393C . . B-Mutation O
SNP . . O B-Mutation
is . . O O
a . . O O
novel . . O O
genetic . . O O
host . . O O
factor . . O O
for . . O O
disease . . O O
progression . . O O
in . . O O
patients . . O O
with . . O O
invasive . . O O
breast . . O O
carcinoma . . O O
. . . O O

GPX . . O O
Pro198Leu . . B-Mutation O
and . . O O
OGG1 . . O O
Ser326Cys . . B-Mutation O
polymorphisms . . B-Mutation B-Mutation
and . . O O
risk . . O O
of . . O O
development . . O O
of . . O O
colorectal . . O O
adenomas . . O O
and . . O O
colorectal . . O O
cancer . . O O
. . . O O

Little . . O O
is . . O O
known . . O O
about . . O O
genetic . . O O
risk . . O O
factors . . O O
for . . O O
colorectal . . O O
cancer . . O O
. . . O O

We . . O O
assessed . . O O
the . . O O
association . . O O
between . . O O
polymorphisms . . B-Mutation O
in . . O O
two . . O O
genes . . O O
involved . . O O
in . . O O
DNA . . O O
repair . . O O
of . . O O
oxidative . . O O
stress . . O O
, . . O O
GPX . . O O
and . . O O
OGG1 . . O O
, . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
carcinoma . . O O
or . . O O
adenomas . . O O
. . . O O

We . . O O
studied . . O O
166 . . O O
cases . . O O
with . . O O
adenocarcinoma . . O O
, . . O O
974 . . O O
with . . O O
adenomas . . O O
and . . O O
397 . . O O
controls . . O O
recruited . . O O
from . . O O
the . . O O
Norwegian . . O O
cohort . . O O
NORCCAP . . O O
. . . O O

No . . O O
associations . . O O
were . . O O
found . . O O
between . . O O
the . . O O
polymorphism . . B-Mutation O
GPX . . O O
Pro198Leu . . B-Mutation O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenomas . . O O
or . . O O
carcinomas . . O O
. . . O O

Carriers . . O O
of . . O O
the . . O O
variant . . O O
allele . . O O
OGG1 . . O O
Ser326Cys . . B-Mutation B-Mutation
polymorphism . . B-Mutation O
had . . O O
a . . O O
lowered . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
, . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
56 . . O O
( . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
0 . . O O
. . . O O
33 . . O O
- . . O O
0 . . O O
. . . O O
95 . . O O
) . . O O
, . . O O
while . . O O
no . . O O
association . . O O
were . . O O
found . . O O
with . . O O
risk . . O O
of . . O O
adenomas . . O O
. . . O O

This . . O O
indicates . . O O
that . . O O
a . . O O
low . . O O
repair . . O O
capacity . . O O
of . . O O
oxidative . . O O
DNA . . O O
damage . . O O
may . . O O
not . . O O
be . . O O
a . . O O
risk . . O O
factor . . O O
for . . O O
development . . O O
of . . O O
colorectal . . O O
adenomas . . O O
or . . O O
carcinoma . . O O
. . . O O

Phase . . O O
I . . O O
pharmacokinetic . . O O
and . . O O
pharmacodynamic . . O O
study . . O O
of . . O O
cetuximab . . O O
, . . O O
irinotecan . . O O
and . . O O
sorafenib . . O O
in . . O O
advanced . . O O
colorectal . . O O
cancer . . O O
. . . O O

Background . . O O
This . . O O
phase . . O O
Ib . . O O
study . . O O
was . . O O
designed . . O O
to . . O O
determine . . O O
the . . O O
maximum . . O O
tolerated . . O O
doses . . O O
( . . O O
MTD . . O O
) . . O O
and . . O O
dose . . O O
limiting . . O O
toxicities . . O O
( . . O O
DLTs . . O O
) . . O O
of . . O O
irinotecan . . O O
and . . O O
cetuximab . . O O
with . . O O
sorafenib . . O O
. . . O O

Secondary . . O O
objectives . . O O
included . . O O
characterizing . . O O
the . . O O
pharmacokinetics . . O O
and . . O O
pharmacodynamics . . O O
and . . O O
evaluating . . O O
preliminary . . O O
antitumor . . O O
activity . . O O
in . . O O
patients . . O O
with . . O O
advanced . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
. . . O O

Methods . . O O
Patients . . O O
with . . O O
metastatic . . O O
, . . O O
pretreated . . O O
CRC . . O O
were . . O O
treated . . O O
at . . O O
five . . O O
dose . . O O
levels . . O O
. . . O O

Results . . O O
Eighteen . . O O
patients . . O O
were . . O O
recruited . . O O
with . . O O
median . . O O
age . . O O
56 . . O O
. . . O O
5 . . O O
years . . O O
. . . O O

In . . O O
the . . O O
first . . O O
five . . O O
patients . . O O
treated . . O O
, . . O O
2 . . O O
irinotecan . . O O
related . . O O
DLTs . . O O
were . . O O
observed . . O O
. . . O O

With . . O O
reduced . . O O
dose . . O O
intensity . . O O
irinotecan . . O O
, . . O O
there . . O O
were . . O O
no . . O O
further . . O O
DLTs . . O O
. . . O O

The . . O O
most . . O O
common . . O O
toxicities . . O O
were . . O O
diarrhea . . O O
, . . O O
nausea . . O O
/ . . O O
vomiting . . O O
, . . O O
fatigue . . O O
, . . O O
anorexia . . O O
and . . O O
rash . . O O
. . . O O

DLTs . . O O
included . . O O
neutropenia . . O O
and . . O O
thrombocytopenia . . O O
. . . O O

Two . . O O
patients . . O O
had . . O O
partial . . O O
responses . . O O
( . . O O
one . . O O
with . . O O
a . . O O
KRAS . . O O
mutation . . B-Mutation B-Mutation
) . . O O
and . . O O
8 . . O O
had . . O O
stable . . O O
disease . . O O
( . . O O
8 . . O O
- . . O O
36 . . O O
weeks . . O O
) . . O O
. . . O O

The . . O O
median . . O O
progression . . O O
free . . O O
survival . . O O
( . . O O
PFS . . O O
) . . O O
and . . O O
overall . . O O
survival . . O O
( . . O O
OS . . O O
) . . O O
were . . O O
2 . . O O
. . . O O
5 . . O O
and . . O O
4 . . O O
. . . O O
7 . . O O
months . . O O
respectively . . O O
. . . O O

Pharmacokinetic . . O O
analyses . . O O
suggest . . O O
sorafenib . . O O
and . . O O
metabolite . . O O
exposure . . O O
correlate . . O O
with . . O O
OS . . O O
and . . O O
DLTs . . O O
. . . O O

Conclusions . . O O
The . . O O
recommended . . O O
phase . . O O
II . . O O
dose . . O O
( . . O O
RP2D . . O O
) . . O O
is . . O O
irinotecan . . O O
100 . . O O
mg . . O O
/ . . O O
m . . O O
( . . O O
2 . . O O
) . . O O
i . . O O
. . . O O
v . . O O
. . . O O
days . . O O
1 . . O O
, . . O O
8 . . O O
; . . O O
cetuximab . . O O
400 . . O O
mg . . O O
/ . . O O
m . . O O
( . . O O
2 . . O O
) . . O O
i . . O O
. . . O O
v . . O O
. . . O O
days . . O O
1 . . O O
and . . O O
250 . . O O
mg . . O O
/ . . O O
m . . O O
( . . O O
2 . . O O
) . . O O
i . . O O
. . . O O
v . . O O
. . . O O
weekly . . O O
; . . O O
and . . O O
sorafenib . . O O
400 . . O O
mg . . O O
orally . . O O
twice . . O O
daily . . O O
in . . O O
advanced . . O O
, . . O O
pretreated . . O O
CRC . . O O
. . . O O

The . . O O
combination . . O O
resulted . . O O
in . . O O
a . . O O
modest . . O O
response . . O O
rate . . O O
. . . O O

Homogeneously . . O O
staining . . O O
chromosomal . . O O
regions . . O O
contain . . O O
amplified . . O O
copies . . O O
of . . O O
an . . O O
abundantly . . O O
expressed . . O O
cellular . . O O
oncogene . . O O
( . . O O
c . . O O
- . . O O
myc . . O O
) . . O O
in . . O O
malignant . . O O
neuroendocrine . . O O
cells . . O O
from . . O O
a . . O O
human . . O O
colon . . O O
carcinoma . . O O
. . . O O

Two . . O O
human . . O O
neuroendocrine . . O O
tumor . . O O
cell . . O O
lines . . O O
derived . . O O
from . . O O
a . . O O
colon . . O O
carcinoma . . O O
contain . . O O
either . . O O
numerous . . O O
double . . B-Mutation O
minute . . I-Mutation O
chromosomes . . I-Mutation O
( . . O O
COLO . . B-Mutation O
320 . . I-Mutation O
DM . . I-Mutation O
) . . O O
or . . O O
a . . O O
homogeneously . . O O
staining . . O O
marker . . O O
chromosome . . O O
( . . O O
COLO . . O O
320 . . O O
HSR . . O O
) . . O O
. . . O O

We . . O O
found . . O O
amplification . . O O
and . . O O
enhanced . . O O
expression . . O O
of . . O O
the . . O O
cellular . . O O
oncogene . . O O
c . . O O
- . . O O
myc . . O O
in . . O O
both . . O O
COLO . . B-Mutation O
320 . . I-Mutation O
DM . . I-Mutation O
and . . O O
HSR . . O O
cells . . O O
, . . O O
and . . O O
we . . O O
were . . O O
able . . O O
to . . O O
show . . O O
that . . O O
the . . O O
homogeneously . . O O
staining . . O O
regions . . O O
of . . O O
the . . O O
COLO . . O O
320 . . O O
HSR . . O O
marker . . O O
chromosome . . O O
contain . . O O
amplified . . O O
c . . O O
- . . O O
myc . . O O
. . . O O

From . . O O
previous . . O O
and . . O O
present . . O O
karyotypes . . O O
, . . O O
it . . O O
appears . . O O
that . . O O
the . . O O
homogeneously . . O O
staining . . O O
regions . . O O
reside . . O O
on . . O O
a . . O O
distorted . . O O
X . . O O
chromosome . . O O
. . . O O

Therefore . . O O
, . . O O
amplification . . O O
of . . O O
c . . O O
- . . O O
myc . . O O
has . . O O
been . . O O
accompanied . . O O
by . . O O
translocation . . B-Mutation O
of . . O O
the . . O O
gene . . O O
from . . O O
its . . O O
normal . . O O
position . . O O
on . . O O
chromosome . . O O
8 . . O O
( . . O O
8q24 . . O O
) . . O O
. . . O O

Because . . O O
double . . B-Mutation O
minute . . I-Mutation O
chromosomes . . I-Mutation O
were . . O O
features . . O O
of . . O O
primary . . O O
cultures . . O O
from . . O O
the . . O O
original . . O O
tumor . . O O
, . . O O
it . . O O
seems . . O O
reasonable . . O O
to . . O O
suspect . . O O
that . . O O
amplification . . O O
of . . O O
c . . O O
- . . O O
myc . . O O
may . . O O
have . . O O
contributed . . O O
to . . O O
tumorigenesis . . O O
. . . O O

Coprocytobiology . . O O
: . . O O
on . . O O
the . . O O
nature . . O O
of . . O O
cellular . . O O
elements . . O O
from . . O O
stools . . O O
in . . O O
the . . O O
pathophysiology . . O O
of . . O O
colonic . . O O
disease . . O O
. . . O O

The . . O O
gastrointestinal . . O O
epithelium . . O O
is . . O O
known . . O O
to . . O O
undergo . . O O
constant . . O O
and . . O O
rapid . . O O
renewal . . O O
resulting . . O O
in . . O O
millions . . O O
of . . O O
cells . . O O
being . . O O
shed . . O O
into . . O O
the . . O O
fecal . . O O
stream . . O O
every . . O O
day . . O O
. . . O O

The . . O O
conventional . . O O
wisdom . . O O
was . . O O
that . . O O
these . . O O
cells . . O O
disintegrate . . O O
upon . . O O
exfoliation . . O O
and . . O O
will . . O O
not . . O O
survive . . O O
the . . O O
transit . . O O
through . . O O
the . . O O
intestinal . . O O
tract . . O O
. . . O O

In . . O O
1990 . . O O
, . . O O
we . . O O
( . . O O
P . . O O
. . . O O
N . . O O
. . . O O
) . . O O
made . . O O
the . . O O
discovery . . O O
that . . O O
a . . O O
significant . . O O
number . . O O
of . . O O
these . . O O
cells . . O O
remain . . O O
intact . . O O
and . . O O
viable . . O O
and . . O O
that . . O O
they . . O O
can . . O O
be . . O O
isolated . . O O
. . . O O

The . . O O
implications . . O O
of . . O O
this . . O O
important . . O O
discovery . . O O
became . . O O
apparent . . O O
when . . O O
we . . O O
demonstrated . . O O
that . . O O
these . . O O
cells . . O O
are . . O O
exclusively . . O O
of . . O O
colonic . . O O
origin . . O O
, . . O O
are . . O O
anatomically . . O O
representative . . O O
of . . O O
the . . O O
entire . . O O
colon . . O O
, . . O O
and . . O O
can . . O O
be . . O O
used . . O O
for . . O O
clinical . . O O
investigations . . O O
of . . O O
disease . . O O
processes . . O O
. . . O O

The . . O O
term . . O O
coprocytobiology . . O O
( . . O O
CCB . . O O
) . . O O
was . . O O
coined . . O O
to . . O O
encompass . . O O
the . . O O
broad . . O O
range . . O O
of . . O O
applications . . O O
of . . O O
this . . O O
new . . O O
technology . . O O
. . . O O

The . . O O
somatic . . O O
cell . . O O
sampling . . O O
and . . O O
recovery . . O O
( . . O O
SCSR . . O O
) . . O O
process . . O O
involves . . O O
the . . O O
isolation . . O O
of . . O O
exfoliated . . O O
colonocytes . . O O
from . . O O
a . . O O
small . . O O
sample . . O O
of . . O O
stool . . O O
( . . O O
approximately . . O O
1 . . O O
g . . O O
) . . O O
collected . . O O
and . . O O
transported . . O O
in . . O O
a . . O O
unique . . O O
medium . . O O
at . . O O
ambient . . O O
temperature . . O O
, . . O O
providing . . O O
cells . . O O
for . . O O
the . . O O
detection . . O O
of . . O O
a . . O O
number . . O O
of . . O O
biomarkers . . O O
of . . O O
disease . . O O
propensity . . O O
. . . O O

These . . O O
exfoliated . . O O
colonocytes . . O O
express . . O O
cytokeratins . . O O
indicating . . O O
epithelial . . O O
lineage . . O O
as . . O O
well . . O O
as . . O O
colon . . O O
- . . O O
specific . . O O
antigen . . O O
. . . O O

Over . . O O
the . . O O
years . . O O
, . . O O
the . . O O
study . . O O
of . . O O
exfoliated . . O O
colonocytes . . O O
has . . O O
provided . . O O
striking . . O O
new . . O O
insights . . O O
into . . O O
the . . O O
biology . . O O
of . . O O
colon . . O O
cancer . . O O
and . . O O
inflammatory . . O O
bowel . . O O
disease . . O O
, . . O O
including . . O O
detection . . O O
of . . O O
p53 . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
, . . O O
reverse . . O O
transcriptase . . O O
polymerase . . O O
chain . . O O
reaction . . O O
amplification . . B-Mutation O
, . . O O
and . . O O
identification . . O O
of . . O O
CD44 . . O O
splice . . B-Mutation O
variants . . I-Mutation O
, . . O O
neoplasia . . O O
- . . O O
associated . . O O
specific . . O O
binding . . O O
of . . O O
plant . . O O
lectins . . O O
, . . O O
and . . O O
expression . . O O
of . . O O
COX . . O O
- . . O O
2 . . O O
, . . O O
the . . O O
inducible . . O O
form . . O O
of . . O O
cyclooxygenase . . O O
. . . O O

The . . O O
functional . . O O
diversity . . O O
of . . O O
cells . . O O
isolated . . O O
by . . O O
SCSR . . O O
is . . O O
revealed . . O O
by . . O O
the . . O O
demonstration . . O O
of . . O O
cell . . O O
surface . . O O
markers . . O O
such . . O O
as . . O O
secretory . . O O
component . . O O
, . . O O
IgA . . O O
, . . O O
and . . O O
IgG . . O O
on . . O O
the . . O O
one . . O O
hand . . O O
and . . O O
the . . O O
amplification . . O O
and . . O O
cloning . . O O
of . . O O
the . . O O
human . . O O
insulin . . O O
receptor . . O O
and . . O O
the . . O O
expression . . O O
of . . O O
the . . O O
multidrug . . O O
resistance . . O O
gene . . O O
mdr . . O O
- . . O O
1 . . O O
on . . O O
the . . O O
other . . O O
hand . . O O
. . . O O

This . . O O
review . . O O
portrays . . O O
the . . O O
immense . . O O
potential . . O O
of . . O O
CCB . . O O
as . . O O
a . . O O
powerful . . O O
tool . . O O
for . . O O
investigating . . O O
the . . O O
pathophysiology . . O O
of . . O O
disease . . O O
, . . O O
identifying . . O O
genetic . . O O
variants . . O O
in . . O O
pharmacogenetics . . O O
, . . O O
assessment . . O O
of . . O O
mucosal . . O O
immunity . . O O
, . . O O
and . . O O
several . . O O
other . . O O
applications . . O O
that . . O O
use . . O O
somatic . . O O
cells . . O O
. . . O O

A . . O O
mutant . . B-Mutation O
allele . . O O
of . . O O
MRE11 . . O O
found . . O O
in . . O O
mismatch . . O O
repair . . O O
- . . O O
deficient . . O O
tumor . . O O
cells . . O O
suppresses . . O O
the . . O O
cellular . . O O
response . . O O
to . . O O
DNA . . O O
replication . . O O
fork . . O O
stress . . O O
in . . O O
a . . O O
dominant . . O O
negative . . O O
manner . . O O
. . . O O

The . . O O
interaction . . O O
of . . O O
ataxia . . O O
- . . O O
telangiectasia . . O O
mutated . . O B-Mutation
( . . O O
ATM . . O O
) . . O O
and . . O O
the . . O O
Mre11 . . O O
/ . . O O
Rad50 . . O O
/ . . O O
Nbs1 . . O O
( . . O O
MRN . . O O
) . . O O
complex . . O O
is . . O O
critical . . O O
for . . O O
the . . O O
response . . O O
of . . O O
cells . . O O
to . . O O
DNA . . O O
double . . O O
- . . O O
strand . . O O
breaks . . O O
; . . O O
however . . O O
, . . O O
little . . O O
is . . O O
known . . O O
of . . O O
the . . O O
role . . O O
of . . O O
these . . O O
proteins . . O O
in . . O O
response . . O O
to . . O O
DNA . . O O
replication . . O O
stress . . O O
. . . O O

Here . . O O
, . . O O
we . . O O
report . . O O
a . . O O
mutant . . B-Mutation O
allele . . O O
of . . O O
MRE11 . . O O
found . . O O
in . . O O
a . . O O
colon . . O O
cancer . . O O
cell . . O O
line . . O O
that . . O O
sensitizes . . O O
cells . . O O
to . . O O
agents . . O O
causing . . O O
replication . . O O
fork . . O O
stress . . O O
. . . O O

The . . O O
mutant . . B-Mutation O
Mre11 . . O O
weakly . . O O
interacts . . O O
with . . O O
Rad50 . . O O
relative . . O O
to . . O O
wild . . O O
type . . O O
and . . O O
shows . . O O
little . . O O
affinity . . O O
for . . O O
Nbs1 . . O O
. . . O O

The . . O O
mutant . . B-Mutation O
protein . . O O
lacks . . O O
3 . . O O
' . . O O
- . . O O
5 . . O O
' . . O O
exonuclease . . O O
activity . . O O
as . . O O
a . . O O
result . . O O
of . . O O
loss . . O O
of . . O O
part . . O O
of . . O O
the . . O O
conserved . . O O
nuclease . . O O
domain . . O O
; . . O O
however . . O O
, . . O O
it . . O O
retains . . O O
binding . . O O
affinity . . O O
for . . O O
single . . O O
- . . O O
stranded . . O O
DNA . . O O
( . . O O
ssDNA . . O O
) . . O O
, . . O O
double . . O O
- . . O O
stranded . . O O
DNA . . O O
with . . O O
a . . O O
3 . . O O
' . . O O
single . . O O
- . . O O
strand . . O O
overhang . . O O
, . . O O
and . . O O
fork . . O O
- . . O O
like . . O O
structures . . O O
containing . . O O
ssDNA . . O O
regions . . O O
. . . O O

In . . O O
cells . . O O
, . . O O
the . . O O
mutant . . B-Mutation O
protein . . O O
shows . . O O
a . . O O
time . . O O
- . . O O
and . . O O
dose . . O O
- . . O O
dependent . . O O
accumulation . . O O
in . . O O
chromatin . . O O
after . . O O
thymidine . . O O
treatment . . O O
that . . O O
corresponds . . O O
with . . O O
increased . . O O
recruitment . . O O
and . . O O
hyperphosphorylation . . O O
of . . O O
replication . . O O
protein . . O O
A . . O O
. . . O O

ATM . . O O
autophosphorylation . . O O
, . . O O
Mre11 . . O O
foci . . O O
, . . O O
and . . O O
thymidine . . O O
- . . O O
induced . . O O
homologous . . O O
recombination . . O O
are . . O O
suppressed . . O O
in . . O O
cells . . O O
expressing . . O O
the . . O O
mutant . . B-Mutation O
allele . . O O
. . . O O

Together . . O O
, . . O O
our . . O O
results . . O O
suggest . . O O
that . . O O
the . . O O
mutant . . B-Mutation O
Mre11 . . O O
suppresses . . O O
the . . O O
cellular . . O O
response . . O O
to . . O O
replication . . O O
stress . . O O
by . . O O
binding . . O O
to . . O O
ssDNA . . O O
regions . . O O
at . . O O
disrupted . . O O
forks . . O O
and . . O O
impeding . . O O
replication . . O O
restart . . O O
in . . O O
a . . O O
dominant . . O O
negative . . O O
manner . . O O
. . . O O

BRAFV600E . . O O
immunohistochemistry . . O O
facilitates . . O O
universal . . O O
screening . . O O
of . . O O
colorectal . . O O
cancers . . O O
for . . O O
Lynch . . O O
syndrome . . O O
. . . O O

BRAFV600E . . O O
mutation . . B-Mutation B-Mutation
in . . O O
microsatellite . . B-Mutation O
- . . I-Mutation O
unstable . . I-Mutation O
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
colorectal . . O O
carcinomas . . O O
( . . O O
CRCs . . O O
) . . O O
virtually . . O O
excludes . . O O
Lynch . . O O
syndrome . . O O
( . . O O
LS . . O O
) . . O O
. . . O O

In . . O O
microsatellite . . O O
- . . O O
stable . . O O
( . . O O
MSS . . O O
) . . O O
CRCs . . O O
it . . O O
predicts . . O O
poor . . O O
prognosis . . O O
. . . O O

We . . O O
propose . . O O
a . . O O
universal . . O O
CRC . . O O
LS . . O O
screening . . O O
algorithm . . O O
using . . O O
concurrent . . O O
reflex . . O O
immunohistochemistry . . O O
( . . O O
IHC . . O O
) . . O O
for . . O O
BRAFV600E . . O O
and . . O O
mismatch . . O O
- . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
proteins . . O O
. . . O O

We . . O O
compared . . O O
BRAFV600E . . O O
IHC . . O O
with . . O O
multiplex . . O O
polymerase . . O O
chain . . O O
reaction . . O O
( . . O O
PCR . . O O
) . . O O
and . . O O
matrix . . O O
- . . O O
assisted . . O O
laser . . O O
desorption . . O O
/ . . O O
ionization . . O O
- . . O O
time . . O O
of . . O O
flight . . O O
mass . . O O
spectrometry . . O O
in . . O O
216 . . O O
consecutive . . O O
CRCs . . O O
from . . O O
2011 . . O O
. . . O O

Discordant . . O O
cases . . O O
were . . O O
resolved . . O O
with . . O O
real . . O O
- . . O O
time . . O O
PCR . . O O
. . . O O

BRAFV600E . . O O
IHC . . O O
was . . O O
performed . . O O
on . . O O
51 . . O O
CRCs . . O O
from . . O O
the . . O O
Australasian . . O O
Colorectal . . O O
Cancer . . O O
Family . . O O
Registry . . O O
( . . O O
ACCFR . . O O
) . . O O
, . . O O
which . . O O
were . . O O
fully . . O O
characterized . . O O
for . . O O
BRAF . . O O
mutation . . B-Mutation B-Mutation
by . . O O
allele . . O O
- . . O O
specific . . O O
PCR . . O O
, . . O O
MMR . . O O
status . . O O
( . . O O
MMR . . O O
IHC . . O O
and . . O O
MSI . . B-Mutation B-Mutation
) . . O O
, . . O O
MLH1 . . O O
promoter . . O O
methylation . . O O
, . . O O
and . . O O
germline . . O O
MLH1 . . O O
mutation . . B-Mutation B-Mutation
. . . O O

We . . O O
then . . O O
assessed . . O O
MMR . . O O
and . . O O
BRAFV600E . . O O
IHC . . O O
on . . O O
1403 . . O O
consecutive . . O O
CRCs . . O O
. . . O O

By . . O O
matrix . . O O
- . . O O
assisted . . O O
laser . . O O
desorption . . O O
/ . . O O
ionization . . O O
- . . O O
time . . O O
of . . O O
flight . . O O
mass . . O O
spectrometry . . O O
15 . . O O
cases . . O O
did . . O O
not . . O O
yield . . O O
a . . O O
BRAF . . O O
result . . O O
, . . O O
whereas . . O O
38 . . O O
/ . . O O
201 . . O O
( . . O O
19 . . O O
% . . O O
) . . O O
were . . O O
positive . . O O
. . . O O

By . . O O
IHC . . O O
45 . . O O
/ . . O O
216 . . O O
( . . O O
20 . . O O
% . . O O
) . . O O
were . . O O
positive . . O O
. . . O O

Of . . O O
the . . O O
7 . . O O
discordant . . O O
cases . . O O
, . . O O
real . . O O
- . . O O
time . . O O
PCR . . O O
confirmed . . O O
the . . O O
IHC . . O O
result . . O O
in . . O O
6 . . O O
. . . O O

In . . O O
the . . O O
51 . . O O
CRCs . . O O
from . . O O
the . . O O
ACCFR . . O O
, . . O O
IHC . . O O
was . . O O
concordant . . O O
with . . O O
allele . . O O
- . . O O
specific . . O O
PCR . . O O
in . . O O
50 . . O O
cases . . O O
. . . O O

BRAFV600E . . O O
and . . O O
MSI . . O B-Mutation
IHC . . O O
on . . O O
1403 . . O O
CRCs . . O O
demonstrated . . O O
the . . O O
following . . O O
phenotypes . . O O
: . . O O
BRAF . . O O
/ . . O O
MSS . . O O
( . . O O
1029 . . O O
cases . . O O
, . . O O
73 . . O O
% . . O O
) . . O O
, . . O O
BRAF . . O O
/ . . O O
MSS . . O O
( . . O O
98 . . O O
, . . O O
7 . . O O
% . . O O
) . . O O
, . . O O
BRAF . . O O
/ . . O O
MSI . . B-Mutation B-Mutation
( . . O O
183 . . O O
, . . O O
13 . . O O
% . . O O
) . . O O
, . . O O
and . . O O
BRAF . . O O
/ . . O O
MSI . . B-Mutation B-Mutation
( . . O O
93 . . O O
, . . O O
7 . . O O
% . . O O
) . . O O
. . . O O

All . . O O
11 . . O O
/ . . O O
1403 . . O O
cancers . . O O
associated . . O O
with . . O O
proven . . O O
LS . . O O
were . . O O
BRAF . . O O
/ . . O O
MSI . . B-Mutation B-Mutation
. . . O O

We . . O O
conclude . . O O
that . . O O
BRAF . . O O
IHC . . O O
is . . O O
highly . . O O
concordant . . O O
with . . O O
2 . . O O
commonly . . O O
used . . O O
PCR . . O O
- . . O O
based . . O O
BRAFV600E . . O O
assays . . O O
; . . O O
it . . O O
performed . . O O
well . . O O
in . . O O
identifying . . O O
MLH1 . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
from . . O O
the . . O O
ACCFR . . O O
and . . O O
identified . . O O
all . . O O
cases . . O O
of . . O O
proven . . O O
LS . . O O
among . . O O
the . . O O
1403 . . O O
CRCs . . O O
. . . O O

Reflex . . O O
BRAFV600E . . O O
and . . O O
MMR . . O O
IHC . . O O
are . . O O
simple . . O O
cheap . . O O
tests . . O O
that . . O O
facilitate . . O O
universal . . O O
LS . . O O
screening . . O O
and . . O O
identify . . O O
the . . O O
poor . . O O
prognosis . . O O
of . . O O
the . . O O
BRAFV600E . . O O
- . . O O
mutant . . B-Mutation O
MSS . . O O
CRC . . O O
phenotype . . O O
. . . O O

A . . O O
genome . . O O
- . . O O
wide . . O O
scan . . O O
of . . O O
10 . . O O
000 . . O O
gene . . O O
- . . O O
centric . . O O
variants . . B-Mutation O
and . . O O
colorectal . . O O
cancer . . O O
risk . . O O
. . . O O

Genome . . O O
scans . . O O
based . . O O
on . . O O
gene . . O O
- . . O O
centric . . O O
single . . B-Mutation O
nucleotide . . I-Mutation O
polymorphisms . . I-Mutation O
( . . O O
SNPs . . B-Mutation O
) . . O O
have . . O O
been . . O O
proposed . . O O
as . . O O
an . . O O
efficient . . O O
approach . . O O
to . . O O
identify . . O O
disease . . O O
- . . O O
causing . . O O
variants . . B-Mutation O
that . . O O
is . . O O
complementary . . O O
to . . O O
scans . . O O
based . . O O
on . . O O
tagging . . O O
SNPs . . B-Mutation O
. . . O O

Adopting . . O O
this . . O O
approach . . O O
to . . O O
identify . . O O
low . . O O
- . . O O
penetrance . . O O
susceptibility . . O O
alleles . . O O
for . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
we . . O O
analysed . . O O
genotype . . O O
data . . O O
from . . O O
9109 . . O O
gene . . O O
- . . O O
centric . . O O
SNPs . . B-Mutation O
, . . O O
7014 . . O O
of . . O O
which . . O O
were . . O O
non . . O O
- . . O O
synonymous . . O O
( . . O O
nsSNPs . . B-Mutation B-Mutation
) . . O O
, . . O O
in . . O O
2873 . . O O
cases . . O O
and . . O O
2871 . . O O
controls . . O O
using . . O O
Illumina . . O O
iselect . . O O
arrays . . O O
. . . O O

Overall . . O O
the . . O O
distribution . . O O
of . . O O
associations . . O O
was . . O O
not . . O O
significantly . . O O
different . . O O
from . . O O
the . . O O
null . . O O
. . . O O

No . . O O
SNP . . B-Mutation O
achieved . . O O
globally . . O O
significant . . O O
association . . O O
after . . O O
correction . . O O
for . . O O
multiple . . O O
testing . . O O
( . . O O
lowest . . O O
P . . O O
value . . O O
1 . . O O
. . . O O
7 . . O O
x . . O O
10 . . O O
( . . O O
- . . O O
4 . . O O
) . . O O
, . . O O
rs727299 . . B-Mutation O
) . . O O
. . . O O

We . . O O
then . . O O
analysed . . O O
the . . O O
dataset . . O O
incorporating . . O O
information . . O O
on . . O O
the . . O O
functional . . O O
consequences . . O O
of . . O O
nsSNPs . . B-Mutation O
. . . O O

We . . O O
used . . O O
results . . O O
from . . O O
the . . O O
in . . O O
silico . . O O
algorithm . . O O
PolyPhen . . O O
as . . O O
prior . . O O
information . . O O
to . . O O
weight . . O O
the . . O O
association . . O O
statistics . . O O
, . . O O
with . . O O
weights . . O O
estimated . . O O
from . . O O
the . . O O
observed . . O O
test . . O O
statistics . . O O
within . . O O
predefined . . O O
groups . . O O
of . . O O
SNPs . . B-Mutation O
. . . O O

Incorporating . . O O
this . . O O
information . . O O
did . . O O
not . . O O
, . . O O
however . . O O
, . . O O
yield . . O O
any . . O O
further . . O O
evidence . . O O
of . . O O
a . . O O
specific . . O O
association . . O O
( . . O O
lowest . . O O
P . . O O
value . . O O
2 . . O O
. . . O O
2 . . O O
x . . O O
10 . . O O
( . . O O
- . . O O
4 . . O O
) . . O O
, . . O O
rs1133950 . . B-Mutation O
) . . O O
. . . O O

There . . O O
was . . O O
a . . O O
strong . . O O
relationship . . O O
between . . O O
effect . . O O
size . . O O
and . . O O
SNPs . . B-Mutation O
predicted . . O O
to . . O O
be . . O O
damaging . . O O
( . . O O
P . . O O
= . . O O
1 . . O O
. . . O O
63 . . O O
x . . O O
10 . . O O
( . . O O
- . . O O
5 . . O O
) . . O O
) . . O O
, . . O O
however . . O O
, . . O O
these . . O O
variants . . B-Mutation O
which . . O O
are . . O O
most . . O O
likely . . O O
to . . O O
impact . . O O
on . . O O
risk . . O O
are . . O O
rare . . O O
( . . O O
MAF . . O O
< . . O O
5 . . O O
% . . O O
) . . O O
. . . O O

Hence . . O O
although . . O O
the . . O O
rationale . . O O
for . . O O
searching . . O O
for . . O O
low . . O O
- . . O O
penetrance . . O O
cancer . . O O
susceptibly . . O O
alleles . . O O
by . . O O
conducting . . O O
genome . . O O
- . . O O
wide . . O O
scans . . O O
of . . O O
coding . . O O
changes . . O O
is . . O O
strong . . O O
, . . O O
in . . O O
practice . . O O
it . . O O
is . . O O
likely . . O O
that . . O O
natural . . O O
selection . . O O
has . . O O
rendered . . O O
such . . O O
alleles . . O O
to . . O O
be . . O O
too . . O O
rare . . O O
to . . O O
be . . O O
detected . . O O
by . . O O
association . . O O
studies . . O O
of . . O O
the . . O O
size . . O O
employed . . O O
. . . O O

DNA . . O O
mismatch . . O O
repair . . O O
and . . O O
cancer . . O O
. . . O O

The . . O O
genetic . . O O
basis . . O O
of . . O O
cancer . . O O
involves . . O O
certain . . O O
classes . . O O
of . . O O
genes . . O O
, . . O O
particularly . . O O
oncogenes . . O O
, . . O O
tumor . . O O
- . . O O
suppressor . . O O
genes . . O O
, . . O O
and . . O O
DNA . . O O
mismatch . . O O
repair . . O O
genes . . O O
. . . O O

Originally . . O O
identified . . O O
in . . O O
bacteria . . O O
and . . O O
yeast . . O O
, . . O O
the . . O O
human . . O O
homologues . . O O
of . . O O
DNA . . O O
mismatch . . O O
repair . . O O
genes . . O O
have . . O O
been . . O O
implicated . . O O
in . . O O
the . . O O
pathogenesis . . O O
of . . O O
the . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
syndromes . . O O
, . . O O
as . . O O
well . . O O
as . . O O
a . . O O
variety . . O O
of . . O O
different . . O O
sporadic . . O O
cancers . . O O
. . . O O

An . . O O
appreciation . . O O
of . . O O
their . . O O
role . . O O
in . . O O
cancer . . O O
is . . O O
predicated . . O O
on . . O O
an . . O O
understanding . . O O
of . . O O
their . . O O
function . . O O
in . . O O
the . . O O
processes . . O O
of . . O O
DNA . . O O
repair . . O O
. . . O O

This . . O O
article . . O O
reviews . . O O
the . . O O
recent . . O O
developments . . O O
and . . O O
advances . . O O
in . . O O
the . . O O
biology . . O O
of . . O O
the . . O O
human . . O O
DNA . . O O
mismatch . . O O
repair . . O O
genes . . O O
and . . O O
their . . O O
involvement . . O O
in . . O O
the . . O O
pathogenesis . . O O
of . . O O
cancer . . O O
. . . O O

Associations . . O O
of . . O O
single . . B-Mutation B-Mutation
nucleotide . . I-Mutation I-Mutation
polymorphisms . . I-Mutation I-Mutation
in . . O O
miR . . O O
- . . O O
146a . . O O
, . . O O
miR . . O O
- . . O O
196a . . O O
, . . O O
miR . . O O
- . . O O
149 . . O O
and . . O O
miR . . O O
- . . O O
499 . . O O
with . . O O
colorectal . . O O
cancer . . O O
susceptibility . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

MicroRNAs . . O O
( . . O O
miRNAs . . O O
) . . O O
are . . O O
an . . O O
abundant . . O O
class . . O O
of . . O O
endogenous . . O O
small . . O O
non . . O O
- . . O O
coding . . O O
RNAs . . O O
of . . O O
20 . . O O
- . . O O
25 . . O O
nucleotides . . O O
in . . O O
length . . O O
that . . O O
function . . O O
as . . O O
negative . . O O
gene . . O O
regulators . . O O
. . . O O

MiRNAs . . O O
play . . O O
roles . . O O
in . . O O
most . . O O
biological . . O O
processes . . O O
, . . O O
as . . O O
well . . O O
as . . O O
diverse . . O O
human . . O O
diseases . . O O
including . . O O
cancer . . O O
. . . O O

Recently . . O O
, . . O O
many . . O O
studies . . O O
investigated . . O O
the . . O O
association . . O O
between . . O O
SNPs . . B-Mutation O
in . . O O
miR . . O O
- . . O O
146a . . O O
rs2910164 . . B-Mutation B-Mutation
, . . O O
miR . . O O
- . . O O
196a2 . . O O
rs11614913 . . B-Mutation B-Mutation
, . . O O
miR . . O O
- . . O O
149 . . O O
rs229283 . . B-Mutation O
, . . O O
miR . . O O
- . . O O
499 . . O O
rs3746444 . . B-Mutation O
and . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
, . . O O
which . . O O
results . . O O
have . . O O
been . . O O
inconclusive . . O O
. . . O O

# . . O O
# . . O O
METHODOLOGY . . O O
/ . . O O
PRINCIPAL . . O O
FINDINGS . . O O

PubMed . . O O
, . . O O
EMBASE . . O O
, . . O O
CNKI . . O O
databases . . O O
were . . O O
searched . . O O
with . . O O
the . . O O
last . . O O
search . . O O
updated . . O O
on . . O O
November . . O O
5 . . O O
, . . O O
2013 . . O O
. . . O O

For . . O O
miR . . O O
- . . O O
196a2 . . O O
rs11614913 . . B-Mutation B-Mutation
, . . O O
a . . O O
significantly . . O O
decreased . . O O
risk . . O O
of . . O O
CRC . . O O
development . . O O
was . . O O
observed . . O O
under . . O O
three . . O O
genetic . . O O
models . . O O
( . . O O
dominant . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
848 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
735 . . O O
- . . O O
0 . . O O
. . . O O
979 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
025 . . O O
; . . O O
recessive . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
838 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
721 . . O O
- . . O O
0 . . O O
. . . O O
974 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
021 . . O O
; . . O O
homozygous . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
754 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
627 . . O O
- . . O O
0 . . O O
. . . O O
907 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
003 . . O O
) . . O O
. . . O O

In . . O O
the . . O O
subgroup . . O O
analyses . . O O
, . . O O
miR . . O O
- . . O O
196a2 . . O B-Mutation
* . . O I-Mutation
T . . B-Mutation I-Mutation
variant . . I-Mutation I-Mutation
was . . O O
associated . . O O
with . . O O
a . . O O
significantly . . O O
decreased . . O O
susceptibility . . O O
of . . O O
CRC . . O O
( . . O O
allele . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
839 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
749 . . O O
- . . O O
0 . . O O
. . . O O
940 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
000 . . O O
; . . O O
dominant . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
770 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
653 . . O O
- . . O O
0 . . O O
. . . O O
980 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
002 . . O O
; . . O O
recessive . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
802 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
685 . . O O
- . . O O
0 . . O O
. . . O O
939 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
006 . . O O
; . . O O
homozygous . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
695 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
570 . . O O
- . . O O
0 . . O O
. . . O O
847 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
000 . . O O
) . . O O
. . . O O

As . . O O
for . . O O
miR . . O O
- . . O O
149 . . O O
rs2292832 . . B-Mutation O
, . . O O
the . . O O
two . . O O
genetic . . O O
models . . O O
( . . O O
recessive . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
199 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
028 . . O O
- . . O O
1 . . O O
. . . O O
398 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
021 . . O O
; . . O O
heterozygous . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
226 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
039 . . O O
- . . O O
1 . . O O
. . . O O
447 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
013 . . O O
) . . O O
demonstrated . . O O
increased . . O O
susceptibility . . O O
to . . O O
CRC . . O O
. . . O O

On . . O O
subgroup . . O O
analysis . . O O
, . . O O
significantly . . O O
increased . . O O
susceptibility . . O O
of . . O O
CRC . . O O
was . . O O
found . . O O
in . . O O
the . . O O
genetic . . O O
models . . O O
( . . O O
recessive . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
180 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
008 . . O O
- . . O O
1 . . O O
. . . O O
382 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
040 . . O O
; . . O O
heterozygous . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
202 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
013 . . O O
- . . O O
1 . . O O
. . . O O
425 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
013 . . O O
) . . O O
in . . O O
the . . O O
Asian . . O O
group . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

These . . O O
findings . . O O
supported . . O O
that . . O O
the . . O O
miR . . O O
- . . O O
196a2 . . O O
rs11614913 . . B-Mutation B-Mutation
and . . O O
miR . . O O
- . . O O
149 . . O O
rs2292832 . . B-Mutation O
polymorphisms . . B-Mutation B-Mutation
may . . O O
contribute . . O O
to . . O O
susceptibility . . O O
to . . O O
CRC . . O O
. . . O O

Identification . . O O
of . . O O
candidate . . O O
predisposing . . O O
copy . . O B-Mutation
number . . O I-Mutation
variants . . O I-Mutation
in . . O O
familial . . O O
and . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
patients . . O O
. . . O O

In . . O O
the . . O O
majority . . O O
of . . O O
colorectal . . O O
cancers . . O O
( . . O O
CRCs . . O O
) . . O O
under . . O O
clinical . . O O
suspicion . . O O
for . . O O
a . . O O
hereditary . . O O
cause . . O O
, . . O O
the . . O O
disease . . O O
- . . O O
causing . . O O
genetic . . O O
factors . . O O
are . . O O
still . . O O
to . . O O
be . . O O
discovered . . O O
. . . O O

To . . O O
identify . . O O
such . . O O
genetic . . O O
factors . . O O
we . . O O
stringently . . O O
selected . . O O
a . . O O
discovery . . O O
cohort . . O O
of . . O O
41 . . O O
CRC . . O O
index . . O O
patients . . O O
with . . O O
microsatellite . . B-Mutation O
- . . I-Mutation O
stable . . I-Mutation O
tumors . . O O
. . . O O

All . . O O
patients . . O O
were . . O O
below . . O O
40 . . O O
years . . O O
of . . O O
age . . O O
at . . O O
diagnosis . . O O
and . . O O
/ . . O O
or . . O O
exhibited . . O O
an . . O O
overt . . O O
family . . O O
history . . O O
. . . O O

We . . O O
employed . . O O
genome . . O O
- . . O O
wide . . O O
copy . . O O
number . . O O
profiling . . O O
using . . O O
high . . O O
- . . O O
resolution . . O O
SNP . . B-Mutation O
arrays . . O O
on . . O O
germline . . O O
DNA . . O O
, . . O O
which . . O O
resulted . . O O
in . . O O
the . . O O
identification . . O O
of . . O O
novel . . O O
copy . . B-Mutation B-Mutation
number . . I-Mutation I-Mutation
variants . . I-Mutation I-Mutation
( . . O O
CNVs . . B-Mutation O
) . . O O
in . . O O
six . . O O
patients . . O O
( . . O O
15 . . O O
% . . O O
) . . O O
encompassing . . O O
, . . O O
among . . O O
others . . O O
, . . O O
the . . O O
cadherin . . O O
gene . . O O
CDH18 . . O O
, . . O O
the . . O O
bone . . O O
morphogenetic . . O O
protein . . O O
antagonist . . O O
family . . O O
gene . . O O
GREM1 . . O O
, . . O O
and . . O O
the . . O O
breakpoint . . O O
cluster . . O O
region . . O O
gene . . O O
BCR . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
two . . O O
genomic . . O O
deletions . . B-Mutation O
were . . O O
encountered . . O O
encompassing . . O O
two . . O O
microRNA . . O O
genes . . O O
, . . O O
hsa . . O O
- . . O O
mir . . O O
- . . O O
491 . . O O
/ . . O O
KIAA1797 . . O O
and . . O O
hsa . . O O
- . . O O
mir . . O O
- . . O O
646 . . O O
/ . . O O
AK309218 . . O O
. . . O O

None . . O O
of . . O O
these . . O O
CNVs . . B-Mutation O
has . . O O
previously . . O O
been . . O O
reported . . O O
in . . O O
relation . . O O
to . . O O
CRC . . O O
predisposition . . O O
in . . O O
humans . . O O
, . . O O
nor . . O O
were . . O O
they . . O O
encountered . . O O
in . . O O
large . . O O
control . . O O
cohorts . . O O
( . . O O
> . . O O
1 . . O O
, . . O O
600 . . O O
unaffected . . O O
individuals . . O O
) . . O O
. . . O O

Since . . O O
several . . O O
of . . O O
these . . O O
newly . . O O
identified . . O O
candidate . . O O
genes . . O O
may . . O O
be . . O O
functionally . . O O
linked . . O O
to . . O O
CRC . . O O
development . . O O
, . . O O
our . . O O
results . . O O
illustrate . . O O
the . . O O
potential . . O O
of . . O O
this . . O O
approach . . O O
for . . O O
the . . O O
identification . . O O
of . . O O
novel . . O O
candidate . . O O
genes . . O O
involved . . O O
in . . O O
CRC . . O O
predisposition . . O O
. . . O O

Assessing . . O O
disease . . O O
risk . . O O
in . . O O
genome . . B-Mutation O
- . . I-Mutation O
wide . . I-Mutation O
association . . I-Mutation O
studies . . O O
using . . O O
family . . O O
history . . O O
. . . O O

We . . O O
show . . O O
how . . O O
to . . O O
use . . O O
reports . . O O
of . . O O
cancer . . O O
in . . O O
family . . O O
members . . O O
to . . O O
discover . . O O
additional . . O O
genetic . . B-Mutation O
associations . . I-Mutation O
or . . O O
confirm . . O O
previous . . O O
findings . . O O
in . . O O
genome . . B-Mutation O
- . . I-Mutation O
wide . . I-Mutation O
association . . I-Mutation O
( . . O O
GWA . . B-Mutation O
) . . O O
studies . . O O
conducted . . O O
in . . O O
case . . O O
- . . O O
control . . O O
, . . O O
cohort . . O O
, . . O O
or . . O O
cross . . O O
- . . O O
sectional . . O O
studies . . O O
. . . O O

Our . . O O
novel . . O O
family . . O O
history . . O O
- . . O O
based . . O O
approach . . O O
allows . . O O
economical . . O O
association . . O O
studies . . O O
for . . O O
multiple . . O O
cancers . . O O
, . . O O
without . . O O
genotyping . . O O
of . . O O
relatives . . O O
( . . O O
as . . O O
required . . O O
in . . O O
family . . O O
studies . . O O
) . . O O
, . . O O
follow . . O O
- . . O O
up . . O O
of . . O O
participants . . O O
( . . O O
as . . O O
required . . O O
in . . O O
cohort . . O O
studies . . O O
) . . O O
, . . O O
or . . O O
oversampling . . O O
of . . O O
specific . . O O
cancer . . O O
cases . . O O
( . . O O
as . . O O
required . . O O
in . . O O
case . . O O
- . . O O
control . . O O
studies . . O O
) . . O O
. . . O O

We . . O O
empirically . . O O
evaluate . . O O
the . . O O
performance . . O O
of . . O O
the . . O O
proposed . . O O
family . . O O
history . . O O
- . . O O
based . . O O
approach . . O O
in . . O O
studying . . O O
associations . . O O
with . . O O
prostate . . O O
and . . O O
ovarian . . O O
cancers . . O O
, . . O O
using . . O O
data . . O O
from . . O O
GWA . . B-Mutation O
studies . . O O
previously . . O O
conducted . . O O
within . . O O
the . . O O
Prostate . . O O
, . . O O
Lung . . O O
, . . O O
Colorectal . . O O
, . . O O
and . . O O
Ovarian . . O O
Cancer . . O O
Screening . . O O
Trial . . O O
. . . O O

The . . O O
family . . O O
history . . O O
- . . O O
based . . O O
method . . O O
may . . O O
be . . O O
particularly . . O O
useful . . O O
for . . O O
investigating . . O O
genetic . . B-Mutation O
susceptibility . . I-Mutation O
to . . O O
rare . . O O
diseases . . O O
for . . O O
which . . O O
accruing . . O O
cases . . O O
may . . O O
be . . O O
very . . O O
difficult . . O O
, . . O O
by . . O O
using . . O O
disease . . O O
information . . O O
from . . O O
nongenotyped . . O O
relatives . . O O
of . . O O
participants . . O O
in . . O O
multiple . . O O
case . . O O
- . . O O
control . . O O
and . . O O
cohort . . O O
studies . . O O
designed . . O O
primarily . . O O
for . . O O
other . . O O
purposes . . O O
. . . O O

Cost . . O O
- . . O O
effectiveness . . O O
of . . O O
surveillance . . O O
programs . . O O
for . . O O
families . . O O
at . . O O
high . . O O
and . . O O
moderate . . O O
risk . . O O
of . . O O
hereditary . . O O
non . . O O
- . . O O
polyposis . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVES . . O O

Surveillance . . O O
programs . . O O
are . . O O
recommended . . O O
to . . O O
both . . O O
families . . O O
at . . O O
high . . O O
risk . . O O
( . . O O
Amsterdam . . O O
- . . O O
positive . . O O
families . . O O
with . . O O
known . . O O
- . . O O
and . . O O
unknown . . O O
mutation . . O B-Mutation
) . . O O
and . . O O
moderate . . O O
risk . . O O
( . . O O
families . . O O
not . . O O
fulfilling . . O O
all . . O O
Amsterdam . . O O
criteria . . O O
) . . O O
of . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
. . . O O

Cost . . O O
- . . O O
effectiveness . . O O
has . . O O
so . . O O
far . . O O
only . . O O
been . . O O
estimated . . O O
for . . O O
the . . O O
group . . O O
at . . O O
high . . O O
risk . . O O
. . . O O

The . . O O
aim . . O O
of . . O O
the . . O O
present . . O O
study . . O O
is . . O O
to . . O O
determine . . O O
cost . . O O
- . . O O
effectiveness . . O O
of . . O O
surveillance . . O O
programs . . O O
where . . O O
families . . O O
at . . O O
both . . O O
high . . O O
and . . O O
moderate . . O O
risk . . O O
of . . O O
HNPCC . . O O
participate . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

A . . O O
decision . . O O
analytic . . O O
model . . O O
( . . O O
Markov . . O O
model . . O O
) . . O O
is . . O O
developed . . O O
to . . O O
assess . . O O
surveillance . . O O
programs . . O O
where . . O O
families . . O O
at . . O O
high . . O O
and . . O O
moderate . . O O
risk . . O O
of . . O O
HNPCC . . O O
are . . O O
offered . . O O
surveillance . . O O
from . . O O
age . . O O
25 . . O O
and . . O O
age . . O O
45 . . O O
, . . O O
respectively . . O O
. . . O O

The . . O O
model . . O O
includes . . O O
costs . . O O
for . . O O
all . . O O
families . . O O
referred . . O O
to . . O O
genetic . . O O
counseling . . O O
, . . O O
including . . O O
genetic . . O O
risk . . O O
assessment . . O O
, . . O O
mutation . . O B-Mutation
analysis . . O O
, . . O O
and . . O O
surveillance . . O O
in . . O O
relevant . . O O
families . . O O
with . . O O
or . . O O
without . . O O
known . . O O
mutation . . O B-Mutation
, . . O O
plus . . O O
the . . O O
costs . . O O
related . . O O
to . . O O
any . . O O
surgical . . O O
treatment . . O O
. . . O O

The . . O O
risk . . O O
of . . O O
metachronous . . O O
CRC . . O O
is . . O O
also . . O O
modeled . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Incremental . . O O
costs . . O O
per . . O O
life . . O O
year . . O O
gained . . O O
are . . O O
estimated . . O O
to . . O O
be . . O O
euro . . O O
980 . . O O
when . . O O
families . . O O
at . . O O
both . . O O
high . . O O
and . . O O
moderate . . O O
risk . . O O
of . . O O
HNPCC . . O O
undergo . . O O
surveillance . . O O
( . . O O
euro . . O O
508 . . O O
for . . O O
high . . O O
risk . . O O
and . . O O
euro . . O O
1600 . . O O
for . . O O
moderate . . O O
risk . . O O
) . . O O
and . . O O
euro . . O O
1947 . . O O
when . . O O
the . . O O
moderate . . O O
risk . . O O
group . . O O
is . . O O
evaluated . . O O
genetically . . O O
but . . O O
not . . O O
offered . . O O
surveillance . . O O
. . . O O

Sensitivity . . O O
analysis . . O O
showed . . O O
these . . O O
findings . . O O
to . . O O
be . . O O
robust . . O O
, . . O O
although . . O O
cost . . O O
- . . O O
effectiveness . . O O
can . . O O
be . . O O
improved . . O O
in . . O O
cases . . O O
of . . O O
more . . O O
conservative . . O O
referrals . . O O
to . . O O
genetic . . O O
counseling . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

The . . O O
result . . O O
for . . O O
high . . O O
risk . . O O
families . . O O
confirms . . O O
the . . O O
findings . . O O
in . . O O
similar . . O O
studies . . O O
. . . O O

Somewhat . . O O
surprisingly . . O O
, . . O O
cost . . O O
- . . O O
effectiveness . . O O
improves . . O O
when . . O O
surveillance . . O O
of . . O O
the . . O O
moderate . . O O
risk . . O O
groups . . O O
are . . O O
included . . O O
in . . O O
the . . O O
decision . . O O
model . . O O
. . . O O

Genetic . . O O
dissimilarity . . O O
between . . O O
primary . . O O
colorectal . . O O
carcinomas . . O O
and . . O O
their . . O O
lymph . . O O
node . . O O
metastases . . O O
: . . O O
ploidy . . O O
, . . O O
p53 . . O O
, . . O O
bcl . . O O
- . . O O
2 . . O O
, . . O O
and . . O O
c . . O O
- . . O O
myc . . O O
expression . . O O
- . . O O
- . . O O
a . . O O
pilot . . O O
study . . O O
. . . O O

The . . O O
current . . O O
paradigm . . O O
of . . O O
metastasis . . O O
proposes . . O O
that . . O O
rare . . O O
cells . . O O
within . . O O
primary . . O O
tumors . . O O
acquire . . O O
metastatic . . O O
capability . . O O
via . . O O
sequential . . O O
mutations . . B-Mutation B-Mutation
, . . O O
suggesting . . O O
that . . O O
metastases . . O O
are . . O O
genetically . . O O
dissimilar . . O O
from . . O O
their . . O O
primary . . O O
tumors . . O O
. . . O O

This . . O O
study . . O O
investigated . . O O
the . . O O
changes . . O O
in . . O O
the . . O O
level . . O O
of . . O O
expression . . O O
of . . O O
a . . O O
well . . O O
- . . O O
defined . . O O
panel . . O O
of . . O O
cell . . O O
proliferation . . O O
, . . O O
differentiation . . O O
, . . O O
and . . O O
apoptosis . . O O
markers . . O O
between . . O O
the . . O O
primary . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
and . . O O
the . . O O
corresponding . . O O
synchronous . . O O
lymph . . O O
node . . O O
( . . O O
LN . . O O
) . . O O
metastasis . . O O
from . . O O
the . . O O
same . . O O
patients . . O O
. . . O O

DNA . . O O
flow . . O O
cytometry . . O O
and . . O O
immunostaining . . O O
of . . O O
p53 . . O O
, . . O O
bcl . . O O
- . . O O
2 . . O O
, . . O O
and . . O O
c . . O O
- . . O O
myc . . O O
were . . O O
carried . . O O
out . . O O
on . . O O
36 . . O O
cases . . O O
of . . O O
CRC . . O O
radical . . O O
resection . . O O
specimens . . O O
with . . O O
their . . O O
corresponding . . O O
LN . . O O
metastases . . O O
. . . O O

There . . O O
was . . O O
very . . O O
low . . O O
probability . . O O
that . . O O
the . . O O
histological . . O O
patterns . . O O
of . . O O
primary . . O O
tumors . . O O
and . . O O
LN . . O O
metastases . . O O
are . . O O
independent . . O O
( . . O O
p . . O O
< . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
. . . O O

Metastatic . . O O
tumors . . O O
were . . O O
significantly . . O O
more . . O O
diffusely . . O O
positive . . O O
for . . O O
p53 . . O O
than . . O O
the . . O O
primary . . O O
tumors . . O O
( . . O O
p . . O O
< . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
. . . O O

Conversely . . O O
, . . O O
primary . . O O
tumors . . O O
were . . O O
significantly . . O O
more . . O O
diffusely . . O O
positive . . O O
for . . O O
c . . O O
- . . O O
myc . . O O
than . . O O
metastatic . . O O
tumors . . O O
( . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
011 . . O O
) . . O O
. . . O O

No . . O O
significant . . O O
difference . . O O
was . . O O
found . . O O
between . . O O
the . . O O
LNs . . O O
and . . O O
the . . O O
primary . . O O
tumors . . O O
in . . O O
bcl . . O O
- . . O O
2 . . O O
positivity . . O O
( . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
538 . . O O
) . . O O
and . . O O
DNA . . O O
aneuploidy . . B-Mutation O
( . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
35 . . O O
) . . O O
, . . O O
with . . O O
a . . O O
tendency . . O O
towards . . O O
negative . . O O
bcl . . O O
- . . O O
2 . . O O
and . . O O
less . . O O
aneuploidy . . B-Mutation O
in . . O O
LN . . O O
metastases . . O O
than . . O O
primary . . O O
tumors . . O O
. . . O O

In . . O O
conclusion . . O O
, . . O O
LN . . O O
metastatic . . O O
colorectal . . O O
carcinomas . . O O
have . . O O
a . . O O
tendency . . O O
of . . O O
being . . O O
less . . O O
differentiated . . O O
, . . O O
with . . O O
a . . O O
higher . . O O
incidence . . O O
of . . O O
diffuse . . O O
p53 . . O O
staining . . O O
, . . O O
lower . . O O
incidence . . O O
of . . O O
bcl . . O O
- . . O O
2 . . O O
staining . . O O
, . . O O
and . . O O
less . . O O
aneuploidy . . B-Mutation O
in . . O O
comparison . . O O
to . . O O
their . . O O
primary . . O O
counterparts . . O O
suggesting . . O O
a . . O O
more . . O O
aggressive . . O O
biological . . O O
behavior . . O O
, . . O O
which . . O O
could . . O O
indicate . . O O
the . . O O
necessity . . O O
for . . O O
more . . O O
aggressive . . O O
adjuvant . . O O
therapy . . O O
. . . O O

Large . . O O
- . . O O
scale . . O O
evaluation . . O O
of . . O O
genetic . . B-Mutation O
variants . . I-Mutation O
in . . O O
candidate . . O O
genes . . O O
for . . O O
colorectal . . O O
cancer . . O O
risk . . O O
in . . O O
the . . O O
Nurses . . O O
' . . O O
Health . . O O
Study . . O O
and . . O O
the . . O O
Health . . O O
Professionals . . O O
' . . O O
Follow . . O O
- . . O O
up . . O O
Study . . O O
. . . O O

Advances . . O O
in . . O O
genomics . . O O
offer . . O O
new . . O O
strategies . . O O
for . . O O
assessing . . O O
the . . O O
association . . O O
of . . O O
common . . O O
genetic . . B-Mutation O
variations . . I-Mutation O
at . . O O
multiple . . O O
loci . . O O
and . . O O
risk . . O O
of . . O O
many . . O O
diseases . . O O
, . . O O
including . . O O
colorectal . . O O
cancer . . O O
. . . O O

Low . . O O
- . . O O
penetrance . . O O
alleles . . O O
of . . O O
genes . . O O
in . . O O
many . . O O
biological . . O O
pathways . . O O
, . . O O
such . . O O
as . . O O
DNA . . O O
repair . . O O
, . . O O
metabolism . . O O
, . . O O
inflammation . . O O
, . . O O
cell . . O O
cycle . . O O
, . . O O
apoptosis . . O O
, . . O O
and . . O O
Wnt . . O O
signaling . . O O
, . . O O
may . . O O
influence . . O O
the . . O O
risk . . O O
of . . O O
nonfamilial . . O O
colorectal . . O O
cancer . . O O
. . . O O

To . . O O
identify . . O O
susceptibility . . O O
genes . . O O
for . . O O
colorectal . . O O
cancer . . O O
, . . O O
we . . O O
designed . . O O
a . . O O
large . . O O
- . . O O
scale . . O O
case . . O O
- . . O O
control . . O O
association . . O O
study . . O O
nested . . O O
within . . O O
the . . O O
Nurses . . O O
' . . O O
Health . . O O
Study . . O O
( . . O O
190 . . O O
cases . . O O
and . . O O
190 . . O O
controls . . O O
) . . O O
and . . O O
the . . O O
Health . . O O
Professionals . . O O
' . . O O
Follow . . O O
- . . O O
up . . O O
Study . . O O
( . . O O
168 . . O O
cases . . O O
and . . O O
168 . . O O
controls . . O O
) . . O O
. . . O O

We . . O O
used . . O O
a . . O O
custom . . O O
GoldenGate . . O O
( . . O O
Illumina . . O O
) . . O O
oligonucleotide . . O O
pool . . O O
assay . . O O
including . . O O
1 . . O O
, . . O O
536 . . O O
single . . B-Mutation O
nucleotide . . I-Mutation O
polymorphisms . . I-Mutation O
( . . O O
SNP . . B-Mutation B-Mutation
) . . O O
selected . . O O
in . . O O
candidate . . O O
genes . . O O
from . . O O
cancer . . O O
- . . O O
related . . O O
pathways . . O O
, . . O O
which . . O O
have . . O O
been . . O O
sequenced . . O O
and . . O O
genotyped . . O O
in . . O O
the . . O O
SNP500Cancer . . O O
project . . O O
; . . O O
1 . . O O
, . . O O
412 . . O O
of . . O O
the . . O O
1 . . O O
, . . O O
536 . . O O
( . . O O
92 . . O O
% . . O O
) . . O O
of . . O O
the . . O O
SNPs . . B-Mutation O
were . . O O
genotyped . . O O
successfully . . O O
within . . O O
388 . . O O
genes . . O O
. . . O O

SNPs . . B-Mutation O
in . . O O
high . . O O
linkage . . O O
disequilibrium . . O O
( . . O O
r . . O O
( . . O O
2 . . O O
) . . O O
> . . O O
/ . . O O
= . . O O
0 . . O O
. . . O O
90 . . O O
) . . O O
with . . O O
another . . O O
assayed . . O O
SNP . . B-Mutation O
were . . O O
excluded . . O O
from . . O O
further . . O O
analyses . . O O
. . . O O

As . . O O
expected . . O O
by . . O O
chance . . O O
( . . O O
and . . O O
not . . O O
significant . . O O
compared . . O O
with . . O O
a . . O O
corrected . . O O
Bonferroni . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
00004 . . O O
) . . O O
, . . O O
in . . O O
the . . O O
additive . . O O
model . . O O
, . . O O
11 . . O O
of . . O O
1 . . O O
, . . O O
253 . . O O
( . . O O
0 . . O O
. . . O O
9 . . O O
% . . O O
) . . O O
SNPs . . B-Mutation O
had . . O O
a . . O O
P . . O O
( . . O O
trend . . O O
) . . O O
< . . O O
0 . . O O
. . . O O
01 . . O O
and . . O O
38 . . O O
of . . O O
1 . . O O
, . . O O
253 . . O O
( . . O O
3 . . O O
. . . O O
0 . . O O
% . . O O
) . . O O
SNPs . . B-Mutation O
had . . O O
a . . O O
P . . O O
( . . O O
trend . . O O
) . . O O
> . . O O
/ . . O O
= . . O O
0 . . O O
. . . O O
01 . . O O
and . . O O
P . . O O
( . . O O
trend . . O O
) . . O O
< . . O O
0 . . O O
. . . O O
05 . . O O
. . . O O

Of . . O O
note . . O O
, . . O O
the . . O O
MGMT . . O O
Lys . . B-Mutation O
( . . I-Mutation O
178 . . I-Mutation O
) . . I-Mutation O
Arg . . I-Mutation O
( . . O O
rs2308237 . . B-Mutation O
) . . O O
SNP . . B-Mutation B-Mutation
, . . O O
in . . O O
linkage . . O O
disequilibrium . . O O
with . . O O
the . . O O
previously . . O O
reported . . O O
MGMT . . O O
Ile . . B-Mutation O
( . . I-Mutation O
143 . . I-Mutation O
) . . I-Mutation O
Val . . I-Mutation O
SNP . . B-Mutation B-Mutation
, . . O O
had . . O O
an . . O O
inverse . . O O
association . . O O
with . . O O
colorectal . . O O
cancer . . O O
risk . . O O
( . . O O
MGMT . . O O
Lys . . B-Mutation O
( . . I-Mutation O
178 . . I-Mutation O
) . . I-Mutation O
Arg . . I-Mutation O
: . . O O
odds . . O O
ratio . . O O
, . . O O
0 . . O O
. . . O O
52 . . O O
; . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
, . . O O
0 . . O O
. . . O O
35 . . O O
- . . O O
0 . . O O
. . . O O
78 . . O O
; . . O O
unadjusted . . O O
P . . O O
( . . O O
trend . . O O
) . . O O
= . . O O
0 . . O O
. . . O O
0003 . . O O
for . . O O
the . . O O
additive . . O O
model . . O O
; . . O O
gene . . O O
- . . O O
based . . O O
test . . O O
global . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
00003 . . O O
) . . O O
. . . O O

The . . O O
SNP500Cancer . . O O
database . . O O
and . . O O
the . . O O
Illumina . . O O
GoldenGate . . O O
Assay . . O O
allowed . . O O
us . . O O
to . . O O
test . . O O
a . . O O
larger . . O O
number . . O O
of . . O O
SNPs . . B-Mutation O
than . . O O
previously . . O O
possible . . O O
. . . O O

We . . O O
identified . . O O
several . . O O
SNPs . . B-Mutation O
worthy . . O O
of . . O O
investigation . . O O
in . . O O
larger . . O O
studies . . O O
. . . O O

Summary . . O O
of . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
test . . O O
results . . O O
from . . O O
laboratories . . O O
participating . . O O
in . . O O
proficiency . . O O
surveys . . O O
: . . O O
proficiency . . O O
survey . . O O
results . . O O
from . . O O
2005 . . O O
to . . O O
2012 . . O O
. . . O O

# . . O O
# . . O O
CONTEXT . . O O

The . . O O
College . . O O
of . . O O
American . . O O
Pathologists . . O O
surveys . . O O
are . . O O
the . . O O
largest . . O O
laboratory . . O O
peer . . O O
comparison . . O O
programs . . O O
in . . O O
the . . O O
world . . O O
. . . O O

These . . O O
programs . . O O
allow . . O O
laboratories . . O O
to . . O O
regularly . . O O
evaluate . . O O
their . . O O
performance . . O O
and . . O O
improve . . O O
the . . O O
accuracy . . O O
of . . O O
the . . O O
patient . . O O
test . . O O
results . . O O
they . . O O
provide . . O O
. . . O O

Proficiency . . O O
testing . . O O
is . . O O
offered . . O O
twice . . O O
a . . O O
year . . O O
to . . O O
laboratories . . O O
performing . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
testing . . O O
. . . O O

These . . O O
surveys . . O O
are . . O O
designed . . O O
to . . O O
emulate . . O O
clinical . . O O
practice . . O O
, . . O O
and . . O O
some . . O O
surveys . . O O
have . . O O
more . . O O
challenging . . O O
cases . . O O
to . . O O
encourage . . O O
the . . O O
refinement . . O O
of . . O O
laboratory . . O O
practices . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVE . . O O

This . . O O
report . . O O
summarizes . . O O
the . . O O
results . . O O
and . . O O
trends . . O O
in . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
proficiency . . O O
testing . . O O
from . . O O
participating . . O O
laboratories . . O O
from . . O O
the . . O O
inception . . O O
of . . O O
the . . O O
program . . O O
in . . O O
2005 . . O O
through . . O O
2012 . . O O
. . . O O

# . . O O
# . . O O
DESIGN . . O O

We . . O O
compiled . . O O
and . . O O
analyzed . . O O
data . . O O
for . . O O
16 . . O O
surveys . . O O
of . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
proficiency . . O O
testing . . O O
during . . O O
2005 . . O O
to . . O O
2012 . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
number . . O O
of . . O O
laboratories . . O O
participating . . O O
in . . O O
the . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
survey . . O O
has . . O O
more . . O O
than . . O O
doubled . . O O
from . . O O
42 . . O O
to . . O O
104 . . O O
during . . O O
the . . O O
8 . . O O
years . . O O
analyzed . . O O
. . . O O

An . . O O
average . . O O
of . . O O
95 . . O O
. . . O O
4 . . O O
% . . O O
of . . O O
the . . O O
laboratories . . O O
correctly . . O O
classified . . O O
each . . O O
of . . O O
the . . O O
survey . . O O
test . . O O
samples . . O O
from . . O O
the . . O O
2005A . . O O
through . . O O
2012B . . O O
proficiency . . O O
challenges . . O O
. . . O O

In . . O O
the . . O O
2011B . . O O
survey . . O O
, . . O O
a . . O O
lower . . O O
percentage . . O O
of . . O O
laboratories . . O O
( . . O O
78 . . O O
. . . O O
4 . . O O
% . . O O
) . . O O
correctly . . O O
classified . . O O
the . . O O
specimen . . O O
, . . O O
possibly . . O O
because . . O O
of . . O O
overlooking . . O O
subtle . . O O
changes . . O O
of . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
and . . O O
/ . . O O
or . . O O
failing . . O O
to . . O O
enrich . . O O
the . . O O
tumor . . O O
content . . O O
of . . O O
the . . O O
specimen . . O O
to . . O O
meet . . O O
the . . O O
limit . . O O
of . . O O
detection . . O O
of . . O O
their . . O O
assay . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

In . . O O
general . . O O
, . . O O
laboratories . . O O
performed . . O O
well . . O O
in . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
testing . . O O
. . . O O

This . . O O
testing . . O O
will . . O O
continue . . O O
to . . O O
be . . O O
important . . O O
in . . O O
screening . . O O
patients . . O O
with . . O O
colorectal . . O O
and . . O O
other . . O O
cancers . . O O
for . . O O
Lynch . . O O
syndrome . . O O
and . . O O
guiding . . O O
the . . O O
management . . O O
of . . O O
patients . . O O
with . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
. . . O O

Deregulation . . O O
of . . O O
Cdk2 . . O O
causes . . O O
Bim . . O O
- . . O O
mediated . . O O
apoptosis . . O O
in . . O O
p53 . . O O
- . . O O
deficient . . O O
tumors . . O O
following . . O O
actin . . O O
damage . . O O
. . . O O

We . . O O
previously . . O O
reported . . O O
that . . O O
actin . . O O
damage . . O O
by . . O O
treatment . . O O
with . . O O
an . . O O
actin . . O O
- . . O O
depolymerizing . . O O
agent . . O O
including . . O O
pectenotoxin . . O O
- . . O O
2 . . O O
induces . . O O
Bim . . O O
- . . O O
mediated . . O O
apoptosis . . O O
in . . O O
p53 . . O O
- . . O O
deficient . . O O
human . . O O
tumors . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
investigated . . O O
a . . O O
molecular . . O O
mechanism . . O O
underlying . . O O
Bim . . O O
- . . O O
mediated . . O O
apoptosis . . O O
of . . O O
p53 . . O O
- . . O O
deficient . . O O
tumor . . O O
cells . . O O
following . . O O
actin . . O O
damage . . O O
. . . O O

We . . O O
found . . O O
that . . O O
actin . . O O
inhibitors . . O O
increased . . O O
the . . O O
protein . . O O
levels . . O O
of . . O O
p53 . . O O
and . . O O
p21 . . O O
and . . O O
thereby . . O O
inactivated . . O O
both . . O O
Cdk2 . . O O
and . . O O
Cdc2 . . O O
kinases . . O O
. . . O O

However . . O O
, . . O O
p53 . . O O
- . . O O
or . . O O
p21 . . O O
- . . O O
knockout . . O O
cells . . O O
fail . . O O
to . . O O
induce . . O O
p21 . . O O
and . . O O
hence . . O O
kept . . O O
both . . O O
Cdk2 . . O O
and . . O O
Cdc2 . . O O
kinases . . O O
active . . O O
even . . O O
after . . O O
treatment . . O O
with . . O O
actin . . O O
inhibitor . . O O
. . . O O

The . . O O
p53 . . O O
- . . O O
or . . O O
p21 . . O O
- . . O O
knockout . . O O
cells . . O O
became . . O O
multinucleate . . O O
and . . O O
polyploidy . . O O
in . . O O
association . . O O
with . . O O
induction . . O O
of . . O O
apoptosis . . O O
. . . O O

Expression . . O O
of . . O O
Bcl . . O O
- . . O O
x . . O O
( . . O O
L . . O O
) . . O O
resulted . . O O
in . . O O
accumulation . . O O
of . . O O
polyploid . . O O
cells . . O O
in . . O O
association . . O O
with . . O O
inhibition . . O O
of . . O O
apoptosis . . O O
. . . O O

However . . O O
, . . O O
expression . . O O
of . . O O
a . . O O
dominant . . B-Mutation O
negative . . I-Mutation O
mutant . . I-Mutation O
( . . O O
Cdk2dn . . O O
) . . O O
and . . O O
treatment . . O O
with . . O O
chemical . . O O
inhibitors . . O O
for . . O O
Cdk2 . . O O
suppressed . . O O
not . . O O
only . . O O
accumulation . . O O
of . . O O
multinucleated . . O O
cells . . O O
, . . O O
but . . O O
also . . O O
induction . . O O
of . . O O
Bim . . O O
expression . . O O
and . . O O
apoptosis . . O O
. . . O O

Therefore . . O O
, . . O O
these . . O O
results . . O O
suggest . . O O
that . . O O
Bim . . O O
- . . O O
mediated . . O O
apoptosis . . O O
following . . O O
actin . . O O
damage . . O O
due . . O O
to . . O O
deregulation . . O O
of . . O O
Cdk2 . . O O
and . . O O
the . . O O
cell . . O O
cycle . . O O
by . . O O
the . . O O
absence . . O O
of . . O O
functional . . O O
p53 . . O O
. . . O O

Antibody . . O O
to . . O O
ras . . O O
proteins . . O O
in . . O O
patients . . O O
with . . O O
colon . . O O
cancer . . O O
. . . O O

The . . O O
current . . O O
study . . O O
examined . . O O
sera . . O O
from . . O O
160 . . O O
colon . . O O
cancer . . O O
patients . . O O
and . . O O
60 . . O O
normal . . O O
individuals . . O O
to . . O O
determine . . O O
whether . . O O
antibody . . O O
to . . O O
mutated . . B-Mutation O
p21 . . O O
ras . . O O
protein . . O O
was . . O O
present . . O O
. . . O O

Studies . . O O
focused . . O O
on . . O O
the . . O O
aspartic . . B-Mutation O
acid . . I-Mutation O
substitution . . I-Mutation O
at . . I-Mutation O
amino . . I-Mutation O
acid . . I-Mutation O
position . . I-Mutation O
12 . . I-Mutation O
( . . O O
denoted . . O O
D12 . . B-Mutation O
) . . O O
, . . O O
one . . O O
of . . O O
the . . O O
most . . O O
common . . O O
mutations . . B-Mutation B-Mutation
in . . O O
colon . . O O
adenocarcinoma . . O O
. . . O O

IgA . . O O
antibodies . . O O
directed . . O O
against . . O O
mutated . . B-Mutation B-Mutation
p21 . . O O
ras . . O O
- . . O O
D12 . . O O
protein . . O O
were . . O O
detected . . O O
in . . O O
51 . . O O
( . . O O
32 . . O O
% . . O O
) . . O O
of . . O O
160 . . O O
colon . . O O
cancer . . O O
patients . . O O
, . . O O
but . . O O
only . . O O
in . . O O
1 . . O O
( . . O O
2 . . O O
. . . O O
5 . . O O
% . . O O
) . . O O
of . . O O
40 . . O O
normal . . O O
individuals . . O O
. . . O O

The . . O O
greater . . O O
incidence . . O O
of . . O O
antibody . . O O
in . . O O
cancer . . O O
patients . . O O
provides . . O O
presumptive . . O O
evidence . . O O
that . . O O
immunization . . O O
to . . O O
the . . O O
ras . . O O
proteins . . O O
occurred . . O O
as . . O O
a . . O O
result . . O O
of . . O O
the . . O O
malignancy . . O O
. . . O O

Examination . . O O
of . . O O
sera . . O O
for . . O O
antibody . . O O
reactivity . . O O
to . . O O
wild . . O O
- . . O O
type . . O O
p21 . . O O
ras . . O O
protein . . O O
( . . O O
denoted . . O O
p21 . . O O
ras . . O O
- . . O O
G12 . . O O
) . . O O
as . . O O
well . . O O
as . . O O
p21 . . O O
ras . . O O
proteins . . O O
bearing . . O O
the . . O O
D12 . . B-Mutation O
, . . O O
V12 . . B-Mutation O
, . . O O
S12 . . B-Mutation O
, . . O O
or . . O O
L61 . . B-Mutation O
mutations . . B-Mutation B-Mutation
showed . . O O
that . . O O
antibody . . O O
detected . . O O
was . . O O
largely . . O O
to . . O O
normal . . O O
segments . . O O
of . . O O
the . . O O
p21 . . O O
ras . . O O
protein . . O O
. . . O O

Epitope . . O O
mapping . . O O
, . . O O
using . . O O
peptide . . O O
neutralization . . O O
assays . . O O
with . . O O
mutated . . B-Mutation B-Mutation
or . . O O
normal . . O O
ras . . O O
peptides . . O O
as . . O O
competitors . . O O
, . . O O
demonstrated . . O O
that . . O O
in . . O O
10 . . O O
( . . O O
67 . . O O
% . . O O
) . . O O
of . . O O
15 . . O O
sera . . O O
examined . . O O
the . . O O
antibody . . O O
reactivity . . O O
to . . O O
p21 . . O O
ras . . O O
- . . O O
G12 . . O O
protein . . O O
was . . O O
neutralized . . O O
by . . O O
peptides . . O O
near . . O O
the . . O O
carboxyl . . O O
terminus . . O O
of . . O O
p21 . . O O
ras . . O O
protein . . O O
, . . O O
but . . O O
not . . O O
by . . O O
peptides . . O O
spanning . . O O
the . . O O
specific . . O O
point . . B-Mutation O
mutation . . I-Mutation B-Mutation
region . . O O
. . . O O

Antibody . . O O
reactivities . . O O
correlated . . O O
with . . O O
peripheral . . O O
blood . . O O
lymphocyte . . O O
count . . O O
, . . O O
but . . O O
did . . O O
not . . O O
correlate . . O O
with . . O O
patient . . O O
age . . O O
, . . O O
sex . . O O
, . . O O
histology . . O O
, . . O O
stage . . O O
, . . O O
tumor . . O O
locus . . O O
, . . O O
lymph . . O O
node . . O O
metastasis . . O O
, . . O O
or . . O O
serum . . O O
carcinoembryonic . . O O
antigen . . O O
. . . O O

Editorial . . O O
: . . O O
sessile . . O O
serrated . . O O
adenomas . . O O
and . . O O
their . . O O
pit . . O O
patterns . . O O
: . . O O
we . . O O
must . . O O
first . . O O
see . . O O
the . . O O
forest . . O O
through . . O O
the . . O O
trees . . O O
. . . O O

Serrated . . O O
lesions . . O O
of . . O O
the . . O O
colorectum . . O O
include . . O O
hyperplastic . . O O
polyps . . O O
, . . O O
which . . O O
are . . O O
non . . O O
- . . O O
neoplastic . . O O
, . . O O
and . . O O
sessile . . O O
serrated . . O O
adenomas . . O O
( . . O O
SSAs . . O O
, . . O O
also . . O O
known . . O O
as . . O O
sessile . . O O
serrated . . O O
polyps . . O O
) . . O O
and . . O O
traditional . . O O
serrated . . O O
adenomas . . O O
, . . O O
which . . O O
are . . O O
premalignant . . O O
. . . O O

It . . O O
is . . O O
believed . . O O
that . . O O
up . . O O
to . . O O
30 . . O O
% . . O O
of . . O O
colon . . O O
cancers . . O O
and . . O O
many . . O O
post . . O O
- . . O O
colonoscopy . . O O
cancers . . O O
arise . . O O
from . . O O
serrated . . O O
neoplasms . . O O
. . . O O

Post . . O O
- . . O O
colonoscopy . . O O
cancers . . O O
have . . O O
been . . O O
found . . O O
to . . O O
have . . O O
a . . O O
molecular . . O O
signature . . O O
similar . . O O
to . . O O
SSAs . . O O
, . . O O
including . . O O
CpG . . O O
island . . O O
methylation . . O O
, . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
, . . O O
and . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
. . . O O

A . . O O
novel . . O O
pit . . O O
pattern . . O O
, . . O O
Type . . O O
II . . O O
- . . O O
O . . O O
, . . O O
has . . O O
been . . O O
demonstrated . . O O
to . . O O
have . . O O
a . . O O
high . . O O
specificity . . O O
for . . O O
SSAs . . O O
. . . O O

Unfortunately . . O O
, . . O O
the . . O O
sensitivity . . O O
is . . O O
too . . O O
low . . O O
to . . O O
utilize . . O O
a . . O O
Type . . O O
II . . O O
- . . O O
O . . O O
pit . . O O
pattern . . O O
to . . O O
determine . . O O
which . . O O
serrated . . O O
lesion . . O O
is . . O O
neoplastic . . O O
and . . O O
needs . . O O
resection . . O O
. . . O O

Moreover . . O O
, . . O O
there . . O O
is . . O O
significant . . O O
endoscopist . . O O
- . . O O
related . . O O
variability . . O O
in . . O O
the . . O O
detection . . O O
of . . O O
serrated . . O O
lesions . . O O
of . . O O
the . . O O
colon . . O O
. . . O O

Efforts . . O O
to . . O O
improve . . O O
the . . O O
detection . . O O
of . . O O
serrated . . O O
neoplasms . . O O
are . . O O
warranted . . O O
. . . O O

Mismatch . . O O
repair . . O O
defects . . O O
and . . O O
Lynch . . O O
syndrome . . O O
: . . O O
The . . O O
role . . O O
of . . O O
the . . O O
basic . . O O
scientist . . O O
in . . O O
the . . O O
battle . . O O
against . . O O
cancer . . O O
. . . O O

We . . O O
have . . O O
currently . . O O
entered . . O O
a . . O O
genomic . . O O
era . . O O
of . . O O
cancer . . O O
research . . O O
which . . O O
may . . O O
soon . . O O
lead . . O O
to . . O O
a . . O O
genomic . . O O
era . . O O
of . . O O
cancer . . O O
treatment . . O O
. . . O O

Patient . . O O
DNA . . O O
sequencing . . O O
information . . O O
may . . O O
lead . . O O
to . . O O
a . . O O
personalized . . O O
approach . . O O
to . . O O
managing . . O O
an . . O O
individual . . O O
' . . O O
s . . O O
cancer . . O O
as . . O O
well . . O O
as . . O O
future . . O O
cancer . . O O
risk . . O O
. . . O O

The . . O O
success . . O O
of . . O O
this . . O O
approach . . O O
, . . O O
however . . O O
, . . O O
begins . . O O
not . . O O
necessarily . . O O
in . . O O
the . . O O
clinician . . O O
' . . O O
s . . O O
office . . O O
, . . O O
but . . O O
rather . . O O
at . . O O
the . . O O
laboratory . . O O
bench . . O O
of . . O O
the . . O O
basic . . O O
scientist . . O O
. . . O O

The . . O O
basic . . O O
scientist . . O O
plays . . O O
a . . O O
critical . . O O
role . . O O
since . . O O
the . . O O
DNA . . O O
sequencing . . O O
information . . O O
is . . O O
of . . O O
limited . . O O
use . . O O
unless . . O O
one . . O O
knows . . O O
the . . O O
function . . O O
of . . O O
the . . O O
gene . . O O
that . . O O
is . . O O
altered . . O O
and . . O O
the . . O O
manner . . O O
by . . O O
which . . O O
a . . O O
sequence . . O O
alteration . . O O
affects . . O O
that . . O O
function . . O O
. . . O O

The . . O O
role . . O O
of . . O O
basic . . O O
science . . O O
research . . O O
in . . O O
aiding . . O O
the . . O O
clinical . . O O
management . . O O
of . . O O
a . . O O
disease . . O O
is . . O O
perhaps . . O O
best . . O O
exemplified . . O O
by . . O O
considering . . O O
the . . O O
case . . O O
of . . O O
Lynch . . O O
syndrome . . O O
, . . O O
a . . O O
hereditary . . O O
disease . . O O
that . . O O
predisposes . . O O
patients . . O O
to . . O O
colorectal . . O O
and . . O O
other . . O O
cancers . . O O
. . . O O

This . . O O
review . . O O
will . . O O
examine . . O O
how . . O O
the . . O O
diagnosis . . O O
, . . O O
treatment . . O O
and . . O O
even . . O O
prevention . . O O
of . . O O
Lynch . . O O
syndrome . . O O
- . . O O
associated . . O O
cancers . . O O
has . . O O
benefitted . . O O
from . . O O
extensive . . O O
basic . . O O
science . . O O
research . . O O
on . . O O
the . . O O
DNA . . O O
mismatch . . O O
repair . . O O
genes . . O O
whose . . O O
alteration . . O O
underlies . . O O
this . . O O
condition . . O O
. . . O O

Instability . . O O
at . . O O
the . . O O
FRA8I . . O O
common . . O O
fragile . . O O
site . . O O
disrupts . . O O
the . . O O
genomic . . O O
integrity . . O O
of . . O O
the . . O O
KIAA0146 . . O O
, . . O O
CEBPD . . O O
and . . O O
PRKDC . . O O
genes . . O O
in . . O O
colorectal . . O O
cancer . . O O
. . . O O

Specific . . O O
patterns . . O O
of . . O O
genomic . . O O
aberrations . . O O
have . . O O
been . . O O
associated . . O O
with . . O O
different . . O O
types . . O O
of . . O O
malignancies . . O O
. . . O O

In . . O O
colorectal . . O O
cancer . . O O
, . . O O
losses . . O O
of . . O O
chromosome . . O O
arm . . O O
8p . . O O
and . . O O
gains . . O O
of . . O O
chromosome . . O O
arm . . O O
8q . . O O
are . . O O
among . . O O
the . . O O
most . . O O
common . . O O
chromosomal . . O O
rearrangements . . O O
, . . O O
suggesting . . O O
that . . O O
the . . O O
centromeric . . O O
portion . . O O
of . . O O
chromosome . . O O
8 . . O O
is . . O O
particularly . . O O
sensitive . . O O
to . . O O
breakage . . O O
. . . O O

Genomic . . O O
alterations . . O O
frequently . . O O
occur . . O O
in . . O O
the . . O O
early . . O O
stages . . O O
of . . O O
tumorigenesis . . O O
at . . O O
specific . . O O
genomic . . O O
regions . . O O
known . . O O
as . . O O
common . . O O
fragile . . O O
sites . . O O
( . . O O
cFSs . . O O
) . . O O
. . . O O

CFSs . . O O
represent . . O O
parts . . O O
of . . O O
the . . O O
normal . . O O
chromosome . . O O
structure . . O O
that . . O O
are . . O O
prone . . O O
to . . O O
breakage . . O O
under . . O O
replication . . O O
stress . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
identified . . O O
the . . O O
genomic . . O O
location . . O O
of . . O O
FRA8I . . O O
, . . O O
spanning . . O O
530 . . O O
kb . . O O
at . . O O
8q11 . . O O
. . . O O
21 . . O O
and . . O O
assessed . . O O
the . . O O
composition . . O O
of . . O O
the . . O O
fragile . . O O
DNA . . O O
sequence . . O O
. . . O O

FRA8I . . O O
encompasses . . O O
KIAA0146 . . O O
, . . O O
a . . O O
large . . O O
protein . . O O
- . . O O
coding . . O O
gene . . O O
with . . O O
yet . . O O
unknown . . O O
function . . O O
, . . O O
as . . O O
well . . O O
as . . O O
CEBPD . . O O
and . . O O
part . . O O
of . . O O
PRKDC . . O O
, . . O O
two . . O O
genes . . O O
encoding . . O O
proteins . . O O
involved . . O O
in . . O O
tumorigenesis . . O O
in . . O O
a . . O O
variety . . O O
of . . O O
cancers . . O O
. . . O O

We . . O O
show . . O O
that . . O O
FRA8I . . O O
is . . O O
unstable . . O O
in . . O O
lymphocytes . . O O
and . . O O
epithelial . . O O
cells . . O O
, . . O O
displaying . . O O
similar . . O O
expression . . O O
rates . . O O
. . . O O

We . . O O
examined . . O O
copy . . O O
number . . O O
alteration . . O O
patterns . . O O
within . . O O
FRA8I . . O O
in . . O O
a . . O O
panel . . O O
of . . O O
25 . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
and . . O O
surveyed . . O O
publically . . O O
available . . O O
profiles . . O O
of . . O O
56 . . O O
additional . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
. . . O O

Combining . . O O
these . . O O
data . . O O
shows . . O O
that . . O O
focal . . O O
recombination . . O O
events . . O O
disrupt . . O O
the . . O O
genomic . . O O
integrity . . O O
of . . O O
KIAA0146 . . O O
and . . O O
neighboring . . O O
cFS . . O O
genes . . O O
in . . O O
12 . . O O
. . . O O
3 . . O O
% . . O O
of . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
. . . O O

Moreover . . O O
, . . O O
data . . O O
analysis . . O O
revealed . . O O
evidence . . O O
that . . O O
KIAA0146 . . O O
is . . O O
a . . O O
translocation . . O O
partner . . O O
of . . O O
the . . O O
immunoglobulin . . O O
heavy . . O O
chain . . O O
gene . . O O
in . . O O
recurrent . . O B-Mutation
t . . B-Mutation I-Mutation
( . . I-Mutation I-Mutation
8 . . I-Mutation I-Mutation
; . . I-Mutation I-Mutation
14 . . I-Mutation I-Mutation
) . . I-Mutation I-Mutation
( . . I-Mutation I-Mutation
q11 . . I-Mutation I-Mutation
; . . I-Mutation I-Mutation
q32 . . I-Mutation I-Mutation
) . . I-Mutation I-Mutation
translocations . . O I-Mutation
in . . O O
a . . O O
subset . . O O
of . . O O
patients . . O O
with . . O O
B . . O O
- . . O O
cell . . O O
precursor . . O O
acute . . O O
lymphoblastic . . O O
leukemia . . O O
. . . O O

Our . . O O
data . . O O
molecularly . . O O
describe . . O O
a . . O O
region . . O O
of . . O O
enhanced . . O O
chromosomal . . O B-Mutation
instability . . O I-Mutation
in . . O O
the . . O O
human . . O O
genome . . O O
and . . O O
point . . O O
to . . O O
a . . O O
role . . O O
of . . O O
the . . O O
KIAA0146 . . O O
gene . . O O
in . . O O
tumorigenesis . . O O
. . . O O

Characteristics . . O O
of . . O O
somatic . . O O
mutation . . O B-Mutation
of . . O O
the . . O O
adenomatous . . O O
polyposis . . O O
coli . . O O
gene . . O O
in . . O O
colorectal . . O O
tumors . . O O
. . . O O

Mutation . . O B-Mutation
of . . O O
the . . O O
adenomatous . . O O
polyposis . . O O
coli . . O O
( . . O O
APC . . O O
) . . O O
gene . . O O
was . . O O
analyzed . . O O
in . . O O
500 . . O O
colorectal . . O O
tumors . . O O
from . . O O
70 . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
( . . O O
FAP . . O O
) . . O O
and . . O O
102 . . O O
non . . O O
- . . O O
FAP . . O O
patients . . O O
and . . O O
in . . O O
normal . . O O
tissues . . O O
from . . O O
119 . . O O
FAP . . O O
patients . . O O
, . . O O
using . . O O
polymerase . . O O
chain . . O O
reaction . . O O
- . . O O
single . . O O
- . . O O
strand . . O O
conformation . . O O
polymorphism . . O O
and . . O O
direct . . O O
sequencing . . O O
methods . . O O
. . . O O

These . . O O
tumors . . O O
were . . O O
histopathologically . . O O
diagnosed . . O O
. . . O O

Sixty . . O O
- . . O O
eight . . O O
germ . . O O
line . . O O
mutations . . O B-Mutation
( . . O O
62 . . O O
% . . O O
deletion . . O B-Mutation
, . . O O
9 . . O O
% . . O O
insertion . . O B-Mutation
, . . O O
and . . O O
29 . . O O
% . . O O
single . . O O
- . . O B-Mutation
base . . O I-Mutation
substitution . . O I-Mutation
) . . O O
and . . O O
241 . . O O
somatic . . O O
mutations . . O B-Mutation
( . . O O
56 . . O O
% . . O O
deletion . . O B-Mutation
, . . O O
12 . . O O
% . . O O
insertion . . O B-Mutation
, . . O O
and . . O O
32 . . O O
% . . O O
single . . O O
- . . O B-Mutation
base . . O I-Mutation
substitution . . O I-Mutation
) . . O O
were . . O O
detected . . O O
. . . O O

All . . O O
mutations . . O B-Mutation
formed . . O O
stop . . O O
codons . . O O
resulting . . O O
in . . O O
truncated . . O O
APC . . O O
proteins . . O O
, . . O O
except . . O O
for . . O O
one . . O O
germ . . O O
line . . O O
mutation . . O B-Mutation
. . . O O

Differences . . O O
were . . O O
found . . O O
between . . O O
somatic . . O O
and . . O O
germ . . O O
line . . O O
mutations . . O B-Mutation
, . . O O
including . . O O
3 . . O O
new . . O O
hot . . O O
spots . . O O
of . . O O
mutation . . O B-Mutation
at . . O O
codons . . O O
1378 . . O O
, . . O O
1450 . . O O
, . . O O
and . . O O
1487 . . O O
- . . O O
1490 . . O O
, . . O O
which . . O O
frequently . . O O
occurred . . O O
in . . O O
somatic . . O O
mutations . . O B-Mutation
but . . O O
not . . O O
in . . O O
germ . . O O
lines . . O O
. . . O O

The . . O O
frequency . . O O
of . . O O
mutation . . O B-Mutation
in . . O O
each . . O O
histopathological . . O O
type . . O O
of . . O O
FAP . . O O
tumor . . O O
was . . O O
53 . . O O
% . . O O
in . . O O
moderate . . O O
adenoma . . O O
, . . O O
64 . . O O
% . . O O
in . . O O
severe . . O O
adenoma . . O O
, . . O O
52 . . O O
% . . O O
in . . O O
intramucosal . . O O
carcinoma . . O O
, . . O O
and . . O O
33 . . O O
% . . O O
in . . O O
invasive . . O O
carcinoma . . O O
, . . O O
whereas . . O O
the . . O O
loss . . O B-Mutation
of . . O I-Mutation
heterozygosity . . O I-Mutation
including . . O O
the . . O O
APC . . O O
gene . . O O
increased . . O O
with . . O O
development . . O O
to . . O O
each . . O O
histopathological . . O O
type . . O O
. . . O O

A . . O O
similar . . O O
tendency . . O O
was . . O O
observed . . O O
in . . O O
non . . O O
- . . O O
FAP . . O O
tumors . . O O
. . . O O

Additionally . . O O
, . . O O
we . . O O
found . . O O
10 . . O O
FAP . . O O
tumors . . O O
that . . O O
had . . O O
both . . O O
somatic . . O O
mutation . . O B-Mutation
and . . O O
loss . . O B-Mutation
of . . O I-Mutation
heterozygosity . . O I-Mutation
. . . O O

These . . O O
tumors . . O O
were . . O O
assumed . . O O
to . . O O
have . . O O
developed . . O O
from . . O O
moderate . . O O
adenomas . . O O
with . . O O
germ . . O O
line . . O O
and . . O O
somatic . . O O
mutations . . O B-Mutation
, . . O O
followed . . O O
by . . O O
deletion . . O B-Mutation
of . . O O
the . . O O
allele . . O O
with . . O O
germ . . O O
line . . O O
mutation . . O B-Mutation
. . . O O

These . . O O
results . . O O
suggest . . O O
that . . O O
inactivation . . O O
of . . O O
the . . O O
APC . . O O
gene . . O O
by . . O O
two . . O O
mutations . . O B-Mutation
is . . O O
involved . . O O
in . . O O
the . . O O
development . . O O
of . . O O
moderate . . O O
adenoma . . O O
, . . O O
and . . O O
loss . . O B-Mutation
of . . O I-Mutation
heterozygosity . . O I-Mutation
of . . O O
the . . O O
APC . . O O
gene . . O O
is . . O O
associated . . O O
with . . O O
further . . O O
development . . O O
to . . O O
carcinoma . . O O
. . . O O

It . . O O
was . . O O
also . . O O
observed . . O O
that . . O O
the . . O O
distribution . . O O
of . . O O
75 . . O O
somatic . . O O
mutations . . O B-Mutation
from . . O O
one . . O O
FAP . . O O
patient . . O O
on . . O O
the . . O O
APC . . O O
sequence . . O O
was . . O O
similar . . O O
to . . O O
the . . O O
distribution . . O O
of . . O O
159 . . O O
somatic . . O O
mutations . . O B-Mutation
from . . O O
83 . . O O
patients . . O O
with . . O O
FAP . . O O
and . . O O
non . . O O
- . . O O
FAP . . O O
, . . O O
which . . O O
suggests . . O O
that . . O O
the . . O O
position . . O O
of . . O O
somatic . . O O
mutation . . O B-Mutation
is . . O O
mostly . . O O
due . . O O
to . . O O
the . . O O
APC . . O O
sequence . . O O
itself . . O O
. . . O O

[ . . O O
Hereditary . . O O
non . . O O
polyposis . . O O
colon . . O O
cancer . . O O
- . . O O
- . . O O
basic . . O O
principle . . O O
and . . O O
ethical . . O O
considerations . . O O
] . . O O
. . . O O

HNPCC . . O O
is . . O O
a . . O O
hereditary . . O O
cancer . . O O
syndrome . . O O
of . . O O
several . . O O
organs . . O O
but . . O O
more . . O O
particularly . . O O
the . . O O
colon . . O O
and . . O O
the . . O O
uterus . . O O
. . . O O

It . . O O
is . . O O
characterized . . O O
by . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
related . . O O
to . . O O
mutations . . B-Mutation B-Mutation
of . . O O
DNA . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
genes . . O O
. . . O O

The . . O O
role . . O O
of . . O O
the . . O O
pathologist . . O O
in . . O O
the . . O O
detection . . O O
of . . O O
colorectal . . O O
cancer . . O O
with . . O O
MSI . . B-Mutation B-Mutation
phenotype . . O O
is . . O O
important . . O O
. . . O O

Among . . O O
the . . O O
available . . O O
tests . . O O
to . . O O
detect . . O O
MSI . . B-Mutation B-Mutation
, . . O O
immunohistochemistry . . O O
appears . . O O
being . . O O
a . . O O
sensitive . . O O
, . . O O
specific . . O O
and . . O O
inexpensive . . O O
test . . O O
. . . O O

The . . O O
detection . . O O
of . . O O
HNPCC . . O O
syndrome . . O O
by . . O O
the . . O O
genetic . . O O
test . . O O
among . . O O
the . . O O
MSI . . B-Mutation O
cancers . . O O
implies . . O O
a . . O O
coordination . . O O
of . . O O
the . . O O
structures . . O O
of . . O O
health . . O O
and . . O O
requires . . O O
a . . O O
follow . . O O
- . . O O
up . . O O
of . . O O
the . . O O
patients . . O O
, . . O O
during . . O O
and . . O O
after . . O O
the . . O O
genetic . . O O
test . . O O
. . . O O

Ethical . . O O
dimension . . O O
related . . O O
to . . O O
these . . O O
hereditary . . O O
cancers . . O O
must . . O O
be . . O O
considered . . O O
without . . O O
constituting . . O O
a . . O O
brake . . O O
for . . O O
their . . O O
detection . . O O
. . . O O

[ . . O O
Significance . . O O
of . . O O
K . . O O
- . . O O
ras . . O O
detection . . O O
in . . O O
colorectal . . O O
cancer . . O O
] . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVE . . O O

To . . O O
determine . . O O
the . . O O
mutation . . O B-Mutation
status . . O O
of . . O O
K . . O O
- . . O O
ras . . O O
gene . . O O
in . . O O
colorectal . . O O
cancer . . O O
and . . O O
analyze . . O O
the . . O O
associations . . O O
between . . O O
its . . O O
mutation . . O B-Mutation
status . . O O
and . . O O
clinicopathological . . O O
characteristics . . O O
in . . O O
colorectal . . O O
cancer . . O O
so . . O O
as . . O O
to . . O O
select . . O O
the . . O O
patients . . O O
likely . . O O
to . . O O
benefit . . O O
from . . O O
a . . O O
targeted . . O O
therapy . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

A . . O O
total . . O O
of . . O O
208 . . O O
colorectal . . O O
cancer . . O O
tissue . . O O
samples . . O O
were . . O O
collected . . O O
from . . O O
September . . O O
2008 . . O O
to . . O O
February . . O O
2009 . . O O
. . . O O

DNA . . O O
was . . O O
extracted . . O O
with . . O O
a . . O O
genomic . . O O
DNA . . O O
miniprep . . O O
kit . . O O
. . . O O

Then . . O O
PCR . . O O
was . . O O
performed . . O O
with . . O O
the . . O O
designed . . O O
primers . . O O
and . . O O
the . . O O
product . . O O
directly . . O O
sequenced . . O O
by . . O O
the . . O O
Sanger . . O O
method . . O O
. . . O O

Then . . O O
the . . O O
associations . . O O
between . . O O
K . . O O
- . . O O
ras . . O O
mutation . . O B-Mutation
status . . O O
and . . O O
clinicopathological . . O O
characteristics . . O O
in . . O O
colorectal . . O O
cancer . . O O
were . . O O
analyzed . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Of . . O O
208 . . O O
cases . . O O
, . . O O
91 . . O O
cases . . O O
of . . O O
K . . O O
- . . O O
ras . . O O
gene . . O O
mutation . . O B-Mutation
were . . O O
detected . . O O
. . . O O

The . . O O
12 . . O O
or . . O O
13 . . O O
codon . . O O
had . . O O
a . . O O
mutation . . O B-Mutation
rate . . O O
of . . O O
43 . . O O
. . . O O
8 . . O O
% . . O O
. . . O O

There . . O O
were . . O O
no . . O O
significant . . O O
differences . . O O
in . . O O
gender . . O O
, . . O O
tumor . . O O
location . . O O
, . . O O
histopathological . . O O
grading . . O O
and . . O O
Duke . . O O
' . . O O
s . . O O
stage . . O O
between . . O O
the . . O O
wild . . O O
and . . O O
mutated . . O B-Mutation
groups . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

Detection . . O O
of . . O O
K . . O O
- . . O O
ras . . O O
gene . . O O
status . . O O
in . . O O
colorectal . . O O
cancer . . O O
will . . O O
help . . O O
to . . O O
select . . O O
the . . O O
patients . . O O
likely . . O O
to . . O O
benefit . . O O
from . . O O
the . . O O
monoclonal . . O O
antibody . . O O
therapy . . O O
of . . O O
targeting . . O O
epidermal . . O O
growth . . O O
factor . . O O
receptor . . O O
. . . O O

Co . . O O
- . . O O
occurrence . . O O
of . . O O
nonsense . . B-Mutation O
mutations . . I-Mutation B-Mutation
in . . O O
MSH6 . . O O
and . . O O
MSH2 . . O O
in . . O O
Lynch . . O O
syndrome . . O O
families . . O O
evidencing . . O O
that . . O O
not . . O O
all . . O O
truncating . . O O
mutations . . B-Mutation B-Mutation
are . . O O
equal . . O O
. . . O O

The . . O O
majority . . O O
of . . O O
pathogenic . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
detected . . O O
in . . O O
Lynch . . O O
syndrome . . O O
patients . . O O
are . . O O
truncating . . O O
( . . O O
frameshift . . B-Mutation O
or . . O O
nonsense . . B-Mutation O
) . . O O
. . . O O

However . . O O
, . . O O
the . . O O
classification . . O O
of . . O O
terminal . . O O
truncating . . O O
mutations . . B-Mutation B-Mutation
is . . O O
sometimes . . O O
difficult . . O O
and . . O O
predictive . . O O
testing . . O O
based . . O O
on . . O O
non . . O O
- . . O O
deleterious . . O O
variants . . B-Mutation O
can . . O O
have . . O O
very . . O O
serious . . O O
consequences . . O O
. . . O O

Here . . O O
, . . O O
we . . O O
report . . O O
eight . . O O
probands . . O O
that . . O O
have . . O O
two . . O O
germline . . O O
nonsense . . B-Mutation O
mutations . . I-Mutation B-Mutation
, . . O O
namely . . O O
MSH6 . . O O
c . . B-Mutation B-Mutation
. . . I-Mutation I-Mutation
1030C . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
, . . O O
p . . B-Mutation O
. . . I-Mutation O
( . . I-Mutation O
Gln344Ter . . I-Mutation O
) . . I-Mutation O
and . . O O
MSH2 . . O B-Mutation
c . . B-Mutation I-Mutation
. . . I-Mutation I-Mutation
2785C . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
, . . O O
p . . B-Mutation O
. . . I-Mutation O
( . . I-Mutation O
Arg929Ter . . I-Mutation O
) . . I-Mutation O
, . . O O
and . . O O
one . . O O
additional . . O O
patient . . O O
who . . O O
presented . . O O
only . . O O
the . . O O
MSH2 . . O O
mutation . . B-Mutation B-Mutation
previously . . O O
reported . . O O
as . . O O
deleterious . . B-Mutation O
. . . O O

The . . O O
novel . . O O
MSH6 . . O O
truncating . . O O
mutation . . B-Mutation B-Mutation
was . . O O
classified . . O O
as . . O O
deleterious . . B-Mutation O
, . . O O
as . . O O
it . . O O
is . . O O
predicted . . O O
to . . O O
encode . . O O
a . . O O
protein . . O O
with . . O O
loss . . B-Mutation O
of . . O O
1017 . . O O
amino . . O O
acid . . O O
residues . . O O
. . . O O

The . . O O
MSH2 . . O O
mutation . . B-Mutation B-Mutation
, . . O O
which . . O O
is . . O O
expected . . O O
to . . O O
encode . . O O
a . . O O
protein . . O O
lacking . . B-Mutation O
six . . O O
amino . . O O
acid . . O O
residues . . O O
, . . O O
was . . O O
considered . . O O
a . . O O
variant . . B-Mutation O
of . . O O
unknown . . O O
significance . . O O
. . . O O

Five . . O O
tumors . . O O
of . . O O
the . . O O
eight . . O O
double . . O O
- . . O O
mutant . . B-Mutation O
individuals . . O O
had . . O O
normal . . O O
MSH2 . . O O
expression . . O O
, . . O O
whereas . . O O
MSH6 . . O O
immunoexpression . . O O
was . . O O
lost . . O O
in . . O O
all . . O O
evaluable . . O O
cases . . O O
. . . O O

None . . O O
of . . O O
the . . O O
variants . . B-Mutation O
were . . O O
detected . . O O
in . . O O
normal . . O O
controls . . O O
or . . O O
associated . . O O
with . . O O
other . . O O
MMR . . O O
germline . . O O
mutations . . B-Mutation B-Mutation
in . . O O
our . . O O
series . . O O
. . . O O

This . . O O
study . . O O
emphasizes . . O O
that . . O O
not . . O O
all . . O O
truncating . . O O
mutations . . B-Mutation B-Mutation
are . . O O
equal . . O O
and . . O O
that . . O O
one . . O O
must . . O O
be . . O O
cautious . . O O
in . . O O
the . . O O
interpretation . . O O
of . . O O
the . . O O
presumed . . O O
deleterious . . B-Mutation O
effect . . O O
of . . O O
terminal . . O O
frameshift . . B-Mutation O
or . . O O
nonsense . . B-Mutation O
mutations . . I-Mutation B-Mutation
. . . O O

Differential . . O O
cancer . . O O
predisposition . . O O
in . . O O
Lynch . . O O
syndrome . . O O
: . . O O
insights . . O O
from . . O O
molecular . . O O
analysis . . O O
of . . O O
brain . . O O
and . . O O
urinary . . O O
tract . . O O
tumors . . O O
. . . O O

Hereditary . . O O
non . . O O
- . . O O
polyposis . . O O
colorectal . . O O
carcinoma . . O O
( . . O O
Lynch . . O O
syndrome . . O O
) . . O O
is . . O O
among . . O O
the . . O O
most . . O O
common . . O O
hereditary . . O O
cancers . . O O
in . . O O
man . . O O
and . . O O
a . . O O
model . . O O
of . . O O
cancers . . O O
arising . . O O
through . . O O
deficient . . O O
DNA . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
. . . O O

Lynch . . O O
syndrome . . O O
patients . . O O
are . . O O
predisposed . . O O
to . . O O
different . . O O
cancers . . O O
in . . O O
a . . O O
non . . O O
- . . O O
random . . O O
fashion . . O O
, . . O O
the . . O O
basis . . O O
of . . O O
which . . O O
is . . O O
poorly . . O O
understood . . O O
. . . O O

We . . O O
addressed . . O O
this . . O O
issue . . O O
by . . O O
determining . . O O
the . . O O
molecular . . O O
profiles . . O O
for . . O O
different . . O O
tumors . . O O
from . . O O
a . . O O
nationwide . . O O
cohort . . O O
of . . O O
Lynch . . O O
syndrome . . O O
families . . O O
( . . O O
approximately . . O O
150 . . O O
tumors . . O O
in . . O O
total . . O O
) . . O O
. . . O O

We . . O O
focused . . O O
on . . O O
some . . O O
less . . O O
prevalent . . O O
cancers . . O O
, . . O O
affecting . . O O
the . . O O
brain . . O O
( . . O O
n . . O O
= . . O O
7 . . O O
) . . O O
and . . O O
urinary . . O O
tract . . O O
( . . O O
five . . O O
bladder . . O O
and . . O O
five . . O O
ureter . . O O
uroepithelial . . O O
cancers . . O O
and . . O O
four . . O O
kidney . . O O
adenocarcinomas . . O O
) . . O O
, . . O O
and . . O O
compared . . O O
their . . O O
molecular . . O O
characteristics . . O O
to . . O O
those . . O O
of . . O O
the . . O O
most . . O O
common . . O O
cancers . . O O
, . . O O
colorectal . . O O
, . . O O
gastric . . O O
and . . O O
endometrial . . O O
adenocarcinomas . . O O
, . . O O
from . . O O
the . . O O
same . . O O
families . . O O
. . . O O

Despite . . O O
origin . . O O
from . . O O
verified . . O O
MMR . . O O
gene . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
, . . O O
the . . O O
frequency . . O O
of . . O O
high . . O O
- . . O O
level . . O O
microsatellite . . O B-Mutation
instability . . O I-Mutation
in . . O O
tumors . . O O
varied . . O O
between . . O O
high . . O O
( . . O O
100 . . O O
- . . O O
96 . . O O
% . . O O
for . . O O
ureter . . O O
, . . O O
stomach . . O O
and . . O O
colon . . O O
) . . O O
, . . O O
intermediate . . O O
( . . O O
63 . . O O
- . . O O
60 . . O O
% . . O O
for . . O O
endometrium . . O O
and . . O O
bladder . . O O
) . . O O
and . . O O
low . . O O
( . . O O
25 . . O O
- . . O O
0 . . O O
% . . O O
for . . O O
kidney . . O O
and . . O O
brain . . O O
) . . O O
. . . O O

In . . O O
contrast . . O O
to . . O O
gastrointestinal . . O O
and . . O O
endometrial . . O O
carcinomas . . O O
, . . O O
active . . O O
( . . O O
nuclear . . O O
) . . O O
beta . . O O
- . . O O
catenin . . O O
was . . O O
rare . . O O
and . . O O
KRAS . . O O
mutations . . B-Mutation B-Mutation
were . . O O
absent . . O O
in . . O O
brain . . O O
and . . O O
urological . . O O
tumors . . O O
. . . O O

Compared . . O O
with . . O O
other . . O O
tumors . . O O
, . . O O
frequent . . O O
stabilization . . O O
of . . O O
p53 . . O O
protein . . O O
characterized . . O O
urinary . . O O
tract . . O O
cancers . . O O
. . . O O

Promoter . . O O
methylation . . O O
of . . O O
tumor . . O O
suppressor . . O O
genes . . O O
discriminated . . O O
the . . O O
tumors . . O O
in . . O O
an . . O O
organ . . O O
- . . O O
specific . . O O
manner . . O O
. . . O O

Our . . O O
findings . . O O
suggest . . O O
that . . O O
different . . O O
Lynch . . O O
syndrome . . O O
tumors . . O O
develop . . O O
along . . O O
different . . O O
routes . . O O
. . . O O

Uroepithelial . . O O
cancers . . O O
of . . O O
the . . O O
ureter . . O O
( . . O O
and . . O O
bladder . . O O
to . . O O
lesser . . O O
extent . . O O
) . . O O
share . . O O
many . . O O
characteristics . . O O
of . . O O
MMR . . O O
deficiency . . B-Mutation O
- . . O O
driven . . O O
tumorigenesis . . O O
, . . O O
whereas . . O O
brain . . O O
tumors . . O O
and . . O O
kidney . . O O
adenocarcinomas . . O O
follow . . O O
separate . . O O
pathways . . O O
. . . O O

The . . O O
frequency . . O O
of . . O O
previously . . O O
undetectable . . O O
deletions . . B-Mutation O
involving . . O O
3 . . O O
' . . O O
Exons . . O O
of . . O O
the . . O O
PMS2 . . O O
gene . . O O
. . . O O

Lynch . . O O
syndrome . . O O
is . . O O
characterized . . O O
by . . O O
mutations . . B-Mutation B-Mutation
in . . O O
one . . O O
of . . O O
four . . O O
mismatch . . O O
repair . . O O
genes . . O O
, . . O O
MLH1 . . O O
, . . O O
MSH2 . . O O
, . . O O
MSH6 . . O O
, . . O O
or . . O O
PMS2 . . O O
. . . O O

Clinical . . O O
mutation . . B-Mutation B-Mutation
analysis . . O O
of . . O O
these . . O O
genes . . O O
includes . . O O
sequencing . . O O
of . . O O
exonic . . O O
regions . . O O
and . . O O
deletion . . B-Mutation B-Mutation
/ . . O O
duplication . . B-Mutation O
analysis . . O O
. . . O O

However . . O O
, . . O O
detection . . O O
of . . O O
deletions . . B-Mutation O
and . . O O
duplications . . B-Mutation O
in . . O O
PMS2 . . O O
has . . O O
previously . . O O
been . . O O
confined . . O O
to . . O O
Exons . . O O
1 . . O O
- . . O O
11 . . O O
due . . O O
to . . O O
gene . . O O
conversion . . O O
between . . O O
PMS2 . . O O
and . . O O
the . . O O
pseudogene . . O O
PMS2CL . . O O
in . . O O
the . . O O
remaining . . O O
3 . . O O
' . . O O
exons . . O O
( . . O O
Exons . . O O
12 . . O O
- . . O O
15 . . O O
) . . O O
. . . O O

We . . O O
have . . O O
recently . . O O
described . . O O
an . . O O
MLPA . . O O
- . . O O
based . . O O
method . . O O
that . . O O
permits . . O O
detection . . O O
of . . O O
deletions . . B-Mutation O
of . . O O
PMS2 . . O O
Exons . . O O
12 . . O O
- . . O O
15 . . O O
; . . O O
however . . O O
, . . O O
the . . O O
frequency . . O O
of . . O O
such . . O O
deletions . . B-Mutation O
has . . O O
not . . O O
yet . . O O
been . . O O
determined . . O O
. . . O O

To . . O O
address . . O O
this . . O O
question . . O O
, . . O O
we . . O O
tested . . O O
for . . O O
3 . . O O
' . . O O
deletions . . B-Mutation O
in . . O O
58 . . O O
samples . . O O
that . . O O
were . . O O
reported . . O O
to . . O O
be . . O O
negative . . O O
for . . O O
PMS2 . . O O
mutations . . B-Mutation B-Mutation
using . . O O
previously . . O O
available . . O O
methods . . O O
. . . O O

All . . O O
samples . . O O
were . . O O
from . . O O
individuals . . O O
whose . . O O
tumors . . O O
exhibited . . O O
loss . . B-Mutation O
of . . O O
PMS2 . . O O
immunohistochemical . . O O
staining . . O O
without . . O O
concomitant . . O O
loss . . B-Mutation O
of . . O O
MLH1 . . O O
immunostaining . . O O
. . . O O

We . . O O
identified . . O O
seven . . O O
samples . . O O
in . . O O
this . . O O
cohort . . O O
with . . O O
deletions . . B-Mutation O
in . . O O
the . . O O
3 . . O O
' . . O O
region . . O O
of . . O O
PMS2 . . O O
, . . O O
including . . O O
three . . O O
previously . . O O
reported . . O O
samples . . O O
with . . O O
deletions . . B-Mutation O
of . . O O
Exons . . O O
13 . . O O
- . . O O
15 . . O O
( . . O O
two . . O O
samples . . O O
) . . O O
and . . O O
Exons . . O O
14 . . O O
- . . O O
15 . . O O
. . . O O

Also . . O O
detected . . O O
were . . O O
deletions . . B-Mutation O
of . . O O
Exons . . O O
12 . . O O
- . . O O
15 . . O O
, . . O O
Exon . . O O
13 . . O O
, . . O O
and . . O O
Exon . . O O
14 . . O O
( . . O O
two . . O O
samples . . O O
) . . O O
. . . O O

Breakpoint . . O O
analysis . . O O
of . . O O
the . . O O
intragenic . . O O
deletions . . B-Mutation O
suggests . . O O
they . . O O
occurred . . O O
through . . O O
Alu . . O O
- . . O O
mediated . . O O
recombination . . O O
. . . O O

Our . . O O
results . . O O
indicate . . O O
that . . O O
∼ . . O O
12 . . O O
% . . O O
of . . O O
samples . . O O
suspected . . O O
of . . O O
harboring . . O O
a . . O O
PMS2 . . O O
mutation . . B-Mutation B-Mutation
based . . O O
on . . O O
immunohistochemical . . O O
staining . . O O
, . . O O
for . . O O
which . . O O
mutations . . B-Mutation B-Mutation
have . . O O
not . . O O
yet . . O O
been . . O O
identified . . O O
, . . O O
would . . O O
benefit . . O O
from . . O O
testing . . O O
using . . O O
the . . O O
new . . O O
methodology . . O O
. . . O O

Egr . . O O
- . . O O
1 . . O O
regulates . . O O
the . . O O
transcription . . O O
of . . O O
NGX6 . . O O
gene . . O O
through . . O O
a . . O O
Sp1 . . O O
/ . . O O
Egr . . O O
- . . O O
1 . . O O
overlapping . . O O
site . . O O
in . . O O
the . . O O
promoter . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

As . . O O
a . . O O
novel . . O O
candidate . . O O
metastasis . . O O
suppressor . . O O
gene . . O O
, . . O O
Nasopharyngeal . . O O
carcinoma . . O O
- . . O O
associated . . O O
gene . . O O
6 . . O O
( . . O O
NGX6 . . O O
) . . O O
is . . O O
involved . . O O
in . . O O
cellular . . O O
growth . . O O
, . . O O
cell . . O O
cycle . . O O
progression . . O O
and . . O O
tumor . . O O
angiogenesis . . O O
. . . O O

Previous . . O O
studies . . O O
have . . O O
shown . . O O
that . . O O
NGX6 . . O O
gene . . O O
is . . O O
down . . O O
- . . O O
regulated . . O O
in . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
. . . O O

However . . O O
, . . O O
little . . O O
is . . O O
known . . O O
about . . O O
its . . O O
transcriptional . . O O
regulation . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

We . . O O
defined . . O O
the . . O O
minimal . . O O
promoter . . O O
of . . O O
NGX6 . . O O
gene . . O O
in . . O O
a . . O O
186 . . O O
- . . O O
bp . . O O
region . . O O
( . . O O
from . . O O
- . . O O
86 . . O O
to . . O O
+ . . O O
100 . . O O
) . . O O
through . . O O
mutation . . B-Mutation B-Mutation
construct . . O O
methods . . O O
and . . O O
luciferase . . O O
assays . . O O
. . . O O

Results . . O O
from . . O O
Electrophoretic . . O O
mobility . . O O
shift . . O O
assays . . O O
( . . O O
EMSA . . O O
) . . O O
and . . O O
Chromatin . . O O
immunoprecipitation . . O O
( . . O O
ChIP . . O O
) . . O O
revealed . . O O
that . . O O
Early . . O O
growth . . O O
response . . O O
gene . . O O
1 . . O O
( . . O O
Egr . . O O
- . . O O
1 . . O O
) . . O O
binds . . O O
to . . O O
the . . O O
Sp1 . . O O
/ . . O O
Egr . . O O
- . . O O
1 . . O O
overlapping . . O O
site . . O O
of . . O O
NGX6 . . O O
minimal . . O O
promoter . . O O
. . . O O

Overexpression . . O O
of . . O O
Egr . . O O
- . . O O
1 . . O O
increased . . O O
the . . O O
promoter . . O O
activity . . O O
and . . O O
mRNA . . O O
level . . O O
of . . O O
NGX6 . . O O
gene . . O O
; . . O O
while . . O O
knock . . O O
- . . O O
down . . O O
of . . O O
endogenous . . O O
Egr . . O O
- . . O O
1 . . O O
decreased . . O O
mRNA . . O O
expression . . O O
of . . O O
NGX6 . . O O
gene . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

These . . O O
results . . O O
demonstrate . . O O
that . . O O
Egr . . O O
- . . O O
1 . . O O
regulates . . O O
NGX6 . . O O
gene . . O O
transcription . . O O
through . . O O
an . . O O
overlapping . . O O
Sp1 . . O O
/ . . O O
Egr . . O O
- . . O O
1 . . O O
binding . . O O
site . . O O
as . . O O
a . . O O
positive . . O O
regulator . . O O
of . . O O
NGX6 . . O O
gene . . O O
. . . O O

Identification . . O O
and . . O O
characterization . . O O
of . . O O
a . . O O
novel . . O O
anticancer . . O O
agent . . O O
with . . O O
selectivity . . O O
against . . O O
deleted . . O O
in . . O O
pancreatic . . O O
cancer . . O O
locus . . O O
4 . . O O
( . . O O
DPC4 . . O O
) . . O O
- . . O O
deficient . . O O
pancreatic . . O O
and . . O O
colon . . O O
cancer . . O O
cells . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVES . . O O

The . . O O
deleted . . O O
in . . O O
pancreatic . . O O
cancer . . O O
locus . . O O
4 . . O O
( . . O O
DPC4 . . O O
) . . O O
/ . . O O
SMAD4 . . O O
tumor . . O O
suppressor . . O O
gene . . O O
is . . O O
frequently . . O O
inactivated . . O O
in . . O O
pancreatic . . O O
( . . O O
approximately . . O O
55 . . O O
% . . O O
) . . O O
and . . O O
colorectal . . O O
cancers . . O O
( . . O O
approximately . . O O
30 . . O O
% . . O O
) . . O O
. . . O O

Like . . O O
other . . O O
tumor . . O O
suppressor . . O O
genes . . O O
, . . O O
the . . O O
loss . . O O
- . . O O
of . . O O
- . . O O
function . . O O
mutations . . B-Mutation B-Mutation
found . . O O
in . . O O
the . . O O
DPC4 . . O O
gene . . O O
are . . O O
specific . . O O
to . . O O
cancer . . O O
cells . . O O
. . . O O

This . . O O
provides . . O O
an . . O O
attractive . . O O
and . . O O
unique . . O O
opportunity . . O O
for . . O O
therapeutic . . O O
intervention . . O O
. . . O O

The . . O O
aim . . O O
of . . O O
this . . O O
study . . O O
was . . O O
to . . O O
identify . . O O
and . . O O
characterize . . O O
small . . O O
molecules . . O O
that . . O O
selectively . . O O
kill . . O O
DPC4 . . O O
- . . O O
deficient . . O O
cancer . . O O
cells . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

An . . O O
unbiased . . O O
chemical . . O O
screening . . O O
using . . O O
isogenic . . O O
cell . . O O
lines . . O O
that . . O O
only . . O O
differ . . O O
in . . O O
the . . O O
DPC4 . . O O
gene . . O O
was . . O O
carried . . O O
out . . O O
to . . O O
identify . . O O
positive . . O O
hits . . O O
. . . O O

Selected . . O O
hits . . O O
were . . O O
further . . O O
verified . . O O
in . . O O
additional . . O O
isogenic . . O O
cell . . O O
lines . . O O
and . . O O
characterized . . O O
in . . O O
cancer . . O O
cells . . O O
using . . O O
several . . O O
different . . O O
cellular . . O O
assays . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

A . . O O
lead . . O O
molecule . . O O
, . . O O
UA62784 . . O O
, . . O O
was . . O O
identified . . O O
to . . O O
be . . O O
selectively . . O O
cytotoxic . . O O
against . . O O
cancer . . O O
cells . . O O
with . . O O
deficient . . O O
DPC4 . . O O
. . . O O

UA62784 . . O O
preferentially . . O O
induces . . O O
cell . . O O
cycle . . O O
arrest . . O O
and . . O O
apoptosis . . O O
in . . O O
cells . . O O
with . . O O
deficient . . O O
DPC4 . . O O
. . . O O

It . . O O
also . . O O
selectively . . O O
reduces . . O O
the . . O O
clonogenicity . . O O
of . . O O
DPC4 . . O O
- . . O O
deficient . . O O
cells . . O O
on . . O O
soft . . O O
agar . . O O
when . . O O
compared . . O O
with . . O O
cells . . O O
with . . O O
wild . . O O
type . . O O
DPC4 . . O O
. . . O O

We . . O O
further . . O O
demonstrate . . O O
that . . O O
UA62784 . . O O
induces . . O O
CDC2 . . O O
kinase . . O O
activity . . O O
preferentially . . O O
in . . O O
DPC4 . . O O
- . . O O
negative . . O O
cells . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

UA62784 . . O O
is . . O O
a . . O O
small . . O O
molecule . . O O
that . . O O
selectively . . O O
kills . . O O
DPC4 . . O O
- . . O O
deficient . . O O
cancer . . O O
cells . . O O
. . . O O

Its . . O O
potent . . O O
activity . . O O
and . . O O
relatively . . O O
low . . O O
molecular . . O O
weight . . O O
make . . O O
it . . O O
a . . O O
decent . . O O
candidate . . O O
for . . O O
further . . O O
lead . . O O
optimization . . O O
. . . O O

Linkage . . O O
disequilibrium . . O O
and . . O O
haplotype . . O O
analysis . . O O
of . . O O
COX . . O O
- . . O O
2 . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
development . . O O
. . . O O

Single . . B-Mutation B-Mutation
nucleotide . . I-Mutation I-Mutation
polymorphisms . . I-Mutation I-Mutation
( . . O O
SNPs . . B-Mutation O
) . . O O
in . . O O
the . . O O
promoter . . O O
and . . O O
untranslated . . O O
region . . O O
of . . O O
cyclooxygenase . . O O
( . . O O
COX . . O O
) . . O O
- . . O O
2 . . O O
, . . O O
an . . O O
inducible . . O O
enzyme . . O O
responsible . . O O
for . . O O
the . . O O
synthesis . . O O
of . . O O
prostaglandins . . O O
, . . O O
have . . O O
been . . O O
reported . . O O
to . . O O
modulate . . O O
the . . O O
risk . . O O
for . . O O
many . . O O
human . . O O
cancers . . O O
. . . O O

We . . O O
performed . . O O
comprehensive . . O O
linkage . . O O
disequilibrium . . O O
( . . O O
LD . . O O
) . . O O
and . . O O
haplotype . . O O
analyses . . O O
of . . O O
13 . . O O
single . . B-Mutation O
nucleotide . . I-Mutation O
polymorphisms . . I-Mutation B-Mutation
of . . O O
the . . O O
COX . . O O
- . . O O
2 . . O O
gene . . O O
and . . O O
examined . . O O
its . . O O
susceptibility . . O O
to . . O O
adenoma . . O O
development . . O O
in . . O O
72 . . O O
African . . O O
American . . O O
cases . . O O
and . . O O
142 . . O O
controls . . O O
. . . O O

Results . . O O
revealed . . O O
significant . . O O
variation . . O O
in . . O O
LD . . O O
patterns . . O O
with . . O O
consequence . . O O
for . . O O
adenoma . . O O
development . . O O
. . . O O

Two . . O O
distinct . . O O
haplotype . . O O
blocks . . O O
were . . O O
identified . . O O
; . . O O
one . . O O
block . . O O
covered . . O O
the . . O O
coding . . O O
regions . . O O
of . . O O
exon . . O O
1 . . O O
, . . O O
introns . . O O
and . . O O
a . . O O
section . . O O
of . . O O
the . . O O
3 . . O O
' . . O O
- . . O O
unstranslated . . O O
region . . O O
( . . O O
3 . . O O
' . . O O
- . . O O
UTR . . O O
) . . O O
, . . O O
whereas . . O O
the . . O O
second . . O O
block . . O O
resided . . O O
solely . . O O
in . . O O
the . . O O
3 . . O O
' . . O O
- . . O O
UTR . . O O
region . . O O
. . . O O

A . . O O
haplotype . . O O
in . . O O
block . . O O
1 . . O O
increased . . O O
the . . O O
risk . . O O
of . . O O
adenoma . . O O
development . . O O
by . . O O
threefold . . O O
( . . O O
odds . . O O
ratio . . O O
[ . . O O
OR . . O O
] . . O O
= . . O O
2 . . O O
. . . O O
9 . . O O
, . . O O
confidence . . O O
interval . . O O
[ . . O O
CI . . O O
] . . O O
= . . O O
1 . . O O
. . . O O
8 . . O O
- . . O O
3 . . O O
. . . O O
7 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
002 . . O O
) . . O O
. . . O O

Regression . . O O
analysis . . O O
showed . . O O
, . . O O
increase . . O O
in . . O O
copies . . O O
of . . O O
minor . . O O
alleles . . O O
of . . O O
6 . . O O
, . . O O
064 . . O O
( . . O O
T . . B-Mutation B-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
) . . O O
polymorphism . . B-Mutation O
associated . . O O
with . . O O
increased . . O O
odds . . O O
of . . O O
adenoma . . O O
development . . O O
by . . O O
80 . . O O
% . . O O
( . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
80 . . O O
, . . O O
CI . . O O
= . . O O
1 . . O O
. . . O O
09 . . O O
- . . O O
3 . . O O
. . . O O
21 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
034 . . O O
) . . O O
, . . O O
10 . . O O
, . . O O
848 . . O O
( . . O O
G . . B-Mutation B-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
) . . O O
by . . O O
84 . . O O
% . . O O
( . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
84 . . O O
, . . O O
CI . . O O
= . . O O
1 . . O O
. . . O O
05 . . O O
- . . O O
3 . . O O
. . . O O
23 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
034 . . O O
) . . O O
and . . O O
10 . . O O
, . . O O
935 . . O O
( . . O O
A . . B-Mutation B-Mutation
> . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
) . . O O
by . . O O
32 . . O O
% . . O O
( . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
32 . . O O
, . . O O
CI . . O O
= . . O O
1 . . O O
. . . O O
12 . . O O
- . . O O
3 . . O O
. . . O O
69 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
036 . . O O
) . . O O
. . . O O

These . . O O
results . . O O
support . . O O
the . . O O
hypothesis . . O O
that . . O O
COX . . O O
- . . O O
2 . . O O
gene . . O O
might . . O O
play . . O O
a . . O O
role . . O O
in . . O O
the . . O O
etiology . . O O
of . . O O
colon . . O O
cancer . . O O
and . . O O
warrant . . O O
further . . O O
investigation . . O O
in . . O O
other . . O O
cancers . . O O
. . . O O

Besides . . O O
, . . O O
these . . O O
variations . . B-Mutation O
should . . O O
be . . O O
taken . . O O
into . . O O
account . . O O
for . . O O
disease . . O O
- . . O O
based . . O O
association . . O O
studies . . O O
in . . O O
which . . O O
the . . O O
COX . . O O
- . . O O
2 . . O O
polymorphism . . O O
is . . O O
considered . . O O
as . . O O
a . . O O
candidate . . O O
gene . . O O
. . . O O

Clin . . O O
Trans . . O O
Sci . . O O
2012 . . O O
; . . O O
Volume . . O O
5 . . O O
: . . O O
60 . . O O
- . . O O
64 . . O O
. . . O O

Mutations . . B-Mutation B-Mutation
in . . O O
two . . O O
short . . O O
noncoding . . O O
mononucleotide . . O O
repeats . . O O
in . . O O
most . . O O
microsatellite . . B-Mutation O
- . . I-Mutation O
unstable . . I-Mutation O
colorectal . . O O
cancers . . O O
. . . O O

DNA . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
- . . O O
deficient . . O O
cells . . O O
typically . . O O
accumulate . . O O
mutations . . B-Mutation B-Mutation
in . . O O
short . . O O
repetitive . . O O
DNA . . O O
tracts . . O O
. . . O O

This . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
facilitates . . O O
malignant . . O O
transformation . . O O
when . . O O
affecting . . O O
genes . . O O
with . . O O
growth . . O O
- . . O O
related . . O O
and . . O O
caretaker . . O O
functions . . O O
. . . O O

To . . O O
date . . O O
, . . O O
several . . O O
putative . . O O
MSI . . B-Mutation B-Mutation
target . . O O
genes . . O O
have . . O O
been . . O O
proposed . . O O
mainly . . O O
based . . O O
on . . O O
high . . O O
mutation . . B-Mutation B-Mutation
frequency . . O O
within . . O O
their . . O O
coding . . O O
regions . . O O
. . . O O

However . . O O
, . . O O
some . . O O
intronic . . O O
repeat . . O O
mutations . . B-Mutation B-Mutation
have . . O O
also . . O O
been . . O O
suggested . . O O
to . . O O
associate . . O O
with . . O O
MSI . . B-Mutation B-Mutation
tumorigenesis . . O O
, . . O O
indicating . . O O
the . . O O
need . . O O
for . . O O
additional . . O O
analyses . . O O
on . . O O
noncoding . . O O
repeats . . O O
. . . O O

Here . . O O
we . . O O
have . . O O
analyzed . . O O
an . . O O
intronic . . O O
T9 . . O O
repeat . . O O
of . . O O
semenogelin . . O O
I . . O O
( . . O O
SEMG1 . . O O
) . . O O
and . . O O
report . . O O
mutation . . B-Mutation B-Mutation
frequencies . . O O
of . . O O
51 . . O O
% . . O O
( . . O O
75 . . O O
of . . O O
146 . . O O
) . . O O
and . . O O
62 . . O O
% . . O O
( . . O O
8 . . O O
of . . O O
13 . . O O
) . . O O
in . . O O
MMR . . O O
- . . O O
deficient . . O O
primary . . O O
colorectal . . O O
cancers . . O O
and . . O O
cell . . O O
lines . . O O
, . . O O
respectively . . O O
. . . O O

The . . O O
putative . . O O
effect . . O O
of . . O O
the . . O O
SEMG1 . . O O
mutations . . B-Mutation B-Mutation
was . . O O
assessed . . O O
by . . O O
RNA . . O O
and . . O O
protein . . O O
level . . O O
analyses . . O O
, . . O O
but . . O O
no . . O O
differences . . O O
were . . O O
detected . . O O
between . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
with . . O O
different . . O O
SEMG1 . . O O
status . . O O
. . . O O

Subsequently . . O O
, . . O O
the . . O O
general . . O O
background . . O O
mutation . . B-Mutation B-Mutation
frequency . . O O
of . . O O
MSI . . B-Mutation B-Mutation
colorectal . . O O
cancers . . O O
was . . O O
assessed . . O O
by . . O O
screening . . O O
for . . O O
intergenic . . O O
T9 . . O O
repeat . . O O
alterations . . B-Mutation O
. . . O O

One . . O O
of . . O O
10 . . O O
examined . . O O
repeats . . O O
was . . O O
mutated . . O B-Mutation
in . . O O
70 . . O O
% . . O O
( . . O O
102 . . O O
of . . O O
145 . . O O
) . . O O
of . . O O
the . . O O
colorectal . . O O
cancers . . O O
evaluated . . O O
. . . O O

The . . O O
frequencies . . O O
observed . . O O
here . . O O
are . . O O
notably . . O O
higher . . O O
than . . O O
previously . . O O
published . . O O
in . . O O
noncoding . . O O
repeats . . O O
shorter . . O O
than . . O O
10 . . O O
bp . . O O
in . . O O
MMR . . O O
- . . O O
deficient . . O O
primary . . O O
tumors . . O O
. . . O O

Our . . O O
results . . O O
indicate . . O O
that . . O O
high . . O O
mutation . . B-Mutation B-Mutation
frequencies . . O O
, . . O O
similar . . O O
or . . O O
higher . . O O
than . . O O
those . . O O
observed . . O O
in . . O O
proposed . . O O
and . . O O
approved . . O O
target . . O O
genes . . O O
, . . O O
can . . O O
be . . O O
detected . . O O
in . . O O
repeat . . O O
tracts . . O O
of . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
without . . O O
any . . O O
apparent . . O O
selection . . O O
pressure . . O O
. . . O O

These . . O O
data . . O O
call . . O O
for . . O O
urgent . . O O
and . . O O
thorough . . O O
large . . O O
- . . O O
scale . . O O
evaluation . . O O
of . . O O
mutation . . B-Mutation B-Mutation
frequencies . . O O
in . . O O
neutral . . O O
short . . O O
repetitive . . O O
sequences . . O O
in . . O O
MMR . . O O
- . . O O
deficient . . O O
tumors . . O O
. . . O O

Marfan . . O O
- . . O O
like . . O O
habitus . . O O
and . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
in . . O O
two . . O O
unrelated . . O O
males . . O O
: . . O O
a . . O O
significant . . O O
association . . O O
? . . O O

Familial . . O O
adenomatous . . O O
polyposis . . O O
( . . O O
FAP . . O O
) . . O O
can . . O O
be . . O O
considered . . O O
as . . O O
a . . O O
condition . . O O
of . . O O
the . . O O
whole . . O O
body . . O O
as . . O O
extracolonic . . O O
features . . O O
derived . . O O
from . . O O
all . . O O
the . . O O
three . . O O
embryonic . . O O
lineages . . O O
are . . O O
recorded . . O O
with . . O O
varying . . O O
frequency . . O O
in . . O O
addition . . O O
to . . O O
the . . O O
presence . . O O
of . . O O
multiple . . O O
adenomas . . O O
in . . O O
the . . O O
large . . O O
intestine . . O O
. . . O O

Here . . O O
, . . O O
we . . O O
describe . . O O
two . . O O
unrelated . . O O
cases . . O O
of . . O O
FAP . . O O
with . . O O
unusual . . O O
extracolonic . . O O
phenotypes . . O O
, . . O O
namely . . O O
several . . O O
abnormalities . . O O
of . . O O
mesodermal . . O O
origin . . O O
strongly . . O O
resembling . . O O
Marfan . . O O
syndrome . . O O
( . . O O
MFS . . O O
) . . O O
or . . O O
a . . O O
Marfan . . O O
- . . O O
like . . O O
habitus . . O O
. . . O O

Conventional . . O O
cytogenetic . . O O
and . . O O
FISH . . O O
analysis . . O O
did . . O O
not . . O O
reveal . . O O
any . . O O
gross . . O O
chromosomal . . O O
rearrangement . . B-Mutation O
on . . O O
the . . O O
long . . O O
arm . . O O
of . . O O
chromosome . . O O
5 . . O O
where . . O O
the . . O O
APC . . O O
and . . O O
FBN2 . . O O
genes . . O O
were . . O O
located . . O O
. . . O O

However . . O O
, . . O O
in . . O O
case . . O O
2 . . O O
the . . O O
FAP . . O O
- . . O O
causing . . O O
mutation . . B-Mutation B-Mutation
in . . O O
the . . O O
APC . . O O
gene . . O O
was . . O O
found . . O O
in . . O O
the . . O O
donor . . O O
splice . . O O
site . . O O
of . . O O
exon . . O O
4 . . O O
and . . O O
was . . O O
shown . . O O
to . . O O
result . . O O
in . . O O
a . . O O
frameshift . . O O
and . . O O
a . . O O
premature . . O O
termination . . O O
codon . . O O
. . . O O

We . . O O
propose . . O O
that . . O O
such . . O O
connective . . O O
tissue . . O O
abnormalities . . O O
may . . O O
result . . O O
from . . O O
germline . . O O
APC . . O O
mutations . . B-Mutation B-Mutation
in . . O O
combination . . O O
with . . O O
specific . . O O
genetic . . O O
and . . O O
/ . . O O
or . . O O
environmental . . O O
modifying . . O O
factors . . O O
. . . O O

Clinical . . O O
impact . . O O
of . . O O
PAI . . O O
1 . . O O
4G . . O O
/ . . O O
5G . . O O
gene . . O O
polymorphism . . B-Mutation O
in . . O O
colorectal . . O O
carcinoma . . O O
patients . . O O
. . . O O

Plasminogen . . O O
activator . . O O
ihnibitor . . O O
( . . O O
PAI . . O O
1 . . O O
) . . O O
belongs . . O O
to . . O O
the . . O O
plasminogen . . O O
activator . . O O
system . . O O
, . . O O
which . . O O
is . . O O
part . . O O
of . . O O
the . . O O
metastatic . . O O
cascade . . O O
and . . O O
significantly . . O O
contributes . . O O
to . . O O
invasive . . O O
growth . . O O
and . . O O
angiogenesis . . O O
of . . O O
malignant . . O O
tumors . . O O
. . . O O

Its . . O O
plasma . . O O
level . . O O
is . . O O
normally . . O O
low . . O O
but . . O O
4G . . O O
/ . . O O
4G . . O O
homozygotes . . O O
have . . O O
higher . . O O
concentrations . . O O
of . . O O
PAI . . O O
1 . . O O
. . . O O

This . . O O
genotype . . O O
may . . O O
be . . O O
associated . . O O
with . . O O
worse . . O O
prognosis . . O O
and . . O O
proximal . . O O
location . . O O
of . . O O
colorectal . . O O
cancer . . O O
than . . O O
5G . . O O
/ . . O O
5G . . O O
homozygotes . . O O
. . . O O

In . . O O
our . . O O
prospective . . O O
evaluation . . O O
we . . O O
examined . . O O
plasma . . O O
level . . O O
PAI . . O O
1 . . O O
( . . O O
using . . O O
photometric . . O O
microplate . . O O
method . . O O
ELISA . . O O
) . . O O
pre . . O O
- . . O O
surgery . . O O
and . . O O
, . . O O
subsequently . . O O
, . . O O
6 . . O O
- . . O O
8 . . O O
weeks . . O O
later . . O O
, . . O O
from . . O O
80 . . O O
patients . . O O
. . . O O

For . . O O
the . . O O
PAI . . O O
1 . . O O
rs1799889 . . B-Mutation O
- . . O O
675 . . O O
4G . . O O
/ . . O O
5G . . O O
polymorphism . . B-Mutation O
test . . O O
the . . O O
PCR . . O O
amplification . . O O
was . . O O
used . . O O
. . . O O
Analysis . . O O
of . . O O
collected . . O O
data . . O O
was . . O O
confirmed . . O O
that . . O O
significantly . . O O
higher . . O O
plasma . . O O
levels . . O O
of . . O O
PAI . . O O
1 . . O O
were . . O O
found . . O O
in . . O O
patients . . O O
before . . O O
starting . . O O
therapy . . O O
, . . O O
which . . O O
decreased . . O O
( . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
004 . . O O
) . . O O
after . . O O
initiation . . O O
of . . O O
treatment . . O O
. . . O O

Patients . . O O
with . . O O
higher . . O O
plasma . . O O
level . . O O
PAI . . O O
1 . . O O
before . . O O
( . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
013 . . O O
) . . O O
and . . O O
after . . O O
therapy . . O O
( . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
004 . . O O
) . . O O
had . . O O
significantly . . O O
shorter . . O O
survival . . O O
. . . O O

We . . O O
found . . O O
no . . O O
relationship . . O O
between . . O O
polymorphisms . . B-Mutation B-Mutation
of . . O O
PAI . . O O
1 . . O O
( . . O O
- . . O O
675 . . O O
4G . . O O
/ . . O O
5G . . O O
) . . O O
in . . O O
relation . . O O
to . . O O
stage . . O O
, . . O O
survival . . O O
or . . O O
tumor . . O O
location . . O O
. . . O O

PAI . . O O
1 . . O O
is . . O O
useful . . O O
as . . O O
a . . O O
negative . . O O
marker . . O O
of . . O O
prognosis . . O O
and . . O O
could . . O O
be . . O O
advantageous . . O O
when . . O O
planning . . O O
adjuvant . . O O
treatment . . O O
of . . O O
patients . . O O
with . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

Although . . O O
opinions . . O O
on . . O O
the . . O O
importance . . O O
of . . O O
polymorphisms . . B-Mutation O
of . . O O
PAI . . O O
1 . . O O
in . . O O
relation . . O O
to . . O O
the . . O O
prognosis . . O O
are . . O O
not . . O O
uniform . . O O
, . . O O
it . . O O
does . . O O
seem . . O O
that . . O O
their . . O O
role . . O O
in . . O O
the . . O O
prognosis . . O O
of . . O O
patients . . O O
with . . O O
colorectal . . O O
cancer . . O O
is . . O O
not . . O O
essential . . O O
. . . O O

BRCA1 . . O O
activation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
. . . O O

Breast . . O O
cancer . . O O
susceptibility . . O O
gene . . O O
BRCA1 . . O O
has . . O O
been . . O O
implicated . . O O
in . . O O
the . . O O
control . . O O
of . . O O
gene . . O O
regulation . . O O
and . . O O
such . . O O
regulated . . O O
genes . . O O
are . . O O
thought . . O O
to . . O O
mediate . . O O
the . . O O
biological . . O O
role . . O O
of . . O O
BRCA1 . . O O
. . . O O

Overexpression . . O O
of . . O O
BRCA1 . . O O
induces . . O O
GADD45 . . O O
, . . O O
a . . O O
p53 . . O O
- . . O O
regulated . . O O
and . . O O
stress . . O O
- . . O O
inducible . . O O
gene . . O O
. . . O O

However . . O O
, . . O O
the . . O O
molecular . . O O
mechanism . . O O
by . . O O
which . . O O
BRCA1 . . O O
induces . . O O
the . . O O
expression . . O O
GADD45 . . O O
remains . . O O
unclear . . O O
. . . O O

In . . O O
this . . O O
report . . O O
, . . O O
we . . O O
have . . O O
shown . . O O
that . . O O
the . . O O
GADD45 . . O O
promoter . . O O
is . . O O
strongly . . O O
activated . . O O
following . . O O
expression . . O O
of . . O O
wild . . O O
- . . O O
type . . O O
BRCA1 . . O O
. . . O O

In . . O O
contrast . . O O
, . . O O
both . . O O
the . . O O
tumor . . O O
- . . O O
derived . . O O
BRCA1 . . O O
mutants . . B-Mutation O
( . . O O
p1749R . . B-Mutation O
and . . O O
Y1853insA . . B-Mutation O
) . . O O
and . . O O
truncated . . O O
BRCA1 . . O O
mutant . . B-Mutation O
protein . . O O
( . . O O
Delta500 . . B-Mutation O
- . . I-Mutation O
1863 . . I-Mutation O
BRCA1 . . O O
) . . O O
, . . O O
which . . O O
lack . . O O
transactivation . . O O
activity . . O O
, . . O O
were . . O O
unable . . O O
to . . O O
activate . . O O
the . . O O
GADD45 . . O O
promoter . . O O
, . . O O
indicating . . O O
that . . O O
the . . O O
BRCA1 . . O O
- . . O O
mediated . . O O
activation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
requires . . O O
normal . . O O
transcriptional . . O O
properties . . O O
of . . O O
BRCA1 . . O O
. . . O O

BRCA1 . . O O
did . . O O
not . . O O
induce . . O O
the . . O O
c . . O O
- . . O O
Jun . . O O
and . . O O
c . . O O
- . . O O
fos . . O O
promoters . . O O
, . . O O
which . . O O
rules . . O O
out . . O O
a . . O O
general . . O O
effect . . O O
of . . O O
BRCA1 . . O O
on . . O O
other . . O O
immediate . . O O
- . . O O
responsive . . O O
genes . . O O
. . . O O

Expression . . O O
of . . O O
the . . O O
human . . O O
papillomavirus . . O O
E6 . . O O
and . . O O
the . . O O
dominant . . O O
- . . O O
negative . . O O
mutant . . B-Mutation O
p53 . . O O
proteins . . O O
had . . O O
no . . O O
effect . . O O
on . . O O
the . . O O
induction . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
by . . O O
BRCA1 . . O O
, . . O O
suggesting . . O O
that . . O O
activation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
by . . O O
BRCA1 . . O O
is . . O O
independent . . O O
of . . O O
cellular . . O O
p53 . . O O
function . . O O
. . . O O

With . . O O
the . . O O
5 . . O O
' . . O O
- . . O O
deletion . . O B-Mutation
analysis . . O O
, . . O O
the . . O O
BRCA1 . . O O
- . . O O
responsive . . O O
element . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
was . . O O
mapped . . O O
at . . O O
the . . O O
region . . O O
from . . O O
- . . O O
121 . . O O
to . . O O
- . . O O
75 . . O O
. . . O O

Disruption . . O O
of . . O O
this . . O O
region . . O O
resulted . . O O
in . . O O
the . . O O
abrogation . . O O
of . . O O
BRCA1 . . O O
activation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
. . . O O

Taken . . O O
together . . O O
, . . O O
these . . O O
results . . O O
demonstrate . . O O
that . . O O
the . . O O
mechanism . . O O
by . . O O
which . . O O
BRCA1 . . O O
induces . . O O
GADD45 . . O O
is . . O O
mainly . . O O
through . . O O
the . . O O
transactivation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
, . . O O
further . . O O
demonstrating . . O O
the . . O O
evidence . . O O
that . . O O
GADD45 . . O O
acts . . O O
as . . O O
one . . O O
of . . O O
the . . O O
BRCA1 . . O O
- . . O O
regulated . . O O
genes . . O O
. . . O O

Oncogene . . O O
( . . O O
2000 . . O O
) . . O O
19 . . O O
, . . O O
4050 . . O O
- . . O O
4057 . . O O
. . . O O

Hypermutability . . O O
and . . O O
mismatch . . O O
repair . . O O
deficiency . . O O
in . . O O
RER . . O O
+ . . O O
tumor . . O O
cells . . O O
. . . O O

A . . O O
subset . . O O
of . . O O
sporadic . . O O
colorectal . . O O
tumors . . O O
and . . O O
most . . O O
tumors . . O O
developing . . O O
in . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
patients . . O O
display . . O O
frequent . . O O
alterations . . O O
in . . O O
microsatellite . . O O
sequences . . O O
. . . O O

Such . . O O
tumors . . O O
have . . O O
been . . O O
thought . . O O
to . . O O
manifest . . O O
replication . . O O
errors . . O O
( . . O O
RER . . O O
+ . . O O
) . . O O
, . . O O
but . . O O
the . . O O
basis . . O O
for . . O O
the . . O O
alterations . . O O
has . . O O
remained . . O O
conjectural . . O O
. . . O O

We . . O O
demonstrate . . O O
that . . O O
the . . O O
mutation . . O B-Mutation
rate . . O O
of . . O O
( . . O O
CA . . O O
) . . O O
n . . O O
repeats . . O O
in . . O O
RER . . O O
+ . . O O
tumor . . O O
cells . . O O
is . . O O
at . . O O
least . . O O
100 . . O O
- . . O O
fold . . O O
that . . O O
in . . O O
RER . . O O
- . . O O
tumor . . O O
cells . . O O
and . . O O
show . . O O
by . . O O
in . . O O
vitro . . O O
assay . . O O
that . . O O
increased . . O O
mutability . . O O
of . . O O
RER . . O O
+ . . O O
cells . . O O
is . . O O
associated . . O O
with . . O O
a . . O O
profound . . O O
defect . . O O
in . . O O
strand . . O O
- . . O O
specific . . O O
mismatch . . O O
repair . . O O
. . . O O

This . . O O
deficiency . . O O
was . . O O
observed . . O O
with . . O O
microsatellite . . O O
heteroduplexes . . O O
as . . O O
well . . O O
as . . O O
with . . O O
heteroduplexes . . O O
containing . . O O
single . . O B-Mutation
base . . O I-Mutation
- . . O I-Mutation
base . . O I-Mutation
mismatches . . O I-Mutation
and . . O O
affected . . O O
an . . O O
early . . O O
step . . O O
in . . O O
the . . O O
repair . . O O
pathway . . O O
. . . O O

Thus . . O O
, . . O O
a . . O O
true . . O O
mutator . . O O
phenotype . . O O
exists . . O O
in . . O O
a . . O O
subset . . O O
of . . O O
tumor . . O O
cells . . O O
, . . O O
the . . O O
responsible . . O O
defect . . O O
is . . O O
likely . . O O
to . . O O
cause . . O O
transitions . . O O
and . . O O
transversions . . O O
in . . O O
addition . . O O
to . . O O
microsatellite . . O O
alterations . . O O
, . . O O
and . . O O
a . . O O
biochemical . . O O
basis . . O O
for . . O O
this . . O O
phenotype . . O O
has . . O O
been . . O O
identified . . O O
. . . O O

Combined . . O O
use . . O O
of . . O O
molecular . . O O
and . . O O
biomarkers . . O O
for . . O O
presymptomatic . . O O
carrier . . O O
risk . . O O
assessment . . O O
in . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
: . . O O
implications . . O O
for . . O O
screening . . O O
guidelines . . O O
. . . O O

Predictive . . O O
carrier . . O O
testing . . O O
for . . O O
the . . O O
inherited . . O O
disorder . . O O
of . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
( . . O O
FAP . . O O
) . . O O
can . . O O
be . . O O
conducted . . O O
using . . O O
DNA . . O O
markers . . O O
linked . . O O
to . . O O
the . . O O
FAP . . O O
locus . . O O
. . . O O

The . . O O
presence . . O O
of . . O O
characteristic . . O O
hypertrophic . . O O
retinal . . O O
lesions . . O O
has . . O O
been . . O O
advocated . . O O
as . . O O
useful . . O O
biomarkers . . O O
for . . O O
FAP . . O O
. . . O O

We . . O O
have . . O O
compared . . O O
molecular . . O O
linkage . . O O
and . . O O
retinal . . O O
screening . . O O
techniques . . O O
by . . O O
evaluating . . O O
the . . O O
presymptomatic . . O O
carrier . . O O
risk . . O O
of . . O O
40 . . O O
at . . O O
- . . O O
risk . . O O
individuals . . O O
from . . O O
15 . . O O
FAP . . O O
families . . O O
. . . O O

Linkage . . O O
analysis . . O O
was . . O O
informative . . O O
in . . O O
all . . O O
and . . O O
retinal . . O O
lesion . . O O
analysis . . O O
in . . O O
25 . . O O
cases . . O O
. . . O O

For . . O O
informative . . O O
at . . O O
- . . O O
risk . . O O
population . . O O
, . . O O
predictive . . O O
diagnosis . . O O
by . . O O
both . . O O
techniques . . O O
was . . O O
completely . . O O
concordant . . O O
and . . O O
identified . . O O
15 . . O O
members . . O O
at . . O O
" . . O O
high . . O O
" . . O O
and . . O O
10 . . O O
at . . O O
" . . O O
low . . O O
" . . O O
risk . . O O
of . . O O
inheriting . . O O
FAP . . O O
. . . O O

Because . . O O
of . . O O
the . . O O
unique . . O O
advantages . . O O
offered . . O O
by . . O O
each . . O O
technique . . O O
, . . O O
a . . O O
strategy . . O O
integrating . . O O
both . . O O
techniques . . O O
will . . O O
increase . . O O
the . . O O
number . . O O
of . . O O
FAP . . O O
families . . O O
that . . O O
can . . O O
be . . O O
screened . . O O
presymptomatically . . O O
. . . O O

Identification . . O O
of . . O O
individuals . . O O
at . . O O
high . . O O
risk . . O O
of . . O O
polyposis . . O O
will . . O O
improve . . O O
their . . O O
clinical . . O O
surveillance . . O O
and . . O O
further . . O O
reduce . . O O
the . . O O
incidence . . O O
of . . O O
colorectal . . O O
cancer . . O O
in . . O O
FAP . . O O
families . . O O
. . . O O

Impact . . O O
of . . O O
Cellular . . O O
Genetic . . O O
Make . . O O
- . . O O
up . . O O
on . . O O
Colorectal . . O O
Cancer . . O O
Cell . . O O
Lines . . O O
Response . . O O
to . . O O
Ellagic . . O O
Acid . . O O
: . . O O
Implications . . O O
of . . O O
Small . . O O
Interfering . . O O
RNA . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

K . . O O
- . . O O
Ras . . O O
activation . . O O
is . . O O
an . . O O
early . . O O
event . . O O
in . . O O
colorectal . . O O
carcinogenesis . . O O
and . . O O
associated . . O O
mutations . . B-Mutation B-Mutation
have . . O O
been . . O O
reported . . O O
in . . O O
about . . O O
40 . . O O
% . . O O
of . . O O
colorectal . . O O
cancer . . O O
patients . . O O
. . . O O

These . . O O
mutations . . B-Mutation B-Mutation
have . . O O
always . . O O
been . . O O
responsible . . O O
for . . O O
enhancing . . O O
malignancy . . O O
and . . O O
silencing . . O O
them . . O O
is . . O O
associated . . O O
with . . O O
attenuation . . O O
of . . O O
tumorigenicity . . O O
. . . O O

Among . . O O
downstream . . O O
effectors . . O O
are . . O O
the . . O O
RAF . . O O
/ . . O O
MEK . . O O
/ . . O O
ERK . . O O
and . . O O
the . . O O
PI3K . . O O
/ . . O O
Akt . . O O
signaling . . O O
pathways . . O O
. . . O O

PI3K . . O O
/ . . O O
Akt . . O O
signaling . . O O
leads . . O O
to . . O O
reduction . . O O
of . . O O
apoptosis . . O O
, . . O O
stimulated . . O O
cell . . O O
growth . . O O
and . . O O
enhanced . . O O
proliferation . . O O
. . . O O

Ellagic . . O O
acid . . O O
( . . O O
EA . . O O
) . . O O
, . . O O
a . . O O
naturally . . O O
occurring . . O O
antioxidant . . O O
, . . O O
has . . O O
recently . . O O
emerged . . O O
as . . O O
a . . O O
promising . . O O
anti . . O O
- . . O O
cancer . . O O
agent . . O O
. . . O O

# . . O O
# . . O O
PURPOSE . . O O

To . . O O
evaluate . . O O
the . . O O
impact . . O O
of . . O O
cellular . . O O
genetic . . O O
make . . O O
- . . O O
up . . O O
of . . O O
two . . O O
colon . . O O
cancer . . O O
cell . . O O
lines . . O O
with . . O O
different . . O O
genetic . . O O
backgrounds . . O O
, . . O O
HCT . . O O
- . . O O
116 . . O O
( . . O O
K . . O O
- . . O O
Ras . . O O
- . . B-Mutation O
/ . . O O
p53 . . O O
+ . . O O
) . . O O
and . . O O
Caco . . O O
- . . O O
2 . . O O
( . . O O
K . . O O
- . . O O
Ras . . O O
+ . . O O
/ . . O O
p53 . . O O
- . . B-Mutation O
) . . O O
, . . O O
on . . O O
response . . O O
to . . O O
potential . . O O
anti . . O O
- . . O O
tumour . . O O
effects . . O O
of . . O O
EA . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
the . . O O
influence . . O O
of . . O O
K . . O O
- . . O O
Ras . . O O
silencing . . B-Mutation O
in . . O O
HCT . . O O
- . . O O
116 . . O O
cells . . O O
was . . O O
investigated . . O O
. . . O O

# . . O O
# . . O O
MATERIALS . . O O
AND . . O O
METHODS . . O O

Cellular . . O O
proliferation . . O O
, . . O O
morphology . . O O
and . . O O
cell . . O O
cycle . . O O
analysis . . O O
were . . O O
carried . . O O
out . . O O
in . . O O
addition . . O O
to . . O O
Western . . O O
blotting . . O O
for . . O O
detecting . . O O
total . . O O
Akt . . O O
and . . O O
p . . O O
- . . O O
Akt . . O O
( . . O O
at . . O O
Thr308 . . O O
and . . O O
Ser473 . . O O
) . . O O
in . . O O
the . . O O
presence . . O O
and . . O O
absence . . O O
of . . O O
different . . O O
concentrations . . O O
of . . O O
EA . . O O
. . . O O

Cell . . O O
proliferation . . O O
was . . O O
also . . O O
assessed . . O O
in . . O O
cells . . O O
transfected . . O O
with . . O O
different . . O O
concentrations . . O O
of . . O O
K . . O O
- . . O O
Ras . . O O
siRNA . . O O
or . . O O
incubated . . O O
with . . O O
ellagic . . O O
acid . . O O
following . . O O
transfection . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
results . . O O
of . . O O
the . . O O
present . . O O
study . . O O
revealed . . O O
that . . O O
EA . . O O
exerts . . O O
anti . . O O
- . . O O
proliferative . . O O
and . . O O
dose . . O O
- . . O O
dependent . . O O
pro . . O O
- . . O O
apoptotic . . O O
effects . . O O
. . . O O

Cytostatic . . O O
and . . O O
cytotoxic . . O O
effects . . O O
were . . O O
also . . O O
observed . . O O
. . . O O

p . . O O
- . . O O
Akt . . O O
( . . O O
at . . O O
Thr308 . . O O
and . . O O
Ser473 . . O O
) . . O O
was . . O O
downregulated . . O O
. . . O O

Moreover . . O O
, . . O O
EA . . O O
treatment . . O O
was . . O O
found . . O O
to . . O O
( . . O O
i . . O O
) . . O O
reduce . . O O
K . . O O
- . . O O
Ras . . O O
protein . . O O
expression . . O O
; . . O O
( . . O O
ii . . O O
) . . O O
in . . O O
cells . . O O
transfected . . O O
with . . O O
siRNA . . O O
and . . O O
co . . O O
- . . O O
treated . . O O
with . . O O
EA . . O O
, . . O O
pronounced . . O O
anti . . O O
- . . O O
proliferative . . O O
effects . . O O
as . . O O
well . . O O
as . . O O
depletion . . O O
of . . O O
p . . O O
- . . O O
Akt . . O O
( . . O O
at . . O O
Thr308 . . O O
) . . O O
were . . O O
detected . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Cellular . . O O
genetic . . O O
makeup . . O O
( . . O O
K . . O O
- . . O O
Ras . . O O
- . . B-Mutation O
/ . . O O
p53 . . O O
- . . B-Mutation O
) . . O O
was . . O O
not . . O O
likely . . O O
to . . O O
impose . . O O
limitations . . O O
on . . O O
targeting . . O O
EA . . O O
in . . O O
treatment . . O O
of . . O O
colon . . O O
cancer . . O O
. . . O O

EA . . O O
had . . O O
a . . O O
multi . . O O
- . . O O
disciplinary . . O O
pro . . O O
- . . O O
apoptotic . . O O
anti . . O O
- . . O O
proliferative . . O O
approach . . O O
, . . O O
having . . O O
inhibited . . O O
Akt . . O O
phosphorylation . . O O
, . . O O
induced . . O O
cell . . O O
cycle . . O O
arrest . . O O
and . . O O
showed . . O O
an . . O O
anti . . O O
- . . O O
proliferative . . O O
potential . . O O
in . . O O
HCT . . O O
- . . O O
116 . . O O
cells . . O O
( . . O O
expressing . . O O
mutant . . B-Mutation O
K . . O O
- . . O O
Ras . . O O
) . . O O
. . . O O

Polymorphisms . . B-Mutation O
in . . O O
the . . O O
mitochondrial . . O O
oxidative . . O O
phosphorylation . . O O
chain . . O O
genes . . O O
as . . O O
prognostic . . O O
markers . . O O
for . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Currently . . O O
, . . O O
the . . O O
TNM . . O O
classification . . O O
of . . O O
malignant . . O O
tumours . . O O
based . . O O
on . . O O
clinicopathological . . O O
staging . . O O
remains . . O O
the . . O O
standard . . O O
for . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
prognostication . . O O
. . . O O

Recently . . O O
, . . O O
we . . O O
identified . . O O
the . . O O
mitochondrial . . O O
oxidative . . O O
phosphorylation . . O O
chain . . O O
as . . O O
a . . O O
consistently . . O O
overrepresented . . O O
category . . O O
in . . O O
the . . O O
published . . O O
gene . . O O
expression . . O O
profiling . . O O
( . . O O
GEP . . O O
) . . O O
studies . . O O
on . . O O
CRC . . O O
prognosis . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

We . . O O
evaluated . . O O
associations . . O O
of . . O O
putative . . O O
regulatory . . O O
single . . B-Mutation B-Mutation
nucleotide . . I-Mutation I-Mutation
polymorphisms . . I-Mutation I-Mutation
( . . O O
SNPs . . B-Mutation O
) . . O O
in . . O O
genes . . O O
from . . O O
the . . O O
oxidative . . O O
phosphorylation . . O O
chain . . O O
with . . O O
survival . . O O
and . . O O
disease . . O O
prognosis . . O O
in . . O O
613 . . O O
CRC . . O O
patients . . O O
from . . O O
Northern . . O O
Germany . . O O
( . . O O
PopGen . . O O
cohort . . O O
) . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Two . . O O
SNPs . . O O
in . . O O
the . . O O
3 . . O O
' . . O O
untranslated . . O O
region . . O O
of . . O O
UQCRB . . O O
( . . O O
complex . . O O
III . . O O
) . . O O
, . . O O
rs7836698 . . B-Mutation O
and . . O O
rs10504961 . . B-Mutation O
, . . O O
were . . O O
associated . . O O
with . . O O
overall . . O O
survival . . O O
( . . O O
HR . . O O
= . . O O
0 . . O O
. . . O O
52 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
0 . . O O
. . . O O
32 . . O O
- . . O O
0 . . O O
. . . O O
85 . . O O
and . . O O
HR . . O O
= . . O O
0 . . O O
. . . O O
64 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
0 . . O O
. . . O O
42 . . O O
- . . O O
0 . . O O
. . . O O
99 . . O O
, . . O O
for . . O O
TT . . O O
carriers . . O O
) . . O O
. . . O O

These . . O O
associations . . O O
were . . O O
restricted . . O O
to . . O O
the . . O O
group . . O O
of . . O O
patients . . O O
with . . O O
cancer . . O O
located . . O O
in . . O O
the . . O O
colon . . O O
( . . O O
HR . . O O
= . . O O
0 . . O O
. . . O O
42 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
0 . . O O
. . . O O
22 . . O O
- . . O O
0 . . O O
. . . O O
82 . . O O
and . . O O
HR . . O O
= . . O O
0 . . O O
. . . O O
46 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
0 . . O O
. . . O O
25 . . O O
- . . O O
0 . . O O
. . . O O
83 . . O O
) . . O O
. . . O O

Multivariate . . O O
analysis . . O O
indicated . . O O
that . . O O
both . . O O
markers . . O O
might . . O O
act . . O O
as . . O O
independent . . O O
prognostic . . O O
markers . . O O
. . . O O

Additionally . . O O
, . . O O
the . . O O
TT . . O O
carriers . . O O
were . . O O
~ . . O O
2 . . O O
times . . O O
more . . O O
likely . . O O
to . . O O
develop . . O O
tumours . . O O
in . . O O
the . . O O
colon . . O O
than . . O O
in . . O O
the . . O O
rectum . . O O
. . . O O

Two . . O O
SNPs . . O O
in . . O O
COX6B1 . . O O
( . . O O
complex . . O O
IV . . O O
) . . O O
were . . O O
associated . . O O
with . . O O
lymph . . O O
node . . O O
metastasis . . O O
in . . O O
a . . O O
dominant . . O O
model . . O O
( . . O O
rs6510502 . . B-Mutation O
, . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
75 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
20 . . O O
- . . O O
2 . . O O
. . . O O
57 . . O O
; . . O O
rs10420252 . . B-Mutation O
, . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
68 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
11 . . O O
- . . O O
2 . . O O
. . . O O
53 . . O O
) . . O O
; . . O O
rs6510502 . . B-Mutation O
was . . O O
associated . . O O
also . . O O
with . . O O
distant . . O O
metastasis . . O O
( . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
67 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
09 . . O O
- . . O O
2 . . O O
. . . O O
56 . . O O
in . . O O
a . . O O
dominant . . O O
model . . O O
) . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

This . . O O
is . . O O
the . . O O
first . . O O
report . . O O
suggesting . . O O
that . . O O
markers . . O O
in . . O O
genes . . O O
from . . O O
the . . O O
mitochondrial . . O O
oxidative . . O O
chain . . O O
might . . O O
be . . O O
prognostic . . O O
factors . . O O
for . . O O
CRC . . O O
. . . O O

Additional . . O O
studies . . O O
replicating . . O O
the . . O O
presented . . O O
findings . . O O
are . . O O
needed . . O O
. . . O O

Protein . . O O
tyrosine . . O O
phosphatase . . O O
receptor . . O O
- . . O O
like . . O O
genes . . O O
are . . O O
frequently . . O O
hypermethylated . . O O
in . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
. . . O O

The . . O O
activity . . O O
of . . O O
phosphatases . . O O
could . . O O
be . . O O
influenced . . O O
by . . O O
genetic . . O O
, . . O O
as . . O O
well . . O O
as . . O O
epigenetic . . O O
alterations . . O O
. . . O O

In . . O O
our . . O O
study . . O O
, . . O O
we . . O O
have . . O O
investigated . . O O
the . . O O
methylation . . O O
status . . O O
of . . O O
four . . O O
PTPRs . . O O
: . . O O
PTPRM . . O O
, . . O O
PTPRT . . O O
, . . O O
PTPRR . . O O
and . . O O
PTPRZ1 . . O O
, . . O O
which . . O O
were . . O O
pre . . O O
- . . O O
selected . . O O
using . . O O
microarray . . O O
techniques . . O O
as . . O O
being . . O O
alternatively . . O O
methylated . . O O
in . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
. . . O O

The . . O O
analyses . . O O
were . . O O
carried . . O O
out . . O O
on . . O O
131 . . O O
surgical . . O O
specimens . . O O
obtained . . O O
from . . O O
sporadic . . O O
CRC . . O O
patients . . O O
. . . O O

The . . O O
methylation . . O O
status . . O O
of . . O O
the . . O O
four . . O O
genes . . O O
was . . O O
examined . . O O
using . . O O
methyl . . O O
specific . . O O
PCR . . O O
( . . O O
MSP . . O O
) . . O O
. . . O O

The . . O O
analysis . . O O
of . . O O
promoter . . O O
methylation . . O O
using . . O O
an . . O O
Illumina . . O O
27K . . O O
microarray . . O O
revealed . . O O
four . . O O
protein . . O O
tyrosine . . O O
phosphatases . . O O
PTPRM . . O O
, . . O O
PTPRT . . O O
, . . O O
PTPRR . . O O
and . . O O
PTPRZ1 . . O O
as . . O O
being . . O O
hypermethylated . . O O
with . . O O
β . . O O
- . . O O
value . . O O
≥ . . O O
0 . . O O
. . . O O
2 . . O O
and . . O O
P . . O O
≤ . . O O
0 . . O O
. . . O O
05 . . O O
. . . O O

Subsequent . . O O
analysis . . O O
using . . O O
MSP . . O O
confirmed . . O O
these . . O O
observations . . O O
- . . O O
the . . O O
frequency . . O O
of . . O O
promoter . . O O
methylation . . O O
was . . O O
significantly . . O O
higher . . O O
in . . O O
tumor . . O O
cells . . O O
compared . . O O
with . . O O
matched . . O O
normal . . O O
tissue . . O O
for . . O O
each . . O O
of . . O O
the . . O O
analyzed . . O O
genes . . O O
. . . O O

There . . O O
was . . O O
no . . O O
association . . O O
observed . . O O
between . . O O
the . . O O
methylation . . O O
status . . O O
of . . O O
PTPRs . . O O
and . . O O
either . . O O
CIMP . . O O
, . . O O
K . . O O
- . . O O
ras . . O O
( . . O O
codon . . O O
12 . . O O
) . . O O
and . . O O
BRAF . . O O
( . . O O
exon . . O O
15 . . O O
, . . O O
V600E . . B-Mutation O
) . . O O
mutations . . O B-Mutation
or . . O O
tumor . . O O
localization . . O O
( . . O O
proximal . . O O
/ . . O O
distal . . O O
) . . O O
. . . O O

The . . O O
results . . O O
of . . O O
our . . O O
study . . O O
show . . O O
a . . O O
statistically . . O O
significant . . O O
difference . . O O
between . . O O
promoter . . O O
methylation . . O O
in . . O O
cancerous . . O O
and . . O O
healthy . . O O
tissue . . O O
. . . O O

This . . O O
result . . O O
supports . . O O
the . . O O
hypothesis . . O O
that . . O O
the . . O O
PTPR . . O O
family . . O O
has . . O O
an . . O O
important . . O O
role . . O O
in . . O O
the . . O O
etiology . . O O
of . . O O
CRC . . O O
. . . O O

Clinical . . O O
benefit . . O O
of . . O O
high . . O O
- . . O O
sensitivity . . O O
KRAS . . O O
mutation . . B-Mutation B-Mutation
testing . . O O
in . . O O
metastatic . . O O
colorectal . . O O
cancer . . O O
treated . . O O
with . . O O
anti . . O O
- . . O O
EGFR . . O O
antibody . . O O
therapy . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVE . . O O

We . . O O
compared . . O O
high . . O O
- . . O O
sensitivity . . O O
KRAS . . O O
mutation . . B-Mutation B-Mutation
testing . . O O
with . . O O
direct . . O O
sequencing . . O O
for . . O O
predicting . . O O
the . . O O
efficacy . . O O
of . . O O
antiepidermal . . O O
growth . . O O
factor . . O O
receptor . . O O
antibodies . . O O
in . . O O
patients . . O O
with . . O O
metastatic . . O O
colorectal . . O O
cancer . . O O
( . . O O
mCRC . . O O
) . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

We . . O O
analyzed . . O O
the . . O O
KRAS . . O O
status . . O O
in . . O O
61 . . O O
tumors . . O O
from . . O O
cetuximab . . O O
- . . O O
treated . . O O
mCRC . . O O
patients . . O O
by . . O O
both . . O O
direct . . O O
sequencing . . O O
and . . O O
a . . O O
high . . O O
- . . O O
sensitivity . . O O
method . . O O
: . . O O
2 . . O O
- . . O O
step . . O O
PCR . . O O
restriction . . O O
fragmentation . . O O
length . . O O
polymorphism . . O O
( . . O O
RFLP . . O O
) . . O O
. . . O O

Therapeutic . . O O
effects . . O O
in . . O O
each . . O O
mutational . . B-Mutation O
status . . O O
were . . O O
evaluated . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
incidences . . O O
of . . O O
KRAS . . O O
mutations . . B-Mutation B-Mutation
determined . . O O
by . . O O
direct . . O O
sequencing . . O O
and . . O O
2 . . O O
- . . O O
step . . O O
PCR . . O O
RFLP . . O O
were . . O O
34 . . O O
. . . O O
4 . . O O
and . . O O
52 . . O O
. . . O O
5 . . O O
% . . O O
, . . O O
respectively . . O O
( . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
02 . . O O
) . . O O
. . . O O

Patients . . O O
were . . O O
categorized . . O O
into . . O O
3 . . O O
groups . . O O
[ . . O O
W . . O O
/ . . O O
W . . O O
, . . O O
wild . . O B-Mutation
- . . O I-Mutation
type . . O I-Mutation
by . . O O
both . . O O
methods . . O O
( . . O O
n . . O O
= . . O O
29 . . O O
) . . O O
; . . O O
W . . O O
/ . . O O
M . . O O
, . . O O
wild . . O B-Mutation
- . . O I-Mutation
type . . O I-Mutation
by . . O O
direct . . O O
sequencing . . O O
, . . O O
detected . . O O
mutation . . B-Mutation B-Mutation
by . . O O
2 . . O O
- . . O O
step . . O O
PCR . . O O
RFLP . . O O
( . . O O
n . . O O
= . . O O
11 . . O O
) . . O O
; . . O O
M . . O O
/ . . O O
M . . O O
, . . O O
mutant . . B-Mutation B-Mutation
- . . O I-Mutation
type . . O I-Mutation
by . . O O
both . . O O
methods . . O O
( . . O O
n . . O O
= . . O O
21 . . O O
) . . O O
] . . O O
. . . O O

The . . O O
response . . O O
rate . . O O
for . . O O
cetuximab . . O O
in . . O O
the . . O O
W . . O O
/ . . O O
M . . O O
group . . O O
( . . O O
0 . . O O
% . . O O
) . . O O
was . . O O
the . . O O
same . . O O
as . . O O
that . . O O
in . . O O
the . . O O
M . . O O
/ . . O O
M . . O O
group . . O O
, . . O O
and . . O O
was . . O O
significantly . . O O
lower . . O O
than . . O O
in . . O O
the . . O O
W . . O O
/ . . O O
W . . O O
group . . O O
( . . O O
41 . . O O
. . . O O
4 . . O O
% . . O O
) . . O O
( . . O O
p . . O O
< . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
. . . O O

Progression . . O O
- . . O O
free . . O O
survival . . O O
in . . O O
the . . O O
W . . O O
/ . . O O
M . . O O
group . . O O
( . . O O
11 . . O O
. . . O O
0 . . O O
weeks . . O O
) . . O O
was . . O O
similar . . O O
to . . O O
that . . O O
in . . O O
the . . O O
M . . O O
/ . . O O
M . . O O
group . . O O
( . . O O
8 . . O O
. . . O O
0 . . O O
weeks . . O O
) . . O O
, . . O O
and . . O O
was . . O O
significantly . . O O
shorter . . O O
than . . O O
in . . O O
the . . O O
W . . O O
/ . . O O
W . . O O
group . . O O
( . . O O
18 . . O O
. . . O O
0 . . O O
weeks . . O O
) . . O O
( . . O O
p . . O O
< . . O O
0 . . O O
. . . O O
002 . . O O
) . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

High . . O O
- . . O O
sensitivity . . O O
KRAS . . O O
mutation . . B-Mutation B-Mutation
testing . . O O
is . . O O
useful . . O O
for . . O O
selecting . . O O
true . . O O
responders . . O O
to . . O O
cetuximab . . O O
. . . O O

Recurrent . . O O
R . . O O
- . . O O
spondin . . O O
fusions . . O O
in . . O O
colon . . O O
cancer . . O O
. . . O O

Identifying . . O O
and . . O O
understanding . . O O
changes . . O O
in . . O O
cancer . . O O
genomes . . O O
is . . O O
essential . . O O
for . . O O
the . . O O
development . . O O
of . . O O
targeted . . O O
therapeutics . . O O
. . . O O

Here . . O O
we . . O O
analyse . . O O
systematically . . O O
more . . O O
than . . O O
70 . . O O
pairs . . O O
of . . O O
primary . . O O
human . . O O
colon . . O O
tumours . . O O
by . . O O
applying . . O O
next . . O O
- . . O O
generation . . O O
sequencing . . O O
to . . O O
characterize . . O O
their . . O O
exomes . . O O
, . . O O
transcriptomes . . O O
and . . O O
copy . . O O
- . . O O
number . . O O
alterations . . O O
. . . O O

We . . O O
have . . O O
identified . . O O
36 . . O O
, . . O O
303 . . O O
protein . . O O
- . . O O
altering . . O O
somatic . . B-Mutation O
changes . . I-Mutation O
that . . O O
include . . O O
several . . O O
new . . O O
recurrent . . O O
mutations . . O B-Mutation
in . . O O
the . . O O
Wnt . . O O
pathway . . O O
gene . . O O
TCF7L2 . . O O
, . . O O
chromatin . . O O
- . . O O
remodelling . . O O
genes . . O O
such . . O O
as . . O O
TET2 . . O O
and . . O O
TET3 . . O O
and . . O O
receptor . . O O
tyrosine . . O O
kinases . . O O
including . . O O
ERBB3 . . O O
. . . O O

Our . . O O
analysis . . O O
for . . O O
significantly . . O O
mutated . . O B-Mutation
cancer . . O O
genes . . O O
identified . . O O
23 . . O O
candidates . . O O
, . . O O
including . . O O
the . . O O
cell . . O O
cycle . . O O
checkpoint . . O O
kinase . . O O
ATM . . O O
. . . O O

Copy . . O O
- . . O O
number . . O O
and . . O O
RNA . . O O
- . . O O
seq . . O O
data . . O O
analysis . . O O
identified . . O O
amplifications . . O O
and . . O O
corresponding . . O O
overexpression . . O O
of . . O O
IGF2 . . O O
in . . O O
a . . O O
subset . . O O
of . . O O
colon . . O O
tumours . . O O
. . . O O

Furthermore . . O O
, . . O O
using . . O O
RNA . . O O
- . . O O
seq . . O O
data . . O O
we . . O O
identified . . O O
multiple . . B-Mutation O
fusion . . I-Mutation O
transcripts . . I-Mutation O
including . . O O
recurrent . . B-Mutation O
gene . . I-Mutation O
fusions . . I-Mutation O
involving . . O O
R . . O O
- . . O O
spondin . . O O
family . . O O
members . . O O
RSPO2 . . O O
and . . O O
RSPO3 . . O O
that . . O O
together . . O O
occur . . O O
in . . O O
10 . . O O
% . . O O
of . . O O
colon . . O O
tumours . . O O
. . . O O

The . . O O
RSPO . . O O
fusions . . B-Mutation O
were . . O O
mutually . . O O
exclusive . . O O
with . . O O
APC . . O O
mutations . . O B-Mutation
, . . O O
indicating . . O O
that . . O O
they . . O O
probably . . O O
have . . O O
a . . O O
role . . O O
in . . O O
the . . O O
activation . . O O
of . . O O
Wnt . . O O
signalling . . O O
and . . O O
tumorigenesis . . O O
. . . O O

Consistent . . O O
with . . O O
this . . O O
we . . O O
show . . O O
that . . O O
the . . O O
RSPO . . O O
fusion . . B-Mutation O
proteins . . O O
were . . O O
capable . . O O
of . . O O
potentiating . . O O
Wnt . . O O
signalling . . O O
. . . O O

The . . O O
R . . O O
- . . O O
spondin . . O O
gene . . O O
fusions . . B-Mutation O
and . . O O
several . . O O
other . . O O
gene . . O O
mutations . . O B-Mutation
identified . . O O
in . . O O
this . . O O
study . . O O
provide . . O O
new . . O O
potential . . O O
opportunities . . O O
for . . O O
therapeutic . . O O
intervention . . O O
in . . O O
colon . . O O
cancer . . O O
. . . O O

Twenty . . O O
- . . O O
four . . O O
non . . O O
- . . O O
synonymous . . O O
polymorphisms . . O B-Mutation
in . . O O
the . . O O
one . . O O
- . . O O
carbon . . O O
metabolic . . O O
pathway . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
in . . O O
the . . O O
Nurses . . O O
' . . O O
Health . . O O
Study . . O O
. . . O O

Dietary . . O O
folate . . O O
and . . O O
alcohol . . O O
consumption . . O O
as . . O O
well . . O O
as . . O O
polymorphic . . O O
variants . . O O
in . . O O
one . . O O
- . . O O
carbon . . O O
metabolism . . O O
genes . . O O
may . . O O
modulate . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
through . . O O
aberrant . . O O
DNA . . O O
methylation . . O O
and . . O O
altered . . O O
nucleotide . . O O
synthesis . . O O
and . . O O
repair . . O O
. . . O O

We . . O O
assessed . . O O
the . . O O
association . . O O
of . . O O
24 . . O O
non . . O O
- . . O B-Mutation
synonymous . . O I-Mutation
single . . O I-Mutation
nucleotide . . O I-Mutation
polymorphisms . . O I-Mutation
( . . O O
nsSNPs . . O B-Mutation
) . . O O
in . . O O
13 . . O O
genes . . O O
in . . O O
the . . O O
one . . O O
- . . O O
carbon . . O O
metabolism . . O O
pathway . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
in . . O O
556 . . O O
incident . . O O
cases . . O O
and . . O O
557 . . O O
controls . . O O
nested . . O O
in . . O O
the . . O O
Nurses . . O O
' . . O O
Health . . O O
Study . . O O
. . . O O

Most . . O O
of . . O O
the . . O O
SNPs . . O O
were . . O O
not . . O O
associated . . O O
with . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
. . . O O

We . . O O
did . . O O
, . . O O
however . . O O
, . . O O
observe . . O O
a . . O O
modest . . O O
increased . . O O
risk . . O O
among . . O O
carriers . . O O
of . . O O
the . . O O
transcobalamin . . O O
( . . O O
TCN . . O O
) . . O O
II . . O O
259 . . B-Mutation O
Pro . . I-Mutation O
/ . . I-Mutation O
Arg . . I-Mutation B-Mutation
+ . . O I-Mutation
Arg . . O I-Mutation
/ . . O I-Mutation
Arg . . O I-Mutation
variant . . O I-Mutation
( . . O O
odds . . O O
ratio . . O O
1 . . O O
. . . O O
48 . . O O
, . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
1 . . O O
. . . O O
09 . . O O
- . . O O
2 . . O O
. . . O O
02 . . O O
) . . O O
for . . O O
colorectal . . O O
adenoma . . O O
. . . O O

The . . O O
TCN . . O O
II . . O O
Pro259Arg . . B-Mutation O
polymorphism . . O O
may . . O O
affect . . O O
TCN . . O O
binding . . O O
and . . O O
transport . . O O
of . . O O
vitamin . . O O
B . . O O
( . . O O
12 . . O O
) . . O O
and . . O O
thus . . O O
warrants . . O O
further . . O O
investigation . . O O
of . . O O
its . . O O
biological . . O O
function . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
the . . O O
methionine . . O O
synthase . . O O
reductase . . O O
( . . O O
MTRR . . O O
) . . O O
Arg415Cys . . B-Mutation O
and . . O O
MTRR . . O O
Ser284Thr . . B-Mutation O
variant . . O O
carriers . . O O
, . . O O
also . . O O
in . . O O
the . . O O
vitamin . . O O
B . . O O
( . . O O
12 . . O O
) . . O O
pathway . . O O
, . . O O
have . . O O
suggestive . . O O
associations . . O O
with . . O O
advanced . . O O
colorectal . . O O
adenoma . . O O
( . . O O
defined . . O O
as . . O O
being . . O O
larger . . O O
than . . O O
1 . . O O
cm . . O O
, . . O O
villous . . O O
, . . O O
tubular . . O O
- . . O O
villous . . O O
or . . O O
carcinoma . . O O
in . . O O
situ . . O O
histology . . O O
) . . O O
. . . O O

We . . O O
observed . . O O
significant . . O O
evidence . . O O
for . . O O
departure . . O O
from . . O O
multiplicative . . O O
interaction . . O O
for . . O O
the . . O O
betaine . . O O
- . . O O
homocysteine . . O O
methyltransferase . . O O
( . . O O
BHMT . . O O
) . . O O
Arg239Gln . . B-Mutation O
with . . O O
dietary . . O O
methyl . . O O
status . . O O
( . . O O
based . . O O
on . . O O
intake . . O O
of . . O O
dietary . . O O
folate . . O O
, . . O O
methionine . . O O
and . . O O
alcohol . . O O
intake . . O O
) . . O O
in . . O O
relation . . O O
to . . O O
colorectal . . O O
adenoma . . O O
; . . O O
no . . O O
such . . O O
interaction . . O O
was . . O O
observed . . O O
for . . O O
the . . O O
other . . O O
23 . . O O
SNPs . . O O
. . . O O

Further . . O O
investigation . . O O
is . . O O
required . . O O
to . . O O
validate . . O O
the . . O O
association . . O O
of . . O O
the . . O O
polymorphisms . . O O
in . . O O
the . . O O
one . . O O
- . . O O
carbon . . O O
metabolic . . O O
genes . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
. . . O O
